Supplement to Vol. 48, No. 1, 1980

INTERNATIONAL JOURNAL OF LEPROSY

And Other Mycobacterial Diseases

Official Organ of the
INTERNATIONAL LEPROSY ASSOCIATION
(Société Internationale de la Lèpre)
(Asociación Internacional contra la Lepra)

Index to Volume 47

Volume 48, Number 1 (SUPPLEMENT)
Printed in the U.S.A.
ISSN 0148-916X

INTERNATIONAL JOURNAL OF LEPROSY

And Other Mycobacterial Diseases

INDEX TO VOLUME 47

INDEX TO AUTHORS

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), and book reviews (B).

ABALOS, R. M., (A) 415
ABE, M., (A) 89, 114, 379, 542
ABER, V. R., (A) 649
ABREU, A., (A) 325, 363, 436, 447
ACKLEY, R. K., (E) 608
ADAPOE, C., (A) 363
AGARWAL, S. K., (O) 1, (A) 219
AGOITIA, D., (A) 404
AGOITIA, L., (A) 403
AGUIAR PUPO, J. DE, (A) 393
AHMED, H. A., (C) 611
AIZER, F., (A) 228
AKIMORI, H., (A) 667
AKSANOVA, R. A., (A) 378
ALA, F. A., (A) 546
ALCHORNE, M. M. A., (A) 388, 640
ALCOCER, J., (A) 350
ALEXANDER, J., (A) 536, 652, 658
ALEXANDER, R., (A) 354, 538
ALMEIDA, KH., (A) 652
ALMEIDA BRANDAO, C. B. P., (A) 388, 421
ALWARENGA, A. E., (A) 339
AMBROSE, E. J., (A) 225, 410
AMENDOLEA, M. A., (O) 171, (A) 393
ANADAN, J. A., (A) 531
ANDERSON, R., (A) 546
ANGELINI, G., (A) 382
ANGULO, M. H., (A) 533
ANNAMALAI, R., (A) 352
ANTHONY, J., (A) 393, 537, 644
ANTHONY, P., (A) 79
ANTHOPOULOS, L., (A) 419
ANTIA, N. H., (A) 76, 410, 416, 427, 429, 446, 537
ANTOLA, M., (A) 452
APONTE-VÁZQUEZ, J., (A) 422
APPEL, G. E., (A) 405
APPLEBAUM, P. C., (A) 74
APTE, N. K., (A) 416
ARANZAZU, N., (A) 220, 338, 373, 386, 415, (O) 570
ARENAS, R., (A) 404
ARTZ, R. P., (A) 680
ARVELO, J. J., (A) 447
ASSEFI, V., (A) 323
AVALOS, E., (A) 355, 376
AVILA, C., (A) 447
AVILA, J. J., (A) 403, 440
AWAD, H. A., (O) 44
AXELSEN, N. H., (A) 84, 541
AYALA URIBE, G., (A) 325
AZIZLERLI, G., (A) 392
AZULAY, R. D., (C) 63, (A) 345, 420
AZZAM, A., (A) 333

BABU, N. V., (A) 444
BACARDI, R., 650
BACHMANN, A., (A) 442
BADACHA, P., (A) 418
BADENOCH-JONES, P., (A) 393
BAE, E. D., (A) 552
BAGGA, V., (A) 341
BAKOS, L., (A) 327
BAKRI, H. I., (A) 231
BALAKRISHNAN, S., (A) 529
BALENTINE, J. D., (A) 228
BALIÑA, L. M., (A) 339, 387, 436, 440, 442, 450, (O) 575
BALIÑA DE VALDEZ, M., (A) 403
BALSINDA, I., (A) 447
BANERJEE, D. K., (A) 79, 385
BAPAT, C. V., (A) 224, 225, 339, 362, 380
BARANTON, G., (A) 386
BARKSDALE, L., (A) 358
BARNETSON, R. ST. C., (A) 378, 396, 434, 538, 639
BARR, R. M., (A) 658
BARRETT-CONNOR, E., (A) 74
BARTON, R. P. E., (A) 348

Basset, A., (A) 635
Bastazini, I., (A) 353, 384
Beach, R. B., (A) 671
Bechelli, L. M., (B) 209, (A) 375, 387, 389
Bedi, B. M. S., (A) 232, 327
Bedi, T. R., (A) 537
Belehu, A., 374, 546
Belk, S. E., (A) 672
Belurkar, B. R., (A) 391
Benedetti, E. L., (A) 652
Benson, M. D., (O) 133
Beoto, T. K., (A) 533
Bergel, M., (C) 63, 200, (A) 410, (C) 520
Bernado, L., (A) 650
Bernardi, C. D. V., (A) 327, 327, 416
Berra y Pamiés, F. F., (A) 403
Beoto, T. K., 533
Besuschio, S., (A) 364
Beverding, A. M., (A) 230
Bhagoliwal, A., (A) 531
Bhanu, T., (A) 538
Bharadwaj, V. P., (O) 167, (A) 219, 224, 391, 641, 644
Bhargava, N. C., (A) 87, 216, 643
Bhat, K. R., (A) 341
Bhide, M. B., (A) 339, 537
Bhutani, L. K., (A) 540
Bianchi, O., (A) 339, 387, 414, 436
Bijleveld, I., (A) 75
Binford, C. H., (A) 106, (B) 206, (A) 230, 342
Birdi, T. J., (A) 537
Bisht, D., (A) 224
Biswas, S. K., (A) 87
Bjune, G., (A) 84, (O) 138, 153, (A) 374, 378, 394, 396, 538, 651
Bloom, B. R., (A) 111, 373, 649, 679
Boddingius, J., (A) 425, 430
Bogaert Diaz, H., (A) 331, 405
Bonnici, E., (A) 81, 332, 434
Bonomo, L., (A) 382
Boopalraj, J. M., (A) 532
Borasit, N., (A) 364
Bose, K. S., (A) 451
Bouckaert, A., (A) 227, 326
Bourges, M., (A) 364, 449
Bourland, J., (A) 437, 639
Bourrel, P., (A) 449
Bowen, A. J., (A) 74
Bozan, G., (A) 392
Bradley, D. J., (A) 321, 654
Bragina, V. S., (A) 437
Brand, P. W., (A) 671, 671
Brascher, H. M., (A) 345
Bravo, L. L., (A) 92
Brokl, O., (A) 651
Brown, H. L., (A) 106
Browne, S. G., (N) 68, 68, (A) 635
Brule, M., (A) 386
Brusch, J. L., (O) 121
Buchanan, T. M., (A) 114, (O) 469, 477, (A) 674
Buckner, J. A., (A) 230
Bullier, R., (A) 532
Bullock, W. E., (A) 83, 226, 677, 680
Burdett, I. D. J., (A) 548
Byun, S. Y., (A) 538

Cabrera, H., (A) 414
Caldwell, H. D., (A) 114, (O) 469, 477
Camargo, E. E., (O) 126
Campbell, P. R., (A) 552
Campilla, E., (A) 83
Campo-Aasen, I., (A) 88
Campos, F. J., (A) 403
Cap, A., (A) 639
Capetanakis, J., (A) 349, 391
Carayon, A., (A) 425, 451
Cardama, J. E., (A) 74, 339, 347, 436, 440, 442, 450
Carlson, E. M., (A) 226
Carvalho, J. C. de S., (A) 441
Cassiano, T. P., (A) 388, 640
Castaneda, S., (A) 403, 404
Castellazzi, Z., (A) 322
Castro, E., (A) 414
Castro-Mussot, M. E., (A) 380, 539
Cauzzi, N. J., (O) 13
Cavelier, J. F., (A) 229
Chacko, C. J. G., (A) 85, 221, 321, 354, 417, 538, 654
Chakrabarty, M. S., (A) 641
Chakrabarty, S. K., (A) 641
Chakraborty, T., (A) 411, 637
Chakravarty, R. N., (O) 18, (A) 349, 650
Chan, S. H., (A) 641
Chandi, S. M., (A) 539
Chandra, J., (A) 531
Chandra, S., (A) 77
Chang, Y. T., (E) 56, (C) 201
Charoon, P., (A) 333
Charosky, C., (A) 450
Chatterjee, B. R., (B) 206, (A) 359, 366
Chaudhuri, S., (A) 411, 637
Chaudhury, D. S., (A) 323
Chaudhury, S., (A) 352
Chen, L. T., (A) 83
Chinelli, C., (A) 364
Chiron, J. P., (A) 330, 532
Cho, K. K., (A) 234
Choi, S. H., (A) 233
Choi, S. R., (A) 329
Choi, T. K., (A) 552
Chopra, J. S., (A) 427, 429
Choudhury, S., (A) 641
Chovet, M., (A) 74
Chow, S. K. W., (A) 370
Christian, M., (A) 324
Christy, S. A., (A) 674
Chu, C. Y., (A) 553
Chulawala, R. G., (A) 225, 410, 430
Chung, T. H., (A) 233
Chung, W. K., (A) 329, 538

Clavel, S., (A) 548
Clément, F., (A) 547, 548
Closs, O., (A) 84, 85, 372, 374, 385, 397, 541, 543, 548
Clotet, V., (A) 650
Cocito, C., (A) 542
Coers, C., (A) 642
Cohen, S. S., (A) 637
Cole, F. S., (O) 121
Cole, G. W., (A) 641
Collins, F. M., (A) 113, 375, 650, 670, 676, 683
Çöloğlu, A. S., (A) 392, 644
Colston, M. J., (A) 79, 79, 79, 368, 411, 679
Colvin, R. B., (A) 642
Connor, D. H., (B) 206
Contreras-Duenas, F., (B) 207
Convit, J., (A) 88, 220, 338, 373, 379, 382, 386, 415, (E) 512, (C) 517, (A) 548, (O) 570
Cormane, R., (A) 220
Cornejo, A. L., (A) 383
Corona, C. J., (O) 13
Coruh, G., (O) 500
Cottenot, F., (A) 80, 84
Crawford, C. L., (A) 340, 341, 341
Curtis, J., (A) 652, 652
Cuxart, A., (A) 650

Daniel Raj, A., (A) 232
Das, P. K., (A) 75, 328
Dasgupta, A., (A) 393, 537, 644
Dash, R. J., (A) 532
Dastur, D. K., (A) 645, 646
Datar, S. V., (A) 532
Date, A., (A) 421
Datta, B. N., 532
Davey, T. F., (A) 550
David, H. L., (A) 547, 548
David-Chaussé, J., (A) 532
Davidson, W. S., (A) 428, (B) 628
Davis, M., (A) 535
Dawson, A. M., (A) 638
Dawson, D. M., (A) 642
Dawson, P. J., (O) 561, (A) 679
Dayal, S. G., (A) 534, 639
Debi, B. P., (A) 639
de Gomez, M. E., (A) 220, 373, 382, (O) 570
de la Cruz, E., (C) 612
Delpino, G. de S., (A) 327, 416
Delville, J., (A) 80, 80, 227, 227, 357, 366, 542, 548
Denderson, A. C. v. (A) 75
Denis, F., (A) 330, 532
Depasquale, G., (A) 81, 332, 434
Desikan, K. V., (A) 214, 219, 222, 223, 359, 366, 391, 529, 529, 536, 540, 545, 641, 644
de Thököly, I., (A) 530
Devi, S., (O) 484
de Vries, R. R. P., (A) 321
de Wit, M., (A) 328
Dharmendra, (B) 628
Dhople, A. M., (A) 103, 361, 667
Diamantopoulos, E., (A) 332, 419
Diaz Almeida, J., (A) 231, 364
Digoutte, J. P., (A) 386
Dillman, R. O., (A) 533
Dimitriu, A., (A) 229
Dogliotti, M., (A) 527
Donaldson, S. R., (B) 629
Donham, K. J., (A) 342, 550
Dorfman, R. F., (A) 78
Draper, P., (A) 357, 548, 653
Dubey, A. L., (A) 534
Duncan, E., (A) 538
Duncan, M. E., (A) 350, 378, 394
Dunia, I., (A) 652
Dutta, A. K., (A) 223
Dutta, R. K., (A) 642
Dutta, R. N., (A) 223
Dy, M., (A) 229

Eckes, L. K., (A) 527
Edlin, G. P., (A) 94
Eknoyan, G., (A) 533
El Amin, A. M., (A) 214
Ellard, G. A., (A) 79, 79, 408
Ellis, B. P. B., (A) 84
Elsler, E. (A) 351
Endo, H., (A) 102, 369
Enna, C. D., 232, 332, 422, 656
Errasti, P., (A) 529
Escourolle, R., (A) 541
Estevez, M. E., (O) 575
Estrada-Parra, S., (A) 376, 380, 383, 394, 394, 396, 539
Evstratova, V. A., (A) 378
Ezer, G., (A) 378

Faber, W. R., (A) 220, 220, 439, 539, 637, 637, 654
Fajardo, T. T., (A) 415
Falcone, M., (A) 440
Fasal, P., (A) 329, 401, (E) 607, (A) 655
Fauci, A. S., (A) 657
Fauxpoint, B., (A) 74
Fernandez Baquero, G., (A) 231, 533
Ferracci, C., (A) 376
Ferrara, G., (A) 380
Ferreira, J., (A) 327, 327, 416
Festenstein, H., (A) 321, 654
Fields, J., (A) 373
Fieldsteel, A. H., (A) 108, (O) 561, (A) 669, 679
File, S. K., (A) 230
Filice, G. A., (A) 90
Fine, P. E. M., (A) 321, 654
Finseth, F., (A) 551
Fiol, L., (A) 440
Fite, G. L., (A) 401, (E) 607
Flament-Durand, J., (A) 642
Fleury, R. N., (A) 353, 353, 354, 384, 416
Fliess, E., (A) 387
Flores, O., (A) 404
Folse, D. S., (A) 230

FOROOZANFAR, N., (A) 546
FOTEDAR, A., (A) 540
FRAGA, A., (A) 350
FRAGUELA RANGEL, J. V., (A) 533
FRASER, D. W., (A) 90
FREERKSEN, E., (A) 81, 81, 434
FREGNAN, R. C., (A) 375
FRIST, T. F., (A) 400
FRITSCHI, E., 401, 417, 551
FUKUNISHI, Y., (A) 668
FUKUSHI, K., (A) 88, 110
FUKUSHIMA, K., (A) 669
FUMAROLA, D., (A) 84
FUNK, H. B., (A) 667
FURUTA, M., (A) 214

GABRIELLI, M., (A) 436, 440, 442
GAILHBAUD, M., (A) 386
GAITONDE, B. B., (A) 435
GALLI, J. J., (A) 351, 449
GAMMON, P. T., (A) 79, 79
GANAPATHY, K. T., (A) 657
GANAPATI, R., (A) 91, 333
GANAPOL, J., (A) 352
GANGULY, N. K., (A) 650
GARCIA, C. A., (A) 533
GARCIA, M., (A) 394
GARCIA-VANRELL, G., (A) 650
GARCILASO, T., (A) 404
GAROFALO, M. A., (A) 450
GARRIDO NEVES, R., (A) 375, 420
GATTAS BARA, M., (A) 421
GATTI, C. F., (A) 82
GATTI, J. C., (A) 74, 339, 436, 440, 442, 450
GEBHARD, J., (A) 641
GELBER, R. H., (A) 83, 409, 681, 684
GERBASE, A. C., (A) 327, 327
GERSHON, R. K., (A) 226
GERSHON, W., (A) 323, 447
GERVACI, V. S., (A) 440
GHEI, S. K., (O) 167
GHOSH, S., (A) 352, 411, 637, 641
GIBSON, J., (A) 684
GIDOH, M., (A) 102, 110
GILLIS, T. P., (A) 674
GINER, M., (A) 535
GIRAUDEAU, P., (A) 448, 449
GIRDHAR, B. K., (A) 214, 222, 223, 529, 529, 540
GIRIJA, D., (A) 333
GLOVER, A., (A) 546
GNENYUCK, T. S., (A) 438
GODAL, T., (A) 372, 527, 540
GOIHMAN-YAHR, M., (A) 220, 373, 382, (C) 521, (O) 570
GOKHALE, S. W., (B) 209
GOLDRING, O. L., (A) 75
GOLDSTEIN, R. A., (A) 657
GOLOSHCHAPOV, N. M., (A) 438
GOMEZ URCUYO, F., (A) 404
GOMEZ V., M., (A) 450
GONZÁLES, O., (A) 394
GONZÁLEZ, M. C., (A) 380
GONZÁLEZ DEL CERRO, S., (A) 402
GONZÁLEZ GALVAN, A., (A) 320
GONZÁLEZ-GARCIA, I., (A) 380
GONZÁLEZ MENDOZA, A., (A) 383
GOODWIN, C. S., (A) 428
GOPINATH, P., (A) 418
GORDON, G., (N) 616, 624
GORDON, G. R., (A) 217, 409, 410, 681, 682
GORDON, R., (A) 536
GOREN, M. B., (A) 651
GOTHI, G. D., (A) 657
GOVIL, D. C., (A) 540
GOYAL, B. M., (A) 217, 534, 639
GOYLE, S., (A) 651
GRANGE, J. M., (A) 225
GRAY, F., (A) 552
GREINER, J., (A) 221, 320
GRIENBERG, O., (A) 402
GROVE, J., (A) 409
GUARDIA, J., (A) 650
GUINTO, R. S., (A) 318
GUPTA, D. K., (A) 221
GUPTA, J. C., (A) 221
GUPTA, P. K., (A) 640
GUPTA, S. C., (A) 224
GUPTE, M. D., (A) 321, 391, 656
GUSSOW, Z., (A) 527
GUZMAN, A., (A) 350
GYI, K. M., (A) 530, 638

HACKETT, E. R., (A) 533
HADDAD, N., (A) 375, 387
HAGAN, K. J., (A) 638, 638
HAILE, G. S., (A) 328, 329, 639
HALLACK, K. A., (A) 421
HAMADA, T. A. Y., (O) 44
HANKS, J. H., (A) 103, 361, 667
HARADA, K., (A) 102, 115, 366, 419
HARADA, N., (A) 214
HARAHAP, M., (N) 524
HARBOE, M., (A) 84, 85, 372, 374, 385, 541, 543, 548, 651
HARDWICKE, P. M. D., (A) 340, 341
HARGRAVE, J. C., (C) 64, (A) 534
HARMAN, D. J., (A) 534, 549
HARRIS, E. B., (A) 223, 344, 359
HARRIS, R. C., (A) 74
HARRISON, S., (A) 551
HART, D'A., (A) 653
HASAN, S., (B) 207
HASTINGS, R. C., (E) 59, (A) 112, 221, 348, 381, 395, 439, (E) 515, 609, (N) 618, (A) 672, 674
HATZIS, J., (A) 349
HAVENS, R. A., (A) 677
HAZAMA, S., (A) 115, 419
HAZRA, S. K., (A) 352, 637
HEGGIE, C. D., (A) 683

HELMY, H. S., (A) 83
HERNANDEZ, O., (A) 436
HERNANDEZ SILVA, J., (A) 440, 530
HERNANDO, F., (A) 322
HERRERA, M. DE, (A) 339, 387, 436, 442
HERRERA, R., (A) 350
HILARIO DE GONZÁLEZ, M., (A) 405
HILDEBRAND, W. M., (A) 441
HILLING, M., (A) 551
HILSON, G. R. F., (A) 79, 79, 368, 411
HIMELSTEIN, M., (A) 77
HIRAMALINI, S., (A) 221
HIRATA, T., (A) 101, (O) 585
HIRSCHBERG, H., (A) 649
HITZEROTH, H. W., (A) 551
HLA, T., (A) 638
HOBBS, H. E., (A) 549
HOGERZEIL, L. M., (A) 541
HONEY, N. R., (A) 91, 365
HOWLAND, C., (A) 92
HUBSCHER, S., (A) 222
HUH, C. D., (A) 234
HUIKESHOVEN, H., (A) 75, 75, 328

IBRAHEIM, A. A., (O) 44
IIJIMA, S., (A) 547
ILTER, Ö., (A) 378
INNAMI, S., (A) 339
IRGENS, L. M., (A) 319
ISHAQUE, M., (A) 360, 363, 651
ITO, T., (A) 107, 228, 397, 673
IWAMOTO, T. (A) 547
IYENGAR, B., (A) 222, 541

JACKETT, P. S., (A) 649
JACOBSON, R. R., (A) 232, 332, 433, 680, 681, 682
JACQUES, P. J., (A) 80, 80, 227
JAGADISAN, T. N., (B) 207
JAIN, A. K., (A) 643
JAIN, N. K., (A) 640
JAMES, A. E., JR., (A) 84
JANO, B., (A) 329, 655
JARIWALA, H. J., (O) 33
JESUDASAN, K., (A) 417
JHA, P. R., (A) 77
JIMÉNEZ, L., (A) 539
JIMÉNEZ-ZAMUDIO, L., (A) 380
JIRILLO, E., (A) 84
JOB, C. K., (C) 63, (A) 85, 112, 221, 222, 322, 417, 426, 439, 538, 539
JOHANNESSEN, B., (C) 522
JOHNEY, K. V., (A) 421
JOHNSON, A. C., (A) 84
JOHNSON, S., (A) 84
JOHSI, L. D., (A) 217
JOPLING, W. H., (B) 208, (A) 213, 415, (C) 610
JOSEPH, N. A., (A) 221
JUAREZ MADRIGAL, M., (A) 404
JUSCENKO, A., (Ob) 61, (A) 360

KAJIHARA, N., (A) 531
KALOFOUTIS, A., (A) 420
KAMARUDIN, A., (A) 641
KANCHANA, K., (A) 326, 333, 334
KANCHANA, M. V., (A) 390
KANDIAH, N., (A) 213
KANIWA, S., (A) 110
KANTOR, I., DE, (A) 387
KAPETANAKIS, J., (A) 420
KAPOOR, P., (A) 208
KAPUR, T. R., (A) 533, 533
KARAT, A. B. A., (A) 214, 533
KARAT, S., (A) 418
KASAI, T., (A) 366
KASBEKAR, V., (A) 416
KATTI, V. A., (A) 532
KATO, L., (A) 358, 360, 363, 530, 651
KATZ, P., (A) 657
KAUFMANN, A. E., (A) 403
KAUR, P., (A) 91
KAUR, S., (O) 18, (A) 215, 222, 349, 427, 429, 532, 650
KAU-VENAKI, S., (A) 402
KAWAGUCHI, Y., (A) 227, 549, 653
KAWATSU, K., (A) 88, 227, 419, 549, 653
KAY, T. L., (A) 683
KAZDA, J., (A) 94
KELKAR, S. S., (O) 33, (A) 642
KERR, D. M., (A) 642
KERTCHER, J. A., (A) 126
KESHWANI, N. H., (A) 542
KHAMNEI, A. A., (A) 215
KHANOLKAR, S. R., (A) 225, 410
KHATTRI, H. N., (A) 215
KHOUBESSARIAN, P., (A) 642
KHUTETA, K. P., (A) 420
KIM, B. I., (A) 219
KIM, D. I., (A) 387
KIM, H. S., (A) 233
KIM, K. J., (A) 234
KIM, S. J., (A) 360, 651
KIM, S. K., (A) 553
KIM, S. M., (A) 233
KINGHAM, J. G. C., (A) 638
KIRCHHEIMER, W. F., (A) 114, 223, 232, 327, 337, 344, 359, 361, 390, (O) 477, (A) 528, 550, 666
KIRKPATRICK, L. L., (A) 533
KLAYMAN, D. L., (A) 670, 683
KLINGMÜLLER, G., (A) 84, (B) 209, (A) 344
KOBAYASHI, S., (A) 428
KOGAN, V. R., (A) 378
KOHSAKA, K., (A) 107, 228, 337, 368, 667, 667, 668, 673
KOLUMBIAN, S. L., (A) 450
KOK, S. H., (A) 440
KONICE, M., (A) 378
KOPOLOVIC, J., (A) 536
KORANNE, R. V., (A) 222, 541
KOSEKI, M., (A) 115, 419, 422, 669
KOTICHA, K. K., (O) 50, (A) 333, 410
KOTOGYAN, A., (A) 378

Kouri, J. B., (A) 364
Krani, P. F., (A) 429
Kraytman, M., (A) 642
Kremer, A., (A) 351
Krieg, R. E., (A) 367
Kronvall, G., (A) 84, (O) 138, 153, (A) 374, 541
Krüger-Theimer, M., (A) 81
Krull, E. A., (A) 216
Kumar, B., (O) 18, (A) 215, 222, 349, 427, 429, 650
Kumar, R., (A) 87, 216, 391, 542
Kundu, S. K., (C) 64, (A) 352, 637
Kunigoshi, U., (A) 88
Kuri, Kh., (A) 652
Kusaka, T., (A) 667
Kvernes, S., (A) 683
Kwapinski, J. B. G., (A) 387
Kywe, W. W., (A) 638

Laing, A. B. G., (A) 82, 83, 432, 437
Lakhan Pal, V. P., (A) 656
Lakshiminarayana, C. S., (A) 390
Lampe, D., (A) 89
Lancaster, R. D., (A) 679
Landheer, J. E., (A) 75, 328
Languillon, J., (O) 37, (A) 330, 436, 532
Lapostolle, G., (A) 326
Lara, C. B., (A) 216
Larcher Almeida, A. A., (A) 421
Larrabee, W. F., Jr. , (A) 553
Larson, S. M., (A) 126
Latapí, F., (A) 376, 396
Laub, R., (A) 542
Lawrence, C., (A) 542
Lechat, M. F., (A) 318, 326, 432, (E) 514
Lee, S. H., (A) 233
Lee, Y. N., (A) 553
Lee, Y. S., (A) 85
Lefford, M. J., (A) 90, 116, 229, 230, 372, 678
Lehto, V.-P., (A) 384
Leiker, D. L., (A) 75, 220, 220, 328, 439, 539, 637, 637
Leininger, J. R., (A) 342, 550
Lenhard, V., (A) 221
Lennox, W. M., (A) 215
Lenzini, L., (A) 553
León, A. P., (A) 440, 530
León-Marischal, M. E., (A) 380
Levan, N. E., (A) 77, 389
Leviatan, A., (A) 536
Levy, L., (A) 94, 108, 228, 408, 409, 531, 531
Lew, J., (A) 553
Lewenstein, W., (A) 225
Lewis, C. W., (A) 77
Li, W. M., (A) 76
Lichtman, D. M., (A) 642
Licourt, P., (A) 447
Liew, F. Y., (A) 224, 377
Lima, A. O., (A) 345
Lindner, E., (A) 384
Lisker, R., (A) 344
Liturri, M., (A) 442
Lobo, D., (A) 448
Loginov, V. K., (Ob) 61, (A) 350
Londner, M. V., (O) 13
Loria, M. P., (A) 382
Lospalluti, M., (A) 382
Louis-Joseph, L., (A) 532
Løvik, M., (A) 397
Lovio, Z., (A) 363, 436
Lowe, C., (A) 338, 343, 380
Lowrie, D. B., (A) 649
Ludosky-Diawara, M. A., (A) 652
Luppi, M., (A) 436, 440
Lwin, M. M., (A) 530, 638, 640
Lynch, P., (A) 534

Machtey, I., (A) 77
MacMoran, J. W., (A) 671
Madanagopalan, N., (A) 87
Maheswari, H. B., (A) 86
Makino, M., (A) 228
Malacara, H., (A) 355
Maldonado-Romero, D., (A) 448
Malik, S. K., (O) 18, (A) 349
Man, N. V., (A) 652
Manghani, D. K., (A) 430
Mangiaterra, M. de, (A) 403
Mani, R. S., (A) 323, 447
Mankiewicz, E., (A) 530
Manzi, R. O., (A) 446
Margarido, L., (A) 355
Marks, S. C., Jr., (O) 26, (A) 534, 536
Marques, A. L. V., (A) 384
Marsch, W. C., (A) 234
Marselou-Kinti, U., (A) 420
Martinelli, B., (A) 83
Martinez, D., (A) 331, 349
Martinez-Vasquez, J.-M., (A) 650
Masala, C., (O) 171, (A) 393
Masana, L., (A) 650
Masi, D. A., (A) 405
Maslou, A. K., (A) 360
Mason, L. H., (A) 373, 679
Massalski, W. K., (A) 225
Masuda, A., (O) 133
Mathai, R., (A) 322, 421
Matsumoto, S., (A) 214
Matsumoto, T., (A) 76
Matsumoto, Y., (A) 214
Matsumura, J., (A) 110
Matsuo, Y., (A) 531, 682
Matsuoka, M., (A) 227, 549, 653
Maupas, Ph., (A) 330, 532
Maurus, J. N., (B) 214
McAdam, K. P. W. J., (A) 382
McCormick, G. T., (O) 495, (A) 666
McDougall, A. C., (O) 37, (A) 91, (E) 176, (A) 231, 343, 348, 348, 432, 436, (O) 500, (C) 522, (A) 531, 534, 549, 549, 643
McKeever, P. E., (A) 228

MEHENDALE, M. S., (A) 93
MEHRA, N. K., (A) 321, 341, 391, 540
MEHRA, V., (A) 111, 373, 649, 679
MEHTA, J. M., (B) 209
MEHTA, L. N., (A) 416, 427
MEISELS, L., (A) 402
MELCHIOR, E., JR., (A) 375
MELSOM, R., (A) 85, 378, 394, 538
MENDES, N. F., (O) 133
MENE, A. R., (A) 223, 223
MENEGHINI, C., (A) 382
MENENDEZ-GARCIA, V. G., (A) 231
MENZEL, S., (O) 138, 153, (A) 374
METAWI, B. A., (O) 44
METGE, P., (A) 74
MEYER, L., (A) 547, 548
MEYERS, W. M., (A) 106, 217, 337, 342, 342, 367, 683
MICHALANY, J., (A) 388, 640
MIGAKI, G., (A) 230
MIGDAL, S., (A) 441
MINAGAWA, F., (A) 89, 110, 115, 542
MIRANDA, R. N., (A) 418
MIRANDA, R. O., (A) 381
MISHRA, R., (A) 531
MISRA, S. N., (A) 643
MISSON, C. B., (A) 326, 432
MITSIALI, M., (A) 391
MITTAL, M. M., (A) 86
MODABBER, F. Z., (O) 597
MODAK, M. S., (A) 224, 362
MOECKLI, R. A., (A) 669
MOFTI, A., (A) 333
MOHAGHEGHPOUR, N., (O) 597
MOHAMMAD, K., (O) 597
MOHAN, N., (A) 417
MOHAN, T. K., (A) 223
MOHANTY, H., (A) 418
MOLERES, R., (A) 422
MØLLER-CHRISTENSEN, V., (B) 210
MONDKAR, A. D., (A) 642
MONZON, H., (A) 528
MORALES, M. J., (A) 395, 672, 674
MORI, T., (A) 101, 103, 107, 228, 368, 369, 397, 667, 673
MORIAMÉ-ROUSSEL, N., (A) 642
MORINI, J. C., (O) 13
MORRISON, N. E., (A) 110, 113, 375, 408, (C) 613, (A) 650, 670, 683
MORROW, R. H., (A) 374
MOULDING, T. S., (O) 601
MOYA, M., (A) 363
MSHANA, R. N., (A) 374, 541, 543
MUFTI, M., (A) 333
MUKHERJEE, A., (A) 223
MUKHERJEE, K. K., (A) 641
MULLER, E. H., (A) 330
MULLER, L. F. B., (A) 327
MUNOZ, H., (A) 231
MUROHASHI, T., (A) 225, 226
MURRAY, J. F., JR., (A) 217, 409, 681, 682
MURTI, J. M. K., (A) 427, 429
MUSTAFA, A. S., (A) 540, 543, 543, 544, 544
MUTATKAR, R. K., (A) 94
MUTHUSAMI, T. C., (A) 532
MYAING, Y. Y., (A) 530, 638
MZKINO, M., (A) 397

NAAFS, B., (O) 7, (A) 76, 85, 374, 427, 452, 546, 651, 655
NABARRA, B., (A) 229
NAGAO, E., (A) 214
NAGY, B. A., (A) 230
NAIK, S. S., (A) 217
NAIR, M. N., (A) 656
NAIR, P. R. R., (O) 50
NAKAMURA, K., (A) 105, 338
NAKAMURA, M., (A) 104, 369, 669
NAKAMURA, R. M., (A) 657
NAKANO, H., (A) 231, 342
NAKAYAMA, T., (A) 102, 369
NAMBA, M., (A) 428, 669
NANWATI, V., (A) 640
NARAIN, R., (A) 657
NARAYANAN, E., (A) 232, 327
NARAYANAN, R. B., (A) 391
NARITA, M., (A) 110
NATH, I., (A) 391
NAVALKAR, R. G., (A) 390
NAVARRETE, J. I., (A) 344
NAZAROV, K. I., (A) 438
NEBOUT, M., (A) 327, 654
NEELAN, P. N., (A) 81, 320
NEGASSI, K., (A) 385
NENGERMAN, I. M., (A) 439, 539, 637
NETO, J. V., (A) 345
NEU, H. C., (A) 644
NEVILLE, P. J., (B) 210, (A) 400, 446
NG, H., (A) 228
NGOAN, T. H., (A) 652
NGUYEN, H. T., (A) 652
NICKERSON, D. A., (A) 677
NIGAM, P., (A) 92, 534, 639
NIMHEDAKAR, K. V., (A) 217
NIRMALA, V., (A) 85
NISHIURA, M., (A) 101, 339, 668
NOMAGUCHI, H., (A) 367, 667
NOORDEEN, S. K., (A) 81, 320
NOSNY, Y., (A) 541
NOUSSITOU, F., (A) 432
NOVALES, J., (A) 414, 544
NURNBERGER, F., (A) 234
NUTI, M., (O) 171, (A) 330, 389, 393, (O) 580
NUTTAL, F. Q., (A) 535
NYEIN, M.-M., (A) 103, 397

OCAMPO, J. C., (A) 436, 440
OCANTO, A., (A) 220, 373, 382, (O) 570
OGASAWARA, T., (A) 214
OGAWA, T., (A) 101, 226
OKADA, S., (A) 101, 665, 668

Okada, Y., (A) 101
Okamura, K., (A) 111
Olivares, L., (A) 450
Oo, K. M., (A) 530, 638
Oon, B. B., (A) 641
Opromolla, D. V. A., (A) 353, 353, 354, 384, 416
Orlowski, E. H., (A) 82
Ortiz, M. C., (A) 452
Ortiz, Y., (A) 383, 394, 535, 539
Otero, R., (A) 529
Ozaki, M., (A) 214
Ozawa, S., (A) 87
Ozawa, T., (A) 115, 419, 422, 669

Packchanian, A., (A) 554
Padierna, J., (A) 376, 383, 396, 539
Pagnano, P. M. G., (A) 375, 389
Palan, V. T., (A) 213
Palande, D. D., (A) 451
Palani, N., (A) 449
Palermo, P., (O) 580
Panchanadam, M., (A) 87
Panda, P. K., (A) 221
Pansare, M. S., (A) 532
Pandya, N. J., (A) 76
Pandya, S. S., (A) 430
Panitch, M. L., (A) 94
Parisis, N., (A) 332, 349, 391, 419
Park, H. B., (A) 234
Park, J. K., (A) 85
Parkash, S., (A) 87
Parvez, M., (A) 643
Pascoe, J. E., (A) 341
Pasqua, J. P., (A) 337, 344
Patel, P. J., (A) 90, 116, 229, 679
Pattyn, S. R., (A) 229, 412, 437, 531, 639
Payro, E., (A) 351
Pearson, J. M. H., (O) 7, (A) 83, 318, 328, 329, 426, (B) 634, (A) 639
Pedroza, E., (A) 394
Pelletier, P., (A) 636
Pennec, J., (A) 80, 84
Pereira, C. A. de C., (A) 388, 421
Pernambuco, J. C. de A. (A) 353, 353, 384
Pérez-Briceno, R., (A) 344
Pérez-Suárez, G., (A) 383
Pervukhin, Yu. V., (A) 378
Peters, J. H., (A) 217, 218, 408, 409, 410, 681, 682
Peters, M., (A) 94
Peterson, L. W., (N) 70
Pettit, J. H. S., (C) 610
Piamphongsant, T., (A) 232
Pichel, A. M., (A) 227
Pinardi, M. E., (A) 338, 379, 386, 415, (O) 570
Pizzariello, G. E. A., (A) 436
Pondman, K. W., (A) 75, 328
Pontiggia, S., (A) 403
Ponzio, H. A. S., (A) 416
Ponzio, T. C., (A) 416
Poulter, L. W., (A) 229, 230
Prabhakaran, K., (A) 223, 359
Prabhudass, N., (A) 541
Prachompol, O., (A) 326, 333, 334
Pradhan, K. S., (A) 339
Pranesh Nigam, S. G. D., (A) 217
Prasad, H. K., (A) 544
Preston, P. M., (A) 653
Price, J., (A) 535
Pritchard, J., (A) 321, 654
Prost, A., (A) 654
Purohit, V. N., (A) 420
Purroy, A., (A) 529

Quesada-Pascual, F., (A) 376, 383, 394, 394, 396, 539
Quiroga, M. J., (B) 209

Rabello, F. E., (A) 347
Radhakrishna, S., (A) 324
Radhakrishnan, K., (A) 215, 429
Raizada, N., (A) 418
Ramanujam, K., (A) 215, 347, (O) 597
Ramirez, L., (A) 350
Rampen, F., (A) 92
Ramu, G., (A) 219, 529, 535, 535, 536, 545, 641, 645
Ranney, D. A., (A) 215
Rao, P. S. S., (A) 214, 322
Rao, S. M. B., (A) 533
Rassi, E., (A) 322, 528
Rastogi, G. K., (A) 532
Ratard, R. C., (A) 92
Rea, T. H., (A) 77, (O) 161, (A) 389, 643, 680
Recipon, A., (A) 401
Reddy, B. S. N., (A) 77
Reddy, R., (A) 84
Redmond, W. B., (A) 225
Rees, R. J. W., (A) 79, 82, 83, 224, 231, 328, 329, 338, 341, 343, 377, 380, 430, 432, 437, 548, 549, 549, 639
Reguer, M., (A) 386
Reich, C. V., (A) 380, (C) 612
Revankar, C. R., (A) 91
Ricart, R., (A) 349
Riccarducci, R., (O) 171, (A) 393
Richardson, E. P., Jr., (A) 642
Ridley, D. S., (C) 63, (A) 86, (O) 161, (A) 350, 380, 415, (C) 611, (A) 636
Ridley, M. J., (A) 86, 393
Rietschel, R. L., (A) 77
Rightsel, W. A., (A) 218
Riji, H. M., (A) 213
Rimon, D., (A) 77
Ringus, J., (O) 561
Roche, J. C., (A) 386
Rodríguez, C., (A) 394
Rodríguez, J. M., (A) 215
Rodríguez, O., (A) 376, 529
Rodríguez-Ochoa, G., (A) 220, 373, (O) 570
Rodríguez-Padilla, A., (A) 450
Rodríguez-Padilla, C., (A) 376, 396

ROJAS-ESPINOSA, O., (A) 383, 394, 394, 422, (C) 521, (A) 539
ROLLER, P., (A) 651
ROLLIER, M., (A) 434, 441
ROLLIER, R., (A) 326, 434, 441
ROLLOLI, L., (A) 553
ROMANO, C. A., (A) 91
ROMERO, G., (A) 396
ROOK, G. A. W., (A) 319, 357, 377, 385
ROSAI, J., (A) 78
ROSE, P., (A) 91
ROSENFELD, M., (A) 81, 81, 434
ROTBERG, A., (A) 322, 355, 388, 636, 640
ROTHENBORG, H. W., (A) 554
ROTTOLI, P., (A) 553
ROUGEMONT, A., (A) 654
ROUX, G., (A) 330
RUBIAL ARES, B. (A) 442
RUBINO, M. J., (A) 342, 550
RUKADIKAR, M. A., (A) 435
RUSSELL, D. A., (A) 329, 334, 435, 655
RYZHOVA, N. YA., (A) 417

SABAPATHY, D. S. P., (A) 325
SADA, M., (A) 87
SAERENS, E. J., (A) 531, 639
SAGARO DELGADO, B., (A) 231
SAHA, K., (O) 1, (A) 86, 219, 223, 545, (C) 614
SAHIB, H. S. M., (A) 545
SAHOO, S. K., (A) 639
SAINT-ANDRÉ, P., (A) 74, 376
SAITO, T., (A) 114, 335
SALGAME, P. R., (A) 537
SAMSON, P. D., (A) 435
SAMUEL, E., (A) 532
SAMUEL, K. C., (A) 217, 534
SAMUEL, N. M., (A) 377, (A) 385
SANABRIA, KH., (A) 652
SANABRIA N., J., (A) 364
SANADA, K., (A) 115, 419, 422, 669
SANCHEZ, R. L., (A) 78
SANCHEZ, R. M., (A) 337, 344, 361, 390, (O) 495, (A) 666
SANCHEZ-CUENCA, J., (A) 330
SANGARD, M., (A) 334
SANSARRICQ, H., (A) 319
SANTABAYA, E., (A) 436
SAOJI, A. M., (A) 223, 223
SARIN, R. C., (A) 87
SASAKI, N., (A) 76, 419, 669
SASIAIN, N. C., (A) 442
SATO, N., (A) 669
SAÚL, A., (A) 215, 351, 396, 551
SAWYERS, M. F., (A) 218
SAXENA, H. N., (A) 534
SAXENA, V. K., (A) 545
SAYLAN, T., (A) 378, 392
SCHEINBERG, M. A., (O) 133
SCHELLEKENS, P. TH. A., (A) 439, 539, 637
SCHIEFFER, H. B., (A) 340
SCHLEE, P., (A) 320
SCHLEIERMACHER, E., (A) 221
SCHMIDT, H., (B) 209
SCHREIBER, A. J., (A) 542
SCHULZ, E. J., (A) 440
SCOLLARD, D. M., (A) 365
SCOTT, G. C., (A) 334, 435
SEAL, K. S., (A) 319
SEBAI, Z. A., (A) 333
SEBILLE, A., (A) 428, 514, 552, 552
SEKIGUCHI, S., (A) 87
SEKKAT, A., (A) 326, 434, 441
SEN, L., (O) 575
SENGUPTA, U., (O) 167, (A) 535, 536, 545
SERIAL, A., (A) 426
SERJEANTSON, S., (A) 86
SHAHA, M. N., (A) 435
SHANKER, A., (A) 640
SHANNON, E. J., (A) 112, 381, 390, 395, 672, 674
SHARDA, D. P., (A) 643
SHARMA, A. K., (A) 391
SHARMA, G. S., (A) 640
SHARMA, K. D., (A) 223
SHARMA, M. K., (A) 546
SHARMA, R. C., (A) 546
SHARMA, S., (A) 87, 650
SHENOY, K. T., (A) 215
SHEPARD, C. C., (A) 90, 115, 329, 435, 654, 655, 677
SHER, R., (A) 546
SHESHADRI, P. S., (A) 529
SHESKIN, J., (A) 218, 224, 402, 433
SHETTY, V., (A) 427, 429
SHIELD, M. J., (A) 319, 357, 377
SHIELDS, E. D., (A) 334
SHRIVASTAVA, K. K., (A) 221
SHRIYAN, S. K., (A) 93
SHUBIN, V., (Ob) 61
SHWE, T., (A) 530, 638, 640
SHYAMA SUNDER, C. V., (A) 657
SIDDHARTHA, T., (A) 341
SIMAO, E. T., (A) 387
SIMMON, V. F., (A) 410
SINGH, A. K., (A) 544, 545
SINGH, G., (A) 77
SINGH, M. P., (O) 18, (A) 349
SINGH, R., (A) 222, 541, 546
SINGH, S., (A) 221
SINGH, U. S., (A) 545
SINHA, S., (A) 535
SINHA, S. N., (A) 224
SKINSNES, O. K., (E) 58, (N) 70, (Ob) 199, (N) 204, (A) 360
SKJAERVEN, R., (A) 319
SLOSAREK, M., (C) 518
SLUVKO, Z. A., 350
SMELT, A. H. M., (A) 224, 377
SMIRNOVA, T. A., (A) 364, 652
SMITH, C. C., (A) 536, 658
SMITH, J. H., (A) 230
SMITH, S. E., (A) 638, 638

Smith, S. R., (A) 382
Smith, T., (A) 221, 320
Smith, W. C. S., (A) 644
Soderstrom, R. M., (A) 216
Solomon, S., (A) 87
Soto, J., (A) 363, 436
Soto Garcia, G., (A) 404
Spargo, R., (A) 428
Sreevatsa, (A) 232, 359, 366, 529, 529, 536
Srivastava, R. N., (A) 92
Stanford, J. L., (A) 319, 357, 377, 385
Staple, E. M., (A) 683
Stek, M., (A) 392
Stella, Sr. M., (B) 211
Stenman, S., (A) 384
Stevens, D. M., (A) 215
Stewart-Tull, D. E. S., (O) 484
Stirling, L., (B) 211
Stone, M. M., (A) 92
Stoner, G. L., (A) 374, 546
Storrs, E. E., (A) 228, 230
Stoupel, E., (A) 642
Stratigos, J., (A) 332, 391
Sturdivant, M. H., (A), 232, 332
Stuttgen, G., (A) 234
Subramaniam, K., (A) 534, 536
Subramanian, S., (A) 87
Sudchit, V., (A) 334
Sugiyama, K., (A) 214
Sundar, P. R., (A) 215
Surasek, S., (A) 326, 333, 334
Suri, S., (A) 429
Sushida, K., (A) 105, 230, 231, 342, 653
Swafford, A. W., (A) 642
Swain, P., (A) 638
Swarbrick, E. T., (A) 638

Tabatabai, H., (O) 597
Taelman, H., (A) 642
Takata, H., (A) 87
Takitaki, F. F., (A) 382
Takitani, S., (A) 110
Takizawa, H., (A) 78
Talarico, L., (O) 121
Talavera, R., (A) 553
Talwar, G. P., 540, 543, 543, 544, 544, 547
Tanaka, W., (A) 410
Tanaka, Y., (O) 487
Tanemura, M., (A) 653
Tarabini, G., (A) 171, 325, 330, 389, 393, (O) 580
Tarabini, G. L., (A) 171, 325, 330, 389, 393, (O) 580
Tatsukawa, H., (A) 682
Taylor, P. M., (A) 538
Teera, R., (A) 326, 333, 334
Tepper, B. S., (O) 126
Terasaki, P. I., (A) 680
Terencio de la Aguas, J., (A) 82, 232, 330, 433
Texier, L., (A) 532
Thamer, G., (A) 330, (O) 580
Than, K. N., (A) 638
Thawerani, H., (A) 78
Theodore, R., (A) 348
Thomas, A., (A) 354, 421
Thomsen, K., (A) 554
Thwe, K., (A) 640
Thyagarajan, S. P., (A) 87
Tin, K. M., (A) 638
Tiphagne, J. L., (A) 324
Tiraboschi-Foss, N., (A) 389
Toledo, G., (A) 231
Tolentino, M. M., (A) 353, 353, 384
Tonello, C. J., (A) 353, 384
Tonetaro, I., (A) 326, 334
Torres, G., (A) 363, 447
Touw, J., (A) 374, 546
Touw-Langendijk, E. M. J., (A) 655
Trach, D. D., (A) 652
Trautman, J. R., (A) 232, 332
Travi, M., (A) 376
Tripathy, N., (A) 639
Tsambaos, D., (A) 420
Tsutsumi, S., (A) 102, 110, 110
Tsvetkova, G. M., (A) 411
Tuculet, M. A., (A) 440
Turk, J. L., (A) 86, 393, 547, 652
Tursi, A., (A) 382

Ulrich, M., (A) 386
Umerov, Z. G., (A) 411
Underdown, R., (A) 430
Utsunomiya, S., (A) 531

Vadez, R., (O) 575
Vaidya, M. C., (A) 321, 341, 341, 391, 393, 418, 537, 542, 644
Vaidyanathan, E. P., (A) 79, 79
Vaidyanathan, S. I., (A) 79
Valdez, R. P., (A) 339
Valdivia, A., (A) 325
van Droogenbroeck, J. B. A., (A) 427, 452
Van Landingham, R. M., (A) 90, 654
Van Rood, J. J., (A) 321
Vargas, P. de O., (A) 388, 640
Varkevisser, C. M., (A) 400, 655
Vaula, D., (A) 319
Vega-Nunez, J., (A) 444
Vegliante, S. N., (A) 364
Vellut, C., (A) 326, 432
Venetsanos, P., (A) 332, 349
Venkatesan, K., (O) 167, (A) 219, 224, 641, 644
Venkatesan, T. V., (A) 82
Verma, B. L., (A) 92
Verma, K. C., (A) 87, 216
Victor, V., (A) 538
Vidyasagar, P. B., (A) 429
Vilaseca, J., (A) 650
Villalba-Pimentel, L., (A) 220, 382
Villarreal, J. O., (A) 331
Vincin, P. R., (A) 334

VINCITORIO, A. G., (A) 351, 449
VIRMANI, V., (A) 651
VIRMOND, M. DA C. L., (A) 327
VISCHER, W., (A) 640
VLASMAN, M., (A) 75
VOGEL, F., (A) 221, 320

WADEE, A. A., (A) 546
WAGNER, H. N., JR., (O) 126
WAHI, P. L., (A) 215
WAKAMATSU, A., (A) 441
WALKER, J. G., (A) 638
WALKER, L. L., (A) 90, 654
WALSH, G. P., (A) 106, 228, 342, 409, 548
WALSH, T. N., (A) 337, 344
WALTER, H., (A) 551
WALTER, J., (A) 319
WARAWDEKAR, W., (A) 642
WARNSDORFF, J., (A) 639
WATERS, M. F. R., (A) 82, 83, 231, 350, 432, 437
WATSON, B., (A) 321, 654
WATSON, S. B., (A) 113
WATSON, S. R., (A) 650, 676
WAUDBY, H., (A) 534
WEBB, L. J., (A) 230
WEE, G. B., (A) 641
WEISSMAN, J. B., (A) 644
WELCH, T. M., (A) 228
WELLS, L. M., (A) 679
WERTHEIN, L. J., (A) 325, 363, 436, 447
WESHLER, Z., (A) 536
WHEATE, H. W., (O) 7, (A) 76, (N) 524, (B) 634
WHITE, S. J., (A) 92
WIERZBICKI, R., (A) 225
WILKINSON, F. F., (A) 364, 440, 442
WOLF, E., (A) 321, 654
WONG, C. K., (A) 76
WONG, J. F., (A) 676
WOODFIELD, D. G., (A) 86
WORTH, R. M., (A) 329, 655

YADAV, S. S., (A) 87, 656
YAMASHITA, K., (A) 547
YAWALKAR, S. J., (O) 37, (A) 436, 640
YIM, B. S., (A) 219
YODER, L., (A) 651
YOGI, Y., (A) 105, 338
YONEDA, K., (A) 107, 667, 673
YOON, C. Y., (A) 234
YOSHIDA, K., (A) 225, 226
YOSHINO, Y., (A) 89, 110, 114, 542
YOUNG, M. R., (A) 653

ZAMBRANO, T., (A) 354
ZARATE, S. R. DE, (A) 325, 363, 436
ZEIJLEMAKER, W. P., (A) 539
ZEIMER, R., (A) 224
ZUNIGA, M., (A) 322

INDEX TO SUBJECTS

Names of authors of original articles (O), editorials (E), and correspondence (C) are distinguished by large and small capital letters. Authors of abstracted articles (A), obituaries (Ob), news and notes (N), and book reviews (B) are in ordinary type. (S) denotes XI International Leprosy Congress materials.

Acedapsone,
in prevention of leprosy, in Micronesia. Russell, D. A., *et al.* ..... (A) 329
(A) 655
in the treatment of 70 lepromatous patients. Samson, P. D., *et al.* ..... (A) 435
trial, status at ten years, in Karimui, New Guinea. Russell, D. A., *et al.* ..... (A) 435

Acetylcholine sweat function test (SFT),
effect of therapeutic regimens, in tuberculoid leprosy. Venetsanos, P., *et al.* ..... (A) 349

Acid,
ascorbic, immunological effects and hazards. ..... (A) 529
fatty, radiometric measurement of differential metabolism of, by *M. lepraemurium.*
CARMARGO, E. E., *et al.* ..... (O) 126
— serum free, glucose tolerance in leprosy. Bharadwaj, V. P., *et al.* ..... (A) 641
mycolic, detection of, in leprous tissue. DEVI, S. and STEWART-TULL, D. E. S. ..... (O) 484

Acid-fast characteristics,
bacilli, attenuation of drug-treated murine leprosy, in mice, A. examination of mice
administered drugs, B. examination of drug resistance. Sushida, K. ..... (A) 230
figures of multiplication, in nude mice macrophages. Fukunishi, Y., *et al.* ..... (A) 668
large bodies, in leprosy material. Nakayama, T. and Endo, H. ..... (A) 102
(A) 369
of *M. leprae,* problems raised by its cultivation. Delville, J. ..... (A) 357
pyridine extractability of, from *M. leprae.* MCCORMICK, G. T. and SANCHEZ, R. M. .. (O) 495

Acro-osteolysis,
in Hansen's disease. Moleres, R. and Enna, C. D. ..... (A) 422

Adenosine 3′:5′-monophosphate,
phagosome-lysosome fusion, in macrophages, infected with mycobacteria. Lowrie,
D. B., *et al.* ..... (A) 649

Africa,
Ethiopia, ALERT, announces provisional program of courses for 1979–1980. ..... (N) 524
—, —, holds Conference on Leprosy Training. ..... (N) 523
—, —, Kellersberger Memorial Lecture given by Dr. R. C. Hastings. Wheate, H. W. (N) 524
—, —, Mr. Onni Niskanen appointed Executive Director. ..... (N) 202
—, dapsone-resistant leprosy in. Pearson, J. M. H., *et al.* ..... (A) 639
Francophone, mass anti-leprosy campaigns in. Nebout, M. ..... (A) 327
Leprosy Mission sponsors seminars in. ..... (N) 66
Malawi, dermatological clinic in, leprosy control scheme in, ten years' experience.
Rampen, F. ..... (A) 92
metabolic disposition of dapsone in . . . leprosy patients. Peters, J. H., *et al.* ..... (A) 217
Morocco, leprosy in. Sekkat, A., *et al.* ..... (A) 326
—, relapse and dapsone resistance in. Rollier, M., *et al.* ..... (A) 434
Sierra Leone, leprosy statistics. ..... (N) 203
—, Rev. Rocco Serra receives Award of Officer of the Order of Rokel (O. R.). ..... (N) 203
Somalia, leprosy control campaign in, integration into National Health Services.
Tarabini, G. L. and Tarabini, G. ..... (A) 325
South Africa, genetic markers and leprosy in . . . Negroes. Hitzeroth, H. W., *et al.* ... (A) 551
Tanzania, Leprosy Association, inauguration of. ..... (N) 66
Uganda, genetic factors, of children in, in leprosy. White, S. J., *et al.* ..... (A) 92

ALERT (All Africa Leprosy and Rehabilitation Training Centre),
announcement of provisional program of courses for 1979–1980. ..... (N) 524
Conference of Leprosy Training held by. ..... (N) 523

Kellersberger Memorial Lecture given by Dr. R. C. Hastings. Wheate, H. W. .....(N) 524
Mr. Bernt Johannessen appointed new Executive Director. .....(N) 202
Mr. Onni Niskanen retires as Executive Director. .....(N) 202

Allergy,
experimental allergic neuritis. Vaidya, M. C., *et al.* .....(A) 341
tuberculin, effect on, of earlier tuberculin tests. Narain, R., *et al.* .....(A) 657

American Leprosy Missions,
19th Annual International Seminar on Leprosy meets in April 1978 at Carville. .....(N) 71
21st Annual International Seminar on Leprosy to meet in April 1980 at Carville. .....(N) 620

Amyloidosis,
secondary, in leprosy. Sharma, S., *et al.* .....(A) 87

Anetoderma,
Schweninger–Buzzi type, in hanseniasis patients. Magarido, L. and Rotberg, A. .....(A) 355

Antibiotics,
aminoglycoside, killing potential of, for *M. leprae*. Gelber, R. and Gibson, J. .....(A) 684

Antibody,
activity against *M. leprae* antigen 7, in leprosy, studies on variation in content, effect on DDS treatment and BT relapse. Yoder, L., *et al.* .....(A) 651
anti-connective tissue, in leprosy. Fleury, R. N., *et al.* .....(A) 384
formation of, against *M. leprae* antigen 7, in armadillos. Harboe, M., *et al.* .....(A) 548
hepatitis B surface antigen, incidence of, in liver disease, blood donors, leprosy patients. Thyagarajan, S. P., *et al.* .....(A) 87
injection with hepatitis B virus, detection of surface antigen, by radioimmunology, in leprosy. Chiron, J. P., *et al.* .....(A) 532
M. leprae specific, detected by radioimmunoassay. Harboe, M., *et al.* .....(A) 84
reacting with fibroblasts, Schwann cells, and connective tissue microfibrils, in leprosy. Linder, E., *et al.* .....(A) 384
response in rabbits, to *M. bovis* BCG. Mshana, R. N., *et al.* .....(A) 543
studies, revival of interest in, in leprosy. Harboe, M. and Closs, O. .....(A) 372
synthesis *de novo*, effect of thalidomide on. Shannon, E. J., *et al.* .....(A) 381

Antigen (hepatitis),
e-(HB_eAg), in leprosy. Nuti, M., *et al.* .....(A) 330
hepatitis B, incidence of positivity, in Korean leprosy patients. Choi, S. R. and Chung, W. K. .....(A) 329
— surface, antibody, incidence of, in liver disease, blood donors, and leprosy patients. Thyagarajan, S. P., *et al.* .....(A) 87
—, in Calcutta leprosy patients, prevalence, subtypes, Chakrabarty, M. S., *et al.* .....(A) 641
incidence of HB_eAg and Ag"e"/Ac anti-"e" system in hospital patients, with Hansen's disease type L. Terencio de las Aguas, J., *et al.* .....(A) 330
infection with hepatitis B virus, detect of surface . . . and antibody, in leprosy, by radioimmunology. Chiron, J. P., *et al.* .....(A) 532
persistence of Australia (Au), in leprosy. Saoji, A. M. and Mene, A. R. .....(A) 223

Antigen (leprosy),
analysis of *M. leprae*. Closs, O., *et al.* .....(A) 374
conversion of Mitsuda negative normals into Mitsuda positive through repeated testing. Pinardi, M. E. and Convit, J. .....(A) 379
Dharmendra, assessment of. Sengupta U., *et al.* .....(A) 545
—, comparison of reactions, of leprosy patients, in normal skin and lesions. Price, J., *et al.* .....(A) 535
fractionation of, from *M. leprae*. Gillis, T. P. and Buchanan, T. H. .....(A) 674
from cutivable acid-fast bacilli from *M. leprae*, isolated from lepromatous nodules, comparative study on skin reactions to *M. leprae*-lepromin and ICRCin. Bapat, C. V. .....(A) 381
histocompatibility, in Iranian leprosy patients. MOHAGHEGHPOUR, N., *et al.* .....(O) 597
HLA-DRW, in Mexican leprosy patients. Rea, T. H. and Terasaki, P. I. .....(A) 480
homologous and heterologous, delayed hypersensitivity skin reactions, in immunized

guinea pigs, with *M. leprae* and four other mycobacterial strains. Mustafa, A. S. and Talwar, G. P. ..... (A) 543
immunization of mice, with *M. leprae*. Shepard, C. C. and Minagawa, F. ..... (A) 115
interrelationships, among selected mycobacterial species, relative to *M. leprae*, in guinea pigs, manifested by cell-mediated immunity. Shannon, E. J., *et al.* ..... (A) 674
—, of *M. leprae*, studies on. Hastings, R. C., *et al.* ..... (A) 112
intracytoplasmic *M. leprae*, demonstration of, in inflammatory exudate of reactional lepromatous leprosy. González-Mendoza, A., *et al.* ..... (A) 383
lepromin induced suppressor cells, mediation by TH_2+ T-cell subset. Mehra, V., *et al.* ..... (A) 679
liver tissue, cross-reactions between serum proteins and, of nine-banded armadillo and man. Negassi, K., *et al.* ..... (A) 385
Mitsuda, of animal origin, absence of hanseniasis in armadillos living in natural state, human hypersensitivity to animal . . . . Pereira, C. A. de C. and Almeida Brandao, C. B. P. ..... (A) 388
M. leprae and *M. vaccae* cytoplasmic protein, delayed hypersensitivity responses to. Collins, F. M. and Morrison, N. E. ..... (A) 375
M. leprae . . . 7, antibody activity against, during first year DDS treatment, in lepromatous (BL-LL) leprosy. Melsom, R., *et al.* ..... (A) 85
—, studies on variation, effect on DDS treatment, relapse in BT leprosy. Yoder, L., *et al.* ..... (A) 651
—, formation of antibody against, in armadillos. Harboe, M., *et al.* ..... (A) 548
M. leprae specific protein, identification of, application for serodiagnosis. CALDWELL, H. D., *et al.* ..... (A) 114
(O) 477
non-myelin human nerve, producing granulomatous hypersensitivity, in rabbits. Hardwicke, P. M. D. and Crawford, C. L. ..... (A) 341
reactions, cultivated *M. leprae* and. Skinsnes, O. K. ..... (A) 360
sensitized T-cell, proliferative response, to lepromin, Wong, J. F. ..... (A) 676
sensory peripheral nerve as, skin lesions, granulomatous hypersensitivity, and cutaneous nerve damage induced by. Crawford, C. L. and Hardwicke, P. M. D. ... (A) 340
skin reactions, comparative study of, to *M. leprae* lepromin, from cultivable saprophytic mycobacteria, in leprosy patients. Sharma, R. C. and Singh, R. ..... (A) 546
—, delayed hypersentivity, to lepromin, prepared from four other mycobacteria. Govil, D. C. and Bhutani, L. K. ..... (A) 540
—, observations on, induced by lepromin. Sahib, H. S. M. and Vellut, C. ..... (A) 545
skin-reactive, of *M. leprae*. Ulrich, M., *et al.* ..... (A) 386
soluble cytoplasmic mycobacterial, effect of, double blind trial on, on reactivity to lepromin. Haddad, N., *et al.* ..... (A) 389
— *M. leprae* and *M. tuberculosis*, mechanisms regulating skin test responsiveness, in leprosy patients. Samuel, N. M., *et al.* ..... (A) 385
specific leprosy, isolated by affinity chromatography, using gel immobilized lepromatous IgG as stationary phase. Reich, C. V. ..... (A) 380
substances of *M. leprae*. Mzkino, M., *et al.* ..... (A) 397

Antigen (miscellaneous),
relationships among *M. vaccae*, *M. nonchromogenicum*, and *M. leprae*. Collins, F. M., *et al.* ..... (A) 113

Argentina,
Argentine Society of Leprosy celebrates Silver Anniversary. Hastings, R. C. ..... (N) 618
armadillos, autochthonous, *M. leprae* inoculation into 3 species of. Baliña, L. M., *et al.* ..... (A) 339

Armadillo (eight banded) (*Dasypus sabanicola*),
experimental leprosy in. Convit, J., *et al.* ..... (A) 338
histopathology of experimental leprosy in, and in nine-banded armadillos. McDougall, A. C., *et al.* ..... (A) 343

Armadillo (nine-banded) (*Dasypus novemcinctus*),
autochthonous, inoculation of *M. leprae* into 3 species of, in Argentina. Baliña, L. M., *et al.* ..... (A) 339

blunders on, Lampe, D. ..... (A) 89
cell-mediated immunity of, effect of specific vaccine on, against, *M. leprae*. Kirchheimer, W. F., *et al.* ..... (A) 390
continuing saga of GSRI. ..... (N) 205
-derived, *M. leprae*, purified, lymphocyte response of leprosy patients to. Smelt, A. H. M., *et al.* ..... (A) 224
examination for mycobacteriosis. Kirchheimer, W. F. ..... (A) 550
— of North American, for mycobacteriosis. Sanchez, R. M. and Kirchheimer, W. F. ..... (A) 361
experimental animal in biomedical research. ..... (A) 633
— leprosy in, imported into U.K. from U.S.A. Rees, R. J. W. and Lowe, C. ..... (A) 338
formation of antibody against *M. leprae* antigen 7 in. Harboe, M., *et al.* ..... (A) 548
histopathology of experimental leprosy in, and eight banded armadillos. McDougall, A. C., *et al.* ..... (A) 343
indigenous leprosy in. Convit, J. ..... (A) 548
—. Meyers, W. M. ..... (A) 337
—. Walsh. G. P., *et al.* ..... (A) 342
infected, studies on *M. leprae* from. Draper, P. ..... (A) 357
lepromin, compared to human lepromin, double blind trail to determine late reactivity of leprosy patients and unaffected persons to different concentrations. Bechelli, L. M., *et al.* ..... (A) 375
—, leukocyte migration inhibition, in human lymphocytes of healthy donors. Fumarola, D. and Jirillo, E. ..... (A) 84
leprous and uninfected macrophages, peroxidase and acid phosphatase, electron microscopy of. McKeever, P. E., *et al.* ..... (A) 228
liver, mycobacterial surface protein antigens, immunochemical and structural integrity of, during separation. Caldwell, H. D. and Buchanan, T. M. ..... (A) 469
liver tissue antigens of, and of man, cross-reactions between serum proteins and. Negassi, K., *et al.* ..... (A) 385
metabolic disposition of dapsone (DDS) and rifampin (RFM) in. Murray, J. F., Jr., *et al.* ..... (A) 409
ocular histopathology, *M. leprae* infections in. McDougall, A. C. and Rees, R. J. W. (A) 549
quantitative aspects of experimental infection of, with *M. leprae*. Kirchheimer, W. F., *et al.* ..... (A) 337
serum glycoprotein studies in, experimentally infected with *M. leprae*. Harris, E. B., *et al.* ..... (A) 344
susceptibility of, to *M. leprae* infection. Innami, S., *et al.* ..... (A) 339
tissue cultures, studies on *M. leprae*. Fieldsteel, A. H., *et al.* ..... (A) 669
wild, leprosy-like disease in. Meyers, W. M., *et al.* ..... (A) 106
—, — French Acadiana, Louisiana. Smith, J. H., *et al.* ..... (A) 230

Art,
fundamentals of the term "Facies Antonina." Kremer, A. and Elsler, E. ..... (A) 351

Arteries,
manifestations in two leprosy cases. David-Chaussé, J., *et al.* ..... (A) 532
vascular changes in leprosy, arteriographic evaluation. Yadav, S. S. ..... (A) 87

Arthritis,
in lepromatous Hansen's disease. Pernambuco, J. C. de A., *et al.* ..... (A) 353

Arthropathy,
inflammatory, in leprosy. Alcocer, J., *et al.* ..... (A) 350

Arthropods,
role of, in transmission of leprosy. Bedi, B. M. S., *et al.* ..... (A) 327

Asia,
carbol fuchsin staining of mycobacteria in Southeastern . . . leprosy institutes of, and Japan. Harada, K., *et al.* ..... (A) 102
latent and chronic infections imported, from Southeast. Barrett-Connor, E. ..... (A) 74

Athymic rat,
immunological status and infection, with *Mycobacterium leprae* in. Colston, M. J., *et al.* ..... (A) 679

Australia,
no enforced segregation in. HARGRAVE, J. C. ..... (C) 64
Northern Territory of Australia, leprosy policy. ..... (A) 635
peripheral nerve biopsies in Aboriginal patients, in Northern Territory. McDougall, A. C., *et al.* ..... (A) 534

Autoantibodies,
in leprosy. Masala, C., *et al.* ..... (A) 393

B8,
increased frequency of, HLA and mycobacterial infection, in Japanese leprosy. Takata, H. ..... (A) 87

B1912,
abortifacient activity of. MORRISON, N. E. ..... (C) 613
pregnant mice, effect on, fed in diet. REICH, C. V. and DE LA CRUZ, E. ..... (C) 612

Bacteremia,
evaluation of, in leprosy patients. Desikan, K. V. and Sreevatsa. ..... (A) 359
—, —. Sreevatsa, *et al.* ..... (A) 536

Bacteriology,
bacillary population, studies of uninvolved skin. Kaur, S. and Kumar, B. ..... (A) 222
study of a rapidly growing strain of mycobacterium. Saxena, V. K., *et al.* ..... (A) 545

BCG,
delayed type hypersensitivity to, strain difference, genetic control in mice. Nakamura, R. M. and Tokunaga, F. ..... (A) 657
immunotherapy, study of immunity, after 3 year interval. Baranton, G., *et al.* ..... (A) 386
— trial of, in lepromatous leprosy. Kim, D. I. ..... (A) 387
infection, in an immunodeficient child, treated with transfer factor. Sharma, M. K., *et al.* ..... (A) 546
—, in mice, interaction of *M. lepraemurium*. Lefford, M. J. ..... (A) 678
lymphocyte response of leprosy patients. Smelt, A. H. M., *et al.* ..... (A) 224
M. bovis, antibody response in rabbits. Mshana, R. N., *et al.* ..... (A) 543
—, phagosome-lysosome fusion, cyclic adenosine 3′:5′-monophosphate, in infected macrophages. Lowrie, D. B., *et al.* ..... (A) 649
protective efficacy of, in Burma, reasons for reduction of. Shield, M. J., *et al.* ..... (A) 319
soluble antigens of, crossed immunoelectrophoretic analysis, cross-reactions between mycobacteria. Harboe, M., *et al.* ..... (A) 540
vaccination, immunity to *M. leprae* infections, in mice. Shepard, C. C., *et al.* ..... (A) 90

Belgium,
Institute of Tropical Medicine meets in Antwerp. ..... (N) 67
24th World Conference of the International Union against Tuberculosis meets in Brussels. ..... (N) 67

B-glucuronidase,
absence of, in *M. leprae*, elevation of infected tissue enzyme. Prabhakaran, K., *et al.* ..... (A) 223
serum, in leprosy. Venkatesan, K., *et al.* ..... (A) 644

Bible,
non-stigmatizing. Rotberg, A. ..... (A) 636

Biochemistry,
comparative, infectious disease drug design. Cohen, S. S. ..... (A) 637

Biopsy,
human skin, cultivation of *M. leprae* from. Scollard, D. M. and Honey, N. R. ..... (A) 365
in vito studies, from leprosy cases, Goyle, S. and Virmani, V. ..... (A) 651

muscle, electromyographic recording, in lepromatous leprosy. Sebille, A. and Gray, F. ..... (A) 552
—, routine, examination data, in leprosy. Gray, F., *et al.* ..... (A) 541
nerve, peripheral, diagnosis of leprosy, in Aboriginal patients. McDougall, A. C., *et al.* ..... (A) 534

Blastogenesis,
T and B lymphocytes, in leprosy. Sharma, S., *et al.* ..... (A) 650

Blood,
defective, mononuclear phagocyte function, in leprosy patients. Estevez, M. E., *et al.* ..... (O) 575
hypoalbuminemia, and dapsone. Kingham, J. G. C., *et al.* ..... (A) 638

Blood groups,
ABO, and leprosy. Datar, S. V., *et al.* ..... (A) 532

Blood vessels,
cutaneous, histopathological findings, in untreated lepromatous leprosy. Coruh, G. and McDougall, A. C. ..... (O) 500

Bly, M.,
personal. ..... (N) 204

Bone,
absorption, in fingers, in leprosy, ten-year radiologic study. MacMoran, J. W. and Brand, P. W. ..... (A) 671
changes in the foot, etiology of, population-based study. Karat, S. ..... (A) 418
loss, alveolar, in leprosy, cellular basis for. Marks, S. C., Jr., and Subramaniam, K. .. (A) 534
—, —, —, clinical and radiologic study, Subramaniam, K. and Marks, S. C., Jr. ..... (A) 536
—, extremity, cellular basis for, in leprosy. Marks, S. C., Jr. ..... (O) 26

Bone marrow,
-derived macrophages, *in vitro*, growth of *M. lepraemurium*. Alexander, J. and Smith, C. C. ..... (A) 536
histiocytes, leprosy's footprints in. Lawrence, C. and Schreiber, A. J. ..... (A) 542
in tuberculoid leprosy. Koranne, R. V., *et al.* ..... (A) 222

Borderline leprosy (dimorphous and intermediate),
characteristics of, in the Dominican Republic. Martinez, D. and Ricart, R. ..... (A) 349
development of reactions, in patients, time interval between start of anti-leprosy treatment. Naafs, B. and Wheate, H. W. ..... (A) 76
leprous dactylitis of all fingers in a case of. Alexander, R., *et al.* ..... (A) 354
nasal mucosa, significance of changes in. Chacko, C. J. G., *et al.* ..... (A) 538
reactions, *in vitro* lymphocyte responses in. Bjune, G. and Barnetson, R. St. C. ..... (A) 396
relapse, *M. leprae* antigen 7, antibody activity against, antibody content variation. Yoder, L., *et al.* ..... (A) 651
short course rifampin treatment of. Bourland, J. and Pattyn, S. R. ..... (A) 437

Brazil,
changes in criteria for granting HD medical certificates. ..... (N) 619
College of Hansenology announces changes. ..... (N) 619
Hanseniasis: Abstracts and News temporarily ceases publication. ..... (N) 619
Phase III of prevention. Rotberg, A. ..... (A) 322
social aspects of leprosy in Pará State, Amazon valley. Appel, G. E. ..... (A) 405
unification of hanseniasis policies detailed. ..... (N) 619

Browne, S. G.,
personal. Gordon G. ..... (N) 616

Bureau Barriere syndrome,
and leprosy. Galli, J. J. and Vincitorio, A. G. ..... (A) 351

Burma,
BCG in, reduction of protective efficacy of, reason for. Shield, M. J., *et al.* ..... (A) 319
reliability of dapsone self-administration, in Rangoon, in leprosy patients. Gyi, K. M., *et al.* ..... (A) 530

—, in Burma, —. Hagan, K. J., *et al.* ..... (A) 638
rifampin, efficacy and tolerability of, in Burmese lepromatous leprosy patients. Shwe, T. *et al.* ..... (A) 640

C3H mouse,
partial inhibition of *M. lepraemurium* growth in, immunized with cell wall skeletons. Tanaka, Y. ..... (O) 487

Canada,
1980 World Congress of Rehabilitation Internationl to be held in Winnipeg. ..... (N) 68
Le Secours aux Lépreux (Canada), Inc. presents 1978 Raoul Follereau Award to Dr. C. C. Shepard. ..... (N) 72

Cancer,
carcinogenic activity of dapsone. Bergel, M. ..... (A) 410
malignant neoplasm, relation to DDS carcinogenicity, in leprosy patients. Namba, M., *et al.* ..... (A) 669
mutagenesis-carcinogenesis of antileprosy drugs, in animal systems, pertinence to man. Peters, J. H., *et al.* ..... (A) 410
squamous cell carcinoma, arising from trophic ulcers. Boopalraj, J. M. and Muthusami, T. C. ..... (A) 532
—, complication of plantar ulcer, in leprosy. Opromolla, D.V.A. and Fleury, R. N. ... (A) 354

Cat leprosy,
feline non-tuberculous mycobacterial skin disease resembling leprosy, experimental transmission of. Schiefer, H. B. ..... (A) 340

Cell(s),
division, in *M. lepraemurium*, intracytoplasmic membrane systems, electron microscopic observations. Hirata, T. ..... (O) 585
envelopes, of *M. leprae* and *M. lepraemurium*, comparative ultrastructure. Nguyen, T. H., *et al.* ..... (A) 652
-free liquid medium, cultivation trials, *M. leprae* growth, in ND-15 MT and ST medium. Nakamura, M. ..... (A) 104
—, —, *M. leprae*, subsequent results. Nakamura, M. ..... (A) 669
populations, immunosuppressive, in experimental mycobacterial infection. Bullock, W. E., *et al.* ..... (A) 226
responses, mononuclear-phagocyte series, in leprosy and related diseases. Ridley, M. J., *et al.* ..... (A) 393
suppressor, decreased activity in leprosy and other disseminated granulomatous infections. Artz, R. P., *et al.* ..... (A) 680
—, splenic, in *M. lepraemurium* infected mice. Bullock, W. E., *et al.* ..... (A) 677
T-, sensitized, lepromin, proliferative response to. Wong, J. F. ..... (A) 676
—, suppressor, lepromin induced. Mehra, V., *et al.* ..... (A) 679
—, —, production, in infected mice. Watson, S. R. and Collins, F. M. ..... (A) 676

Cell culture,
of *M. leprae* and *M. lepraemurium*, studies on. Nomaguchi, H., *et al.* ..... (A) 368

Cell-mediated immunity,
effect of specific vaccine on, of armadillos, against *M. leprae*. Kirchheimer, W. F., *et al.* ..... (A) 390
induction, in mice, to *M. leprae*. Patel, P. J. and Lefford, M. J. ..... (A) 90
—, to human *M. leprae*, in guinea pigs. Mehra, V. and Bloom, B. R. ..... (A) 111
manifestation, in guinea pigs, antigenic relationships, in selected mycobacteria relative to *M. leprae*. Shannon, E. J., *et al.* ..... (A) 674
methods of stimulating, in lepromatous leprosy. Saint-André, P., *et al.* ..... (A) 376
relation between delayed-type hypersensitivity and. Turk, J. C. ..... (A) 547
to *M. leprae*, in guinea pigs. Mehra, V. and Bloom, B. R. ..... (A) 649
—, in mice. Lefford, M. J. ..... (A) 372

Cell walls,
skeletons, used to immunize C3H mice, *M. lepraemurium* growth, partial inhibition of. Tanaka, Y. ..... (A) 487

Chemical compounds,
investigation of, with antileprosy activity. BERGEL, M. ..... (C) 63

Chemoprophylaxis,
against leprosy, studies on. Noordeen, S. K. and Neelan, P. N. ..... (A) 81

Chemotaxis,
in lepromatous leprosy. Azulay, R. D. ..... (A) 345

Chemotherapy,
activity of agents, clinical and experimental evaluation. Freerksen, E. and Rosenfeld, M. ..... (A) 81
combined, and immunotherapy, short-term leprosy treatment, pilot trial. León, A. P. and Silva, J. H. ..... (A) 440
(A) 530
—, in leprosy. Freerksen, E., *et al.* ..... (A) 81
—, in leprosy. Yim, B. S. and Kim, D. I. ..... (A) 219
— therapy in leprosy, practical experience with. Rosenfeld, M., *et al.* ..... (A) 434
experimental, workshop on. ..... (S) 297
for leprosy and anterior uveitis. Okamura, K. ..... (A) 111
in Hansen's disease, clinical course and prognosis. Takizawa, H. ..... (A) 78
joint trial meeting. ..... (B) 630
"Mandukaparni," common Indian herb effective against leprosy. Chaudhuri, S., *et al.* ..... (A) 411
(A) 637
of lepromatous leprosy, persistence and drug resistance of *M. leprae*. Levy, L. ..... (A) 408
— leprosy, with nude mice. Kohsaka, K., *et al.* ..... (A) 107
(A) 673
rational, of leprosy. Prabhakaran, K., *et al.* ..... (A) 359
two trials, statistical analysis, in lepromatous leprosy. U.S. Leprosy Panel and the Leonard Wood Memorial. ..... (A) 219
workshop on experimental. ..... (S) 297

Child(ren),
DDS chemoprophylaxis for, with leprosy. Lara, C. B. ..... (A) 216
early signs of leprosy in. Saúl, A. ..... (A) 215
effect of leprosy in mothers on, before and after birth. Duncan, M. E. ..... (A) 350
genetic factors in leprosy, in Uganda. White, S. J., *et al.* ..... (A) 92
immunodeficient, BCG infection in, with transfer factor. Sharma, M. K., *et al.* ..... (A) 546
Iranian, clinical and epidemiological study of leprosy in. Assefi, V. ..... (A) 323
leprosy in. Harris, R. C. ..... (A) 74
school, with leprosy, associated cases in families. Ganapati, R., *et al.* ..... (A) 91
two cases of leprosy in. Rodriguez, J. M. and Stevens, D. M. ..... (A) 215

Chimpanzee,
leprosy in, morphology of skin lesions. Leininger, J. R., *et al.* ..... (A) 550
spontaneous leprosy in. Leininger, J. R., *et al.* ..... (A) 342

Chipmunk,
Korean, diagnosis of tuberculosis using. Bae, C. D. and Choi, T. K. ..... (A) 552

Cholesterol,
growth factor for mycobacteria from leprous tissues. Kato, L. ..... (A) 358

Chromotography,
affinity, specific leprosy antigen isolated by, using gel immobilized lepromatous IgG as stationary phase. Reich, C. V. ..... (A) 380

Classifcation, leprosy,
clinical spectrum of leprosy. Opromolla, D. V. A. and Fleury, R. N. ..... (A) 416
importance of lipid staining in. Garriso Neves, R. and Azulay, R. D. ..... (A) 420
polar concept, as it stands today. Rabello, F. E. ..... (A) 347
Ridley-Jopling, features of. AHMED, H. A. ..... (C) 611
—, —. RIDLEY, D. S. ..... (C) 611
—, —, clinical application. KUNDU, S. K. ..... (C) 64

—, five group, correlations of parameters, in 1,429 leprosy patients. Meyers, W. M., *et al.* ..... (A) 683
spectrum of leprosy, intermediate zone. McDougall, A. C. ..... (A) 348
three instructive cases. Jopling, W. H. and Ridley, D. S. ..... (A) 415

Clofazimine (B663) (Lamprene),
and sulfones, association in leprosy treatment. Terencio de las Aguas, J. and Gatti, C. F. ..... (A) 82
favorable effect in lepromatous leprosy. Cottenot, F. and Pennec, J. ..... (A) 80
in leprosy. Yawalkar, S. J. and Vischer, W. ..... (A) 640
mechanism of action of. Morrison, N. E. ..... (A) 408
mode of action. Tsutsumi, S. and Morrison, N. E. ..... (A) 110
treatment of pyoderma gangrenosum. Thomsen, K. and Rothenborg, H. W. ..... (A) 554
use in leprosy treatment. Venkatesan, T. V. ..... (A) 82

Colchicine,
effect of, on serum amyloid A elevation, during ENL. McAdam, K. P. W. J., *et al.* ... (A) 382

Contacts, leprosy,
healthy, lymphocyte transformation test in, exposure in households. MENZEL, S., *et al.* ..... (O) 138
(A) 374
—, —, influence of consanguinity. MENZEL, S., *et al.* ..... (O) 153
household, of leprosy patients, management of. Filice, G. A. and Fraser, D. W. ..... (A) 90
—, primary leprosy involvement of nasal mucosa. Chacko, C. J. G., *et al.* ..... (A) 417
immunologic skin titration in. CAUZZI, N. J., *et al.* ..... (O) 13

Control of leprosy,
and prevention, of water-related diseases, in the tropics. ..... (N) 68
Brazilian Phase III of prevention. Rotberg, A. ..... (A) 322
computer usage in. Ferreira, J., *et al.* ..... (A) 327
current societal attitudes, role of National Leprosy Control Centre, Sungei Buloh, Malaysia. Kandiah, N., *et al.* ..... (A) 213
day in the life of Yeeranna, a cautionary tale. Davey, T. F. ..... (A) 550
eradication project in Malta, 6 year report. Depasquale, G. and Bonnici, E. ..... (A) 332
evaluation of mass campaigns, in Francophone Africa. Nebout, M. ..... (A) 327
footwear manual in. Neville, P. J. ..... (B) 210
guide to. Kapoor, P. ..... (B) 208
importance of surgery in a national program. Giraudeau, P. ..... (A) 448
in Cuba, 1977, new program. Ruiz de Zarate, S., *et al.* ..... (A) 325
in Guyana, integrated. McDougall, A. C. and Rose, P. ..... (A) 91
in Mahasarakam Province, northeastern Thailand, 20 year results. Prachompol, O., *et al.* ..... (A) 334
in Morelos, Mexico. Villarreal, J. O. ..... (A) 331
in Shanghai, China. CHANG, Y. T. ..... (E) 56
(C) 201
in Somalia, integration into National Health Services. Tarabini, G. L. and Tarabini, G. ..... (A) 325
in the Dominican Republic (1973–1977). Bogaert, H. D. and Martinez, D. ..... (A) 331
in the western Pacific. ..... (N) 204
integration into Provincial Health Service, of Phuket Island, Southern Thailand, five year results. Surasak, S., *et al.* ..... (A) 326
laboratory aids in. Guinto, R. S. ..... (A) 318
Leprosy Board of Paraguay, present program of. Masi, D. A. ..... (A) 405
leprosy in primary health care. Gonzáles Galvan, A. ..... (A) 320
non-medical objectives of. Neville, P. J. ..... (A) 400
official program, history, in Mexico. Ayala Uribe, G. ..... (A) 325
operational classification in. Bernardi, C. D. V., *et al.* ..... (A) 327
prevention of leprosy. Kaur, P. ..... (A) 91
prospects for. Lechat, M. F. ..... (A) 318
reason for reduction of BCG protective efficacy in Burma. Shield, M. J., *et al.* ..... (A) 319

relapse after release. Touw-Langendijk, E. M. J. and Naafs, B. ..... (A) 655
scheme using dermatological clinic, in Malawi, ten years' experience. Rampen, F. ..... (A) 92
social aspects, research methodology. Varkevisser, C. M. ..... (A) 655
strategy of. World Health Organization. ..... (A) 93
urban, perspectives in. Chaudhury, D. S., *et al.* ..... (A) 323
workshop on. ..... (S) 304

Cord factor (trehalose-6,6′-dimycolate),
of *in vivo* derived *M. lepraemurium*. Goren, M. B., *et al.* ..... (A) 651

Coronary heart disease,
in leprosy patients. Diamantopoulos, E., *et al.* ..... (A) 419

Corynebacteria,
immunological relatedness of ribosomes, from mycobacteria, nocardiae, and . . . , and microorganisms in leprosy lesions. Laub, R., *et al.* ..... (A) 542

C-reactive protein (CRP),
in leprosy. SCHEINBERG, M. A., *et al.* ..... (O) 133

Cross-reactivity,
between mycobacteria, crossed immunoelectrophoretic analysis, of soluble antigens of BCG. Harboe, M., *et al.* ..... (A) 541
— serum proteins and liver tissue antigens, of nine banded armadillo and man. Negassi, K., *et al.* ..... (A) 385

Cuba,
clinico-epidemiologic study at "El Rincon" hospital. Diaz Almeida, J., *et al.* ..... (A) 231
medical and socio-economic rehabilitation, of leprosy patients. Werthein, L. J., *et al.* (A) 447
new program of leprosy control, 1977. Ruiz de Zarate, S. ..... (A) 325
rifampin, treatment, of 5000 leprosy patients with. Abreu, A., *et al.* ..... (A) 436

Cultivation, mycobacteria,
acid-fastness of, and problems raised by. Delville, J. ..... (A) 357
etiologic agent. Pan American Health Organization. ..... (B) 631
from human skin biopsy. Scollard, D. M. and Honey, N. R. ..... (A) 365
M. leprae, in vitro, in a lepromatous leprosy case. Massalski, W. K. ..... (A) 225
—, isolation, using semisynthetic solid agar medium. Murohashi, T. and Yoshida, K. (A) 225
—, stimulating effect of leucine. Murohashi, T. and Yoshida, K. ..... (A) 226
M. lepraemurium, continuous *in vitro* growth. Dhople, A. M. and Hanks, J. H. ..... (A) 103
—, pathogenicity of bacilli, from smooth colonies. Kawaguchi, Y., *et al.* ..... (A) 549
—, in flask system. Nakamura, M. ..... (A) 369
—, —, of Hawaiian-Ogawa strain in mice. Kawaguchi, Y., *et al.* ..... (A) 653

Cytochrome,
oxidase and peroxidase of *M. leprae, M. lepraemurium, M. tuberculosis, M. kansasii,* and *M. balnei,* electroncytochemical study of. Juscenko, A. A. and Maslov, A. K. ..... (A) 360

Dactylitis,
leprous, of fingers, in borderline leprosy. Alexander, R., *et al.* ..... (A) 354

Damien-Dutton Award,
1978, Dr. Fernando Latapí receives. ..... (S) 256
1979, Dr. Stanley G. Browne receives. Gordon, G. ..... (N) 616

Dapsone, (DDS),
—, McDougall, A. C. ..... (A) 531
action of, on *M. kansasii.* Panitch, M. L. and Levy, L. ..... (A) 94
activity of derivatives and analogs, against *M. leprae.* Levy, L. ..... (A) 531
and severe hypoalbuminemia. Kingham, J. G. C., *et al.* ..... (A) 638
as a chemoprophylactic against leprosy, value of. Noordeen, S. R. and Neelan, P. N. (A) 320
carcinogenic activity of. Bergel, M. ..... (A) 410
carcinogenicity of, related to malignant neoplasm, in leprosy patients. Namba, M., *et al.* ..... (A) 669

chemoprophylaxis, in children, at Culion Sanitorium, Philippines. Lara, C. B. .....(A) 216
combined with ethionamide and intermittent ethionamide, effect of, in experimental leprosy in mice. Colston, M. J. and Hilson, G. R. F. .....(A) 411
— rifampin, in *M. leprae* infected neonatally thymectomized Lewis rats. Fieldsteel, A. H., *et al.* .....(A) 108
daily dose of 50 mg, therapeutic effects of adding Rimactane® (rifampin) 450 mg daily or 1200 mg once monthly, in lepromatous leprosy. LANGUILLON, J., *et al.* .....(O) 37
(A) 436
demonstration in urine and serum, by ELISA inhibition. Huikeshoven, H., *et al.* .....(A) 75
—, by enzyme-linked immunosorbent inhibition technique. Huikeshoven, H., *et al.* ...(A) 328
effect on treatment, of antibody activity against *M. leprae* antigen 7. Yoder, L., *et al.* .....(A) 651
excretion in urine, influence of rifampin on. Balakrishnan, S. and Sheshadri, P. S. .....(A) 529
first year treatment, in lepromatous leprosy, antibody activity against *M. leprae* antigen 7. Melsom, R., *et al.* .....(A) 85
in combination with isoniazid and prothionamide, in treating pulmonary tuberculosis, in adults. Orlowski, E. H. .....(A) 82
irregularity of intake, in infectious patients. Naik, S. S. .....(A) 217
metabolic disposition, in African patients. Peters, J. H., *et al.* .....(A) 217
—, in nine-banded armadillos. Murray, J. F., Jr., *et al.* .....(A) 409
poisoning, acute fatal. Saboo, S. K., *et al.* .....(A) 639
proven primary resistance, in leprosy. Waters, M. F. R., *et al.* .....(A) 82
reliability of self-administration, in Burmese patients. Hagan, K. J., *et al.* .....(A) 638
—, in patients, in Rangoon. Gyi, K. M., *et al.* .....(A) 530
resistance, and relapse, in Morocco. Rollier, M., *et al.* .....(A) 434
-resistant leprosy, in Cebu, Philippines, proven. Fajardo, T. T. and Abalos, R. M. .....(A) 415
—, in Ethiopia. Pearson, J. M. H., *et al.* .....(A) 639
tissue levels of, during combined dapsone-rifampin therapy. Peters, J. H. .....(A) 408
treatment, and deformities. Gupte, M. D. .....(A) 656
urinary . . . /creatinine concentration ratios, variability of, in fully compliant patients. Hagan, K. J. and Smith, S. E. .....(A) 638
— metabolites of, in man. Gordon, G. R., *et al.* .....(A) 681
urine analysis, in registered leprosy patients, in Kenya. Huikeshoven, H. and Bijleveld, I. .....(A) 75
with another drug, comparative study of five groups of patients. Rollier, R., *et al.* .....(A) 441

Datar, J. G.,
personal. .....(N) 202

Default,
observations on, among leprosy patients. Bhagoliwal, A., *et al.* .....(A) 531

Delayed-type hypersensitivity (see Hypersensitivity, delayed-type),

Dermal neuroma,
simulating leprosy. McDougall, A. C. .....(A) 643

Dermatology,
invisible dermatoses. Rietschel, R. L. and Lewis, C. W. .....(A) 77
peculiarities in. El Amin, A. M. .....(A) 214
perspectives in, Thailand 1973–1977. Piamphongsant, T. .....(A) 232

Diabetes mellitus,
screening for, in leprosy patients, with complicated ulcers. Smith, W. C. S. .....(A) 644

Diagnosis,
blood sialic acid (N-acetyl neuraminic acid—NANA) levels for, in leprosy. Purohit, V. N. and Khuteta, K. P. .....(A) 420
contribution of histology in, in early leprosy. Bianchi, O. and Cabrera, H. .....(A) 414
early hand pain in, of leprosy. Rimon, D., *et al.* .....(A) 77
greater auricular nerve in, of leprosy. Lynch, P. .....(A) 534
newly formulated mycobacterial media, application in rapid, of chronic mycobacterial diseases. Lew, J., *et al.* .....(A) 553
of tuberculosis, using Korean chipmunks. Bae, E. D. and Choi, T. K. .....(A) 552

peripheral nerve biopsies in, in Aboriginal patients, in leprosy. McDougall, A. C., *et al.* ..... (A) 534
practical guide to, in basic health unit. Wheate, H. W. and Pearson, J. M. H. ..... (B) 634
superficial peroneal nerve thickening as early sign, in leprosy. Vaidyanathan, E. P. and Vaidyanathan, S. I. ..... (A) 79

Dihydrofolate reductase,
inhibitors, activity of, against *M. leprae* infection, of mouse foot pad. Gelber, R. and Levy, L. ..... (A) 409

Dinitrochlorobenzene,
responsitivity, throughout granulomatous spectrum of leprosy. Rea, T. H. and Levan, N. E. ..... (A) 389

Diphenoloxidase,
activity, and *M. leprae*. Kim, S. J., *et al.* ..... (A) 360

Disabilities,
and displacement, and role of reconstructive surgery, in leprosy. Lobo, D. ..... (A) 448
prevention of, in leprosy patients. Arvelo, J. J. ..... (A) 447

Diuciphon (Diuciphonum),
experimental and clinical data. Goloshchapov, N. M. ..... (A) 438

Dominican Republic,
leprosy control program in, 1973–1977. Bogaert Diaz, H. and Martinez, D. ..... (A) 331
methods of communication, in fight against leprosy, 1966–1977. Hilario de González, M. and Bogaert Diaz, H. ..... (A) 405

Drug(s),
antithyroid, action of, on *M. leprae*. Levy, L. and Anandan, J. A. ..... (A) 531
for combined therapy, experimental studies on antileprosy activity of ethionamide and prothionamide. Colston, M. J., *et al.* ..... (A) 79

Drug design,
and comparative biochemistry, for infectious disease. Cohen, S. S. ..... (A) 637
pharmacological considerations of drug combinations, in treatment of lepromatous leprosy. Ellard, G. A. ..... (A) 408

Drug effects,
approach for *in vitro* screening, against leprosy. Kato, L., *et al.* ..... (A) 530
in vitro test for drug response of *M. leprae*, using of labelled metabolites. Ambrose, E. J., *et al.* ..... (A) 410
"proportional bactericidal test," for assessing drug activity against *M. leprae*. Colston, M. J., *et al.* ..... (A) 79

Drug resistance,
frequency of, results of long-term sulfone therapy, with special reference to renal abnormalities. Terencio de las Aguas, J. ..... (A) 433
murine leprosy bacilli (resistant), *in vitro* examination of. Sushida, K. ..... (A) 230
primary sulfone, preliminary report. Girdhar, B. K., *et al.* ..... (A) 529

***E. coli*-12,**
treated with liquid paraffin, effect of, against murine leprosy. Kunigoshi, U. ..... (A) 88

Eczema,
important complication of leprosy. Ghosh, S., *et al.* ..... (A) 352

Electromyography,
and muscle biopsy in lepromatous leprosy. Sebille, A. and Gray, F. ..... (A) 552

Electron microscopy,
findings regarding figures of multiplication of acid-fast bacilli in macrophages of nude mice. Fukunishi, Y., *et al.* ..... (A) 668
observations, of intracytoplasmic membrane systems and cell division, in *M. lepraemurium*. HIRATA, T. ..... (O) 585
—, of *M. leprae*, using serial ultrathin sectioning. Hirata, T. ..... (A) 101

of perioxidase and acid phosphatase, in leprous and unaffected armadillo macrophages. McKeever, P. E. ..... (A) 228
scanning studies, of activated macrophages in the mouse. Nabarra, B., *et al.* ..... (A) 229
studies, in the neuropathy of leprosy, correlations of *in vitro* electrophysiological, light, and. ..... (A) 430
—, of colonies of *M. lepraemurium*. Okada, S., *et al.* ..... (A) 101
—, of *M. leprae*, during breakdown in human lepromatous tissue. Bourges, M. ..... (A) 364

ELEP (see ILEP),

XI International Leprosy Congress,
address by President-elect of ILA, Dr. M. F. Lechat. ..... (S) 276
— of President of, Dr. Jacinto Convit. ..... (E) 512
closing session of. ..... (S) 270
closing statement, by Dr. F. Latapí. ..... (S) 278
Committee of Honor of. ..... (S) 240
films available for viewing at. ..... (S) 468
formal inaugural ceremony. ..... (S) 258
general meeting of members of. ..... (S) 263
inaugural statement, by the President of Mexico. ..... (S) 263
Ladies Committe of. ..... (S) 241
list of countries represented, and number of participants from each. ..... (S) 255
López Portillo, J., President of Mexico, photograph of. ..... (S) 239
members, list of. ..... (S) 245
message from the President of Mexico. ..... (S) 238
— of welcome, from Dr. F. Latapí, President of the Organizing Committee. ..... (S) 259
Mexican songs performed. ..... (S) 261
official stamping of the commemorative postage stamp of the. ..... (S) 262
Organizing Committee of. ..... (S) 241
Patrons of. ..... (S) 242
photographs, of the Congress. ..... (S) 280
report on, by Secretary-General of ILA. ..... (S) 271
sites of previous International Leprosy Congresses. ..... (S) 240
speech by Dr. Hubert Sansarricq ..... (S) 260

England,
Browne, S. G., receives Damien-Dutton Award, for 1979. Gordon, G. ..... (N) 616
International Symposium on Prevention and Control of Water-Related Diseases meets in London. ..... (N) 68
McDougall, A. C., becomes Editor of *Leprosy Review*. Browne, S. G. ..... (N) 68
Rees, R. J. W., made Companion of St. Michael and St. George. ..... (N) 202
WHO Regional Committee for Europe meets in London. Browne, S. G. ..... (N) 68

Enzyme,
-linked immunosorbent inhibition technique, demonstration of dapsone in urine and serum by. Huikeshoven, H., *et al.* ..... (A) 328

Epidemiology,
and immunologic studies on subclinical infections with *M. leprae*. Abe, M., *et al.* ..... (A) 114
— therapy, in Lucio's leprosy. Saúl, A. ..... (A) 551
clinico- study, in rural population of Bundelkhand. Nigam, P., *et al.* ..... (A) 92
—, of patients admitted to "El Rincon" hospital. Diaz Almeida, J., *et al.* ..... (A) 231
distribution of leprosy, in population groups at different risks, in Venezuela. Zuniga, M., *et al.* ..... (A) 322
epidemiometric modelling for leprosy. Lechat, M. F., *et al.* ..... (A) 326
laboratory aids in. Guinto, R. S. ..... (A) 318
leprosy in Greece (1928–1977), 50 year assessment of main characteristics. Parisis, N., *et al.* ..... (A) 332
— Hong Kong. Honey, N. R. ..... (A) 91
— Karimui, investigation into genetic susceptibility. Shields, E. D., *et al.* ..... (A) 334
— Morocco. Sekkat, A., *et al.* ..... (A) 326
— Okinawa, present situation. Saito, T. ..... (A) 335
— Saudi Arabia, preliminary study. Sebai, Z. A., *et al.* ..... (A) 333

— Sri Lanka. Sabapathy, D. S. P. ..... (A) 325
— The Netherlands, at Department of Dermatology, U. of Amsterdam, 1972–1976. Faber, W. R. ..... (A) 654
— the United States (1967–1976). Enna, C. D., *et al.* ..... (A) 232
(A) 332
leprosy survey in industries. Tiphagne, J. L. ..... (A) 324
of leprosy in Iranian children, and clinical study. Assefi, V. ..... (A) 323
— New Hebrides. Ratard, R. C. and Bravo, L. L. ..... (A) 92
— South India. Christian, M. and Radhakrishna, S. ..... (A) 324
— Spain. Terencio de las Aguas, J. ..... (A) 232
of sulfone-resistant leprosy. Pearson, J. M. H. ..... (A) 318
population survey, in rural Thailand, two methods compared. Teera, R., *et al.* ..... (A) 333
prevalence rate, in urban slums of Bombay. Ganapati, R. and Girija, D. ..... (A) 333
risks of treating leprosy in a general hospital. Mathai, R., *et al.* ..... (A) 322
school surveys in Bombay. Koticha, K. ..... (A) 333
workshop on. ..... (S) 304
WHO activities from 1973–1978. Sansarricq, H., *et al.* ..... (A) 319

Erythema multiforme bullosum,
due to rifampin. Nigam, P., *et al.* ..... (A) 639

Erythema nodosum leprosum (ENL),
—, a review. Soderstrom, R. M. and Krull, E. A. ..... (A) 216
and polymorphonuclear cell function, in polar types of leprosy. Sher, R., *et al.* ..... (A) 546
clinical and histopathologic observation in patients with. Park, J. K. and Lee, Y. S. ... (A) 85
— aspects, reactional episodes. Hastings, R. C. ..... (A) 348
effect of colchicine on serum amyloid A elevation during. McAdam, K. P. W. J., *et al.* ..... (A) 382
immune complexes in. Anthony, J., *et al.* ..... (A) 393
immunoglobulin deposits in. Anthony, J., *et al.* ..... (A) 644
in mice, immunological methods employed attempting to induce. Anthony, J., *et al.* .. (A) 537
study of patients with. Dutta, R. K. ..... (A) 642
thalidomide analogs with potential activity in. Hastings, R. C., *et al.* ..... (A) 672

Ethionamide,
and prothionamide, combined therapy, experimental studies on. Colston, M. J., *et al.* (A) 79
—, data on effect of, in experimental leprosy. Pattyn, S. R. ..... (A) 229
effect of intermittent, and in combination with dapsone, in mice. Colston, M. J. and Hilson, G. R. F. ..... (A) 411
toxic psychosis to isoniazid and, in a patient with pulmonary tuberculosis. Sharma, G. S., *et al.* ..... (A) 640

Ethiopia,
ALERT, announcement of provisonal program of courses for 1979–1980. ..... (N) 524
—, appoints new Executive Director, Mr. Bernt Johannessen. ..... (N) 202
—, holds Conference on Leprosy Training. ..... (N) 523
—, Kellersberger Memorial Lecture given by Dr. R. C. Hastings. Wheate, H. W. ..... (N) 524
dapsone-resistant leprosy in. Pearson, J. M. H., *et al.* ..... (A) 638
sulfone-resistant leprosy in. Haile, G. S., *et al.* ..... (A) 329

Etiology,
agent, cultivation of, in leprosy. ..... (B) 631
lepromatous leprosy reaction, as factor in posterior lepromatous uveitis. Chovet, M., *et al.* ..... (A) 74
of bone changes in the foot, population-based study, in leprosy. Karat, S. ..... (A) 418
study, of 107 cases, of granulomatous hepatitis. Vilaseca, J., *et al.* ..... (A) 650

Experimental leprosy,
animal model of human disease, lepromatous disease. Storrs, E., *et al.* ..... (A) 230
effect of ethionamide and prothionamide in, data on. Pattyn, S. R. ..... (A) 229
— penicillin, on infection with *M. leprae* in mice. Delville, J., *et al.* ..... (A) 227
effects of ALS, on transmission of bacilli, in mice. Sushida, K. ..... (A) 105
establishment in nude mice. Kohsaka, K., *et al.* ..... (A) 228

histopathology of, in the armadillo, *Dasypus novemcinctus* and *Dasypus sabanicola*. McDougall, A. C., *et al.* ..... (A) 343
in *Dasypus sabanicola*. Convit, J., *et al.* ..... (A) 338
— mice, effect of ethionamide, and ethionamide and dapsone combinations in. Colston, M. J. and Hilson, G. R. F. ..... (A) 411
— nine-banded armadillos, in the U.K. Rees, R. J. W. and Lowe, C. ..... (A) 338
— the white-handed gibbon (*Hylobatus lar*), inoculated with leprosy bacilli of human origin. Waters, M. F. R., *et al.* ..... (A) 231
infection of armadillos with *M. leprae*, quantitative aspects of. Kirchheimer, W. F., *et al.* ..... (A) 337
infectiousness of human leprosy bacilli in mice. Sushida, K. and Nakano, H. ..... (A) 342
nude mouse as a model, enhancing effect of thymus cells in infected nude mice. Nakamura, K. and Yogi, Y. ..... (A) 105
(A) 338
ocular histopathology in *M. leprae* and *M. lepraemurium* infected mice. Hobbs, H. E., *et al.* ..... (A) 549
— infected armadillos. McDougall, A. C. and Rees, R. J. W. ..... (A) 549
persistence and distribution of *M. leprae* in *Aedes aegypti* and *Culex fatigans* fed on leprosy patients. Narayanan, E., *et al.* ..... (A) 232
serum glycoprotein studies in *M. leprae* infected armadillos. Harris, E. B., *et al.* ..... (A) 344
workshop on. ..... (S) 287

"Facies Antonina,"
fundamentals of. Kremer, A. and Elsler, E. ..... (A) 351

Fasal, P.,
personal. ..... (N) 72

Feet,
concentration and persistence of bacilli in fingers and toes of lepromatous leprosy patients. Hiramalini, S., *et al.* ..... (A) 221
etiology of bone changes in, population-based study. Karat, S. ..... (A) 418
leprosy of the. Campailla, E. and Martinelli, B. ..... (A) 83
neuropathic, in leprosy. Vincitorio, A. G. and Galli, J. J. ..... (A) 449

Fetus,
immunity in leprosy, lymphocyte responses to *M. leprae* and phytohemagglutinin, at birth, in mother and baby. Barnetson, R. St. C. ..... (A) 378

Fluorescence microscopy,
for *M. leprae* detection, in tissue sections. JARIWALA, H. J. and KELKAR, S. S. ..... (O) 33

Fluorescent leprosy antibody absorption (FLA-ABS) test,
as a screening test, for early case detection. Mitsiali, M., *et al.* ..... (A) 391
for detecting subclinical *M. leprae* infection. Abe, M. ..... (A) 379
— early serodiagnosis of leprosy. Bharadwaj, V. P. and Desikan, K. V. ..... (A) 391

Follereau, Raoul, Award,
Dr. C. C. Shepard receives, for 1978. ..... (N) 72
(S) 279

Follereau, Raoul, Foundations,
celebration of 25th World Leprosy Day. Recipon, A. ..... (A) 401

Foot pad (mouse),
activity of dihydrofolate reductase inhibitors, against *M. leprae* infection of. Gelber, R. and Levy, L. ..... (A) 409
effect of treatment *in vivo* with Triton WR-1339 and Macrocyclon, on *M. leprae* infection of. Delville, J. and Jacques, P. J. ..... (A) 80
ICRC bacilli, growth of, in the. Bapat, C. V. and Modak, M. S. ..... (A) 224
—, —, strain C-44. Modak, M. S. and Bapat, C. V. ..... (A) 362
—, vaccine from, against *M. leprae* infection in. Bhide, M. B., *et al.* ..... (A) 339
(A) 537

Footwear,
manual for leprosy control programs. Neville, P. J. ..... (B) 210

Genetic control,
in mice, strain difference of delayed-type hypersensitivity to BCG and. Nakamura, R. M. and Tokunaga, T. ..... (A) 657

Genetic factors,
immune deficit in patients with lepromatous leprosy. SAHA, K. and AGARWAL, S. K. (O) 1
in leprosy, study in children, in Uganda. White, S. J., *et al.* ..... (A) 92

Genetic markers,
and leprosy in South African Negroes, serum protein polymorphisms. Hitzeroth, H. W., *et al.* ..... (A) 551

Genetic susceptibility,
immunogenetic aspects of leprosy, association with major histocompatibility complex (HLA, Ch, GLO 1, PGM_3). Greiner, J., *et al.* ..... (A) 320
investigation in the Karimui, in leprosy. Shields, E. D., *et al.* ..... (A) 334
the NI (Neuron invasion) gene of *M. leprae*. Barksdale, L. ..... (A) 358
to leprosy. Fine, P. E. M., *et al.* ..... (A) 321

Germany,
German Leprosy Relief Association (GLRA) joins in celebration of World Leprosy Day and the International Year of the Child. ..... (N) 202
International Committee of Dermatology meets in Munich. ..... (A) 69
Rehabilitation International announces available publications. ..... (N) 619

Gibbon, white-handed (*Hylobatus lar*),
experimental lepromatous leprosy in, successful inoculation with bacilli of human origin. Waters, M. F. R., *et al.* ..... (A) 231

Glomerulonephritis,
immune complex, in leprosy. Çöloğlu, A. S. ..... (A) 644

Glucan (yeast),
therapeutic effect of, in *M. leprae* infected mice. Delville, J. and Jacques, P. J. ..... (A) 227

Glucose,
tolerance, and serum free fatty acid levels, in leprosy. Bharadwaj, V. P., *et al.* ..... (A) 641

Graft(s),
human fetal thymic, transplantation, reversal reaction in patients with lepromatous leprosy after. Saha, K. ..... (A) 223

Granuloma,
decreased suppressor cell activity, in leprosy and other disseminated granulomatous infections. Artz, R. P., *et al.* ..... (A) 680
M. marinum, in man, ultrastructure of. Marsch, W. C., *et al.* ..... (A) 234

Granulomatosis,
lymphomatoid, multiple neuropathy in, similarity to leprosy. Garcia, C. A. ..... (A) 533

Greece,
leprosy in, 1928–1977, epidemiological characteristics of last 50 years. Parisis, N. ..... (A) 332

Guinea pig,
cell-mediated immunity in, antigenic interrelationships among selected mycobacterial species relative to *M. leprae* as manifested by. Shannon, E. J., *et al.* ..... (A) 674
—, induction of, to human *M. leprae*. Mehra, V. and Bloom, B. R. ..... (A) 111
—, —, to *M. leprae*. Mehra, V. and Bloom, B. R. ..... (A) 649
delayed hypersensitivity responses in mice and, to *M. leprae*, *M. vaccae*, and *M. nonchromogenicum* cytoplasmic proteins. Watson, S. R., *et al.* ..... (A) 650
immunological studies in, and in man, on bacteria and cell-free extracts of purified armadillo derived (PAD) *M. leprae*. Rees, R. J. W., *et al.* ..... (A) 380
skin reaction to homologous and heterologous antigens in, immunized with *M. leprae* and four selected cultivable mycobacterial strains. Mustafa, A. S. and Talwar, G. P. ..... (A) 543

Guyana,
integrated leprosy control in. McDougall, A. C. and Rose, P. ..... (A) 91

Gynecomastia,
as a physical finding in normal men. Nuttall, F. Q. ..... (A) 535

Hairless mouse (see nude mouse),

Hand(s),
bone absorption in fingers, ten-year radiologic study, in leprosy. MacMoran, J. W. and Brand, P. W. ..... (A) 671
claw, reconstructive surgery of, in leprosy. Lakhan Pal, V. P., *et al.* ..... (A) 656
concentration and persistence of bacilli in the fingers and toes of patients with lepromatous leprosy. Hiramalini, S., *et al.* ..... (A) 221
extensor pollicis brevis transfer to flexor digitorum sublimis, four year follow up study, in leprosy. Vaidyanathan, E. P. and Anthony, P. ..... (A) 79
infectious diseases of the. Klingmüller, G., *et al.* ..... (B) 209
leprous dactylitis of all fingers in borderline leprosy. Alexander, R., *et al.* ..... (A) 354
lesions in leprosy. Gomez V., M. and Rodriguez Padilla, A. ..... (A) 450
pain, in early diagnosis of leprosy. Rimon, D., *et al.* ..... (A) 77
partially anesthetic due to ulnar nerve in leprosy, protective value of a neurovascular island pedicle transfer in. Ranney, D. A. and Lennox, W. M. ..... (A) 215
skeletal deformities of the denervated, in leprosy. Enna, C. D. ..... (A) 656

Hedgehog (*Erinaceus europaeus*),
inoculation of, with *M. leprae*. Klingmüller, G. ..... (A) 344

Hepatitis,
granulomatous, etiological study of 107 cases. Viiaseca, J., *et al.* ..... (A) 650
leprous, clinico-pathologic study and therapeutic efficacy of. Pranesh Nigam, S. G. D., *et al.* ..... (A) 217

Hepatitis B,
infection, in leprosy, detection of surface antigen and antibody, by radioimmunology. Chiron, J. P., *et al.* ..... (A) 532
surface antigen, and antibody, in patients with liver diseases, blood donors, and leprosy patients. Thyagarajan, S. P., *et al.* ..... (A) 87
— (HB_sAg), in leprosy patients, in Calcutta, prevalence and subtypes. Chakrabarty, M. S., *et al.* ..... (A) 641
virus, immune response of leprosy patients to. Serjeantson, S. and Woodfield, D. G. .. (A) 86
— indicators, in leprosy. Chiron, J. P., *et al.* ..... (A) 330
— markers, incidence of HB_sAg and HB_eAg, in Somalian leprosy patients. NUTI, M., *et al.* ..... (O) 580

Hepatitis associated antigen (HAA) (see Antigen, Hepatitis),

Hind Kusht Nivaran Sangh,
issues annual report for 1977. ..... (N) 69

Histamine,
morphological changes in mast cells and levels of serotonin and, in leprosy patients. Kumar, R., *et al.* ..... (A) 391

Histiocyte(s),
bone marrow, leprosy's footprints in. Lawrence, C. and Schreiber, A. J. ..... (A) 542

Histiocytosis,
sinus, cutaneous manifestations of, with massive lymphadenopathy. Thawerani, H. .... (A) 78

Histology,
and clinical evaluation of 417 suspected leprosy cases. Delpino, G. de S., *et al.* ..... (A) 416
clinical studies, of the nose, in treated lepromatous leprosy. Barton, R. P. E., *et al.* .. (A) 348
contribution of, in early diagnosis of leprosy. Bianchi, O. and Cabrera, H. ..... (A) 414
Lucio's phenomenon, comparative study. REA, T. H. and RIDLEY, D. S. ..... (O) 161

Histopathology,
and clinical observation in ENL. Park, J. K. and Lee, Y. S. ..... (A) 85
aspects concerning Lucio's leprosy. Novales, J. ..... (A) 544
documented reversal reaction in lepromatous leprosy following treatment with transfer factor. Hastings, R. C. and Job, C. K. ..... (A) 439

findings in cutaneous blood vessels, in untreated lepromatous leprosy. CORUH, G. and McDOUGALL, A. C. ..... (O) 500
ocular, in *M. leprae* and *M. lepraemurium* infected mice. Hobbs, H. E., *et al.* ..... (A) 549
—, in *M. leprae* infected armadillos. McDougall, A. C. and Rees, R. J. W. ..... (A) 549
of experimental leprosy in the armadillo. McDougall, A. C., *et al.* ..... (A) 343
— tongue lesions, in leprosy. Mukherjee, A., *et al.* ..... (A) 223
study of, clinically normal appearing skin in lepromatous leprosy. Bedi, T. R., *et al.* ..... (A) 537
—, evolution of nasal mucosa lesions, in leprosy. Mehta, L., *et al.* ..... (A) 416
—, liver, in leprosy. Verma, K. C., *et al.* ..... (A) 87
—, lymph nodes, in 43 leprosy cases. Gupta, J. C., *et al.* ..... (A) 221
tuberculoid leprosy and tuberculosis skin compared. Nirmala, V., *et al.* ..... (A) 85

History,
Havens of Refuge. Davidson, W. S. ..... (B) 628
of leprosy in Louisiana. Gussow, Z. ..... (A) 527
of Lucio's leprosy. Rodríguez, O. ..... (A) 529

HLA,
and leprosy in Chinese. Chan, S. H., *et al.* ..... (A) 641
— mycobacterial infection, increased frequency of B8, in Japanese leprosy. Takata, H., *et al.* ..... (A) 87
-D-identical siblings, of lepromatous leprosy patients, *in vitro* lymphoproliferative response to *M. leprae*. Stoner, G. L., *et al.* ..... (A) 546
-DRW antigens, in Mexican leprosy patients. Rea, T. H. and Terasaki, P. I. ..... (A) 680
histocompatibility antigens in patients with leprosy from Azarbaijan, Iran. MOHAGHEGHPOUR, N., *et al.* ..... (O) 597
-linked genes and leprosy, family study, in Karigiri, South India. Fine, P. E. M., *et al.* ..... (A) 654
system, and leprosy in Thailand. Greiner, J., *et al.*, ... (A) 221

Hodgkin's disease,
development in a leprosy patient. Weshler, Z., *et al.* ..... (A) 536

Hong Kong,
leprosy in, past, present, and future. Honey, N. R. ..... (A) 91

Human aspects,
workshop on, in treatment of leprosy patients. ..... (S) 307

Hypersensitivity,
granulomatous, skin lesions, cutaneous nerve damage, induced by sensory peripheral nerve as antigen. Crawford, C. L. and Hardwicke, P. M. D. ..... (A) 340
—, in rabbits, non-myelin human nerve antigen producing. Hardwicke, P. M. D. and Crawford, C. L. ..... (A) 341
human, to Mitsuda antigen of animal origin, and absence of leprosy in armadillos in natural state. Pereira, C. A. de C. and Almeida Brandao, C. B. P. ..... (A) 388

Hypersensitivity, delayed-type (DTH),
and cell-mediated immunity. Turk, J. L. ..... (A) 547
— the progression of *M. lepraemurium* infection. Poulter, L. W. and Lefford, M. J. ..... (A) 230
attempts to induce, to *M. leprae* in healthy individuals and in "burnt out" lepromatous patients. Smelt, A. H. M., *et al.* ..... (A) 377
development of responses, in *M. lepraemurium* infections, in resistant and susceptible strains of mice. Alexander, J. and Curtis, J. ..... (A) 652
dissociation in mice between, to sonic extract of *M. lepraemurium* and resistance to MLM infection. Løvik, M. and Closs, O. ..... (A) 397
responses in mice and guinea pigs to *M. leprae*, *M. vaccae*, and *M. nonchromogenicum* cytoplasmic proteins. Watson. S. R., *et al.* ..... (A) 650
— to *M. leprae* and *M. vaccae* cytoplasmic proteins antigens. Collins, F. M. and Morrison, N. E. ..... (A) 375
skin reactions, to homologous and heterologous antigens, in guinea pigs immunized with *M. leprae* and four cultivable mycobacterial strains. Mustafa, A. S. and Talwar, G. P. ..... (A) 543

—, to lepromin, and antigens, from four other mycobacteria. Govil, D. C. and Bhutani, L. K. ..... (A) 540
—, —, from *M. leprae* and selected cultivable mycobacteria. Hogerzeil, L. M. and Prabhudass, N. ..... (A) 541
— tests, compared to PHA skin test in leprosy patients. Ozawa, T., *et al.* ..... (A) 422
strain difference of, to BCG, and its genetic control in mice. Nakamura, R. M. and Tokunaga, T. ..... (A) 657
systemic immunological reactivity in the absence of, during murine leprosy. Poulter, L. W. ..... (A) 229

Hypoalbuminemia,
severe, and dapsone. Kingham, J. G. C., *et al.* ..... (A) 638

ICRC bacilli,
ability of *M. leprae*, *M. w*, and, to produce macrophage activity factors from lymphocytes of leprosy patients. Prasad, H. K., *et al.* ..... (A) 544
effect of vaccine from, against *M. leprae* infection in mouse foot pad. Bhide, M. B., *et al.* ..... (A) 339
(A) 537
growth of, in the foot pad of mice. Bapat, C. V. and Modat, M. S. ..... (A) 224
—, strain C-44 in the foot pads of mice. Modak, M. A. and Bapat, C. V. ..... (A) 362
immunological evaluation of, *in vitro* isolate of *M. leprae*. Lakshiminarayana, C. S., *et al.* ..... (A) 362
local reactions to intradermal instillation of *M. w* and. Fotedar, A. F., *et al.* ..... (A) 540

ILEP,
Medical Commission meets at Carville. ..... (N) 66

Ichthyosis,
in leprosy, histological, clinical, and smear studies. Annamalai, R. ..... (A) 352

Immune complexes,
deposit, in leprosy, percutaneous renal biopsy study. Almeida Brandao, C. B. P., *et al.* ..... (A) 421
glomerulonephritis, in leprosy. Çöloğlû, A. S. ..... (A) 644
in erythema nodosum leprosum. Anthony, J., *et al.* ..... (A) 393
micro-technique enzyme-linked immunosorbent assay of Clq-reactive circulating, in leprosy. Stek, M. ..... (A) 392

Immune deficit,
in patients with lepromatous leprosy, nature and relation to genetic factors, spectrum, and duration. SAHA, K. and AGARWAL, S. K. ..... (O) 1

Immune response,
early, in nude mouse, following intravenous injection of *M. leprae*. Minagawa, F., *et al.* ..... (A) 89
(A) 542
of leprosy patients to hepatitis B virus. Serjeantson, S. and Woodfield, D. G. ..... (A) 86

Immunity,
ancestral, in the evolution of endemic leprosy, in the tropical zones. Aguiar Pupo, J. de ..... (A) 393
fetal, lymphocyte responses to *M. leprae* and phytohemagglutinin, in mother and baby at birth, in leprosy. Barnetson, R. St. C., *et al.* ..... (A) 378
humoral and cellular, in lepromatous leprosy. Meneghini, C., *et al.* ..... (A) 382
macrophage-mediated, in *M. lepraemurium*, model for impaired macrophage, in leprosy. Preston, P. M. ..... (A) 653
passive transfer of, to leprosy patients, by transfusion of allogeneic lymphocytes inactivated with mitomycin C. Saha, K., *et al.* ..... (A) 86

Immunity, cell-mediated (CMI),
in guinea pigs, antigenic interrelationships among selected mycobacterial species relative to *M. leprae*. Shannon, E. J., *et al.* ..... (A) 674
—, induction of, to human *M. leprae*. Mehra, V. and Bloom, B. R. ..... (A) 111
(A) 649

relation between delayed hypersensitivity and. Turk, J. L. ..... (A) 547
to *M. leprae*, induction of, in mice. Patel, P. J. and Lefford, M. J. ..... (A) 90

Immunization,
of mice, with *M. leprae* antigen. Shepard, C. C. and Minagawa, F. ..... (A) 115

Immunoelectrophoresis,
crossed, analysis of soluble antigens of BCG, compared to other mycobacteria. Harboe, M., *et al.* ..... (A) 541
electrophoresis and, in leprosy. Saoji, A., *et al.* ..... (A) 223

Immunofluorescence (see also fluorescent leprosy antibody absorption),
studies, across the leprosy spectrum. Faber, W. R. and Leiker, D. L. ..... (A) 220
—, direct and indirect, of lesions, normal skin, and sera of leprosy patients. Saylan, T., *et al.* ..... (A) 392
—, in reactional leprosy, with relevance to treatment. Faber, W. R., *et al.* ..... (A) 220

Immunogenicity,
heat stability of *M. leprae*. Shepard, C. C., *et al.* ..... (A) 654

Immunoglobulin(s),
concentration in mothers and healthy controls and their babies at birth. Melsom, R., *et al.* ..... (A) 394
deposits in erythema nodosum leprosum. Anthony, J., *et al.* ..... (A) 644
serum, in leprosy. Kelkar, S. S., *et al.* ..... (A) 642

Immunohistochemistry,
observation of lysozyme in macrophages, in leprosy. Yamashita, K., *et al.* ..... (A) 547

Immunologic perturbation,
model of, in chronic infection, in leprosy. Bullock, W. E. ..... (A) 83

Immunologic reactivity,
systemic, in the absence of delayed-type hypersensitivity, during murine leprosy. Poulter, L. W. ..... (A) 229

Immunology,
and epidemiologic studies on subclinical infections with *M. leprae*. Abe, M., *et al.* .... (A) 114
— the changing profile of leprosy. Job, C. K. ..... (A) 222
ascorbic acid, effects and hazards. ..... (A) 529
aspects of leprosy, present status. Godal, T. ..... (A) 540
assessment of sera of leprosy patients. Sengupta, U., *et al.* ..... (A) 535
athymic rat, status and infection with *M. leprae*. Colston, M. J., *et al.* ..... (A) 679
cultivation of etiologic agent, animal models, in leprosy. ..... (B) 631
immunopotentiative substances, studies on. Tsutsumi, S., *et al.* ..... (A) 110
immunoregulation in infection by *M. tuberculosis*, presence of suppressor monocytes, alteration of subpopulations of T lymphocyte subpopulations. Katz, P., *et al.* ..... (A) 657
Lucio's leprosy, profile. Estrada-Parra, S., *et al.* ..... (A) 539
methods employed to induce erythema nodosum leprosum. Anthony, J., *et al.* ..... (A) 537
of leprosy, and the WHO Special Programme. Godal, T. ..... (A) 372
persistence of Australia antigen, in leprosy. Saoji, A. M. and Mene, A. R. ..... (A) 223
profile of hospitalized patients with different types of leprosy. Estrada-Parra, S., *et al.* ..... (A) 394
skin titration in leprosy patients and contacts. CAUZZI, N. J., *et al.* ..... (O) 13
studies in leprosy patients in leprosy reaction treated with thalidomide. Rodríguez-Padilla, C., *et al.* ..... (A) 396
workshop on. ..... (S) 295

Immunomodulation,
action of two drugs given together in bacilliferous lepromatous leprosy. Sasiain, M. C. ..... (A) 442

Immunopathology,
observations in long-term BI negative lepromatous leprosy patients. Koseki, M., *et al.* ..... (A) 115

Immunosuppression,
effects, by whole body irradiation, distribution in pregnant mice of radioactivity after injection of ^{131}I and. Sushida, K. and Nakano, H. ..... (A) 231
evolution of, cell populations, in experimental mycobacterial infection. Bullock, W. E., *et al.* ..... (A) 226
M. leprae induced, of *in vitro* responses in leprosy patients. Mehra, V., *et al.* ..... (A) 373

Immunotherapy,
in leprosy. Gatti, J. C. and Cardama, J. E. ..... (A) 74
of patients with lepromatous leprosy, results. Nazarov, K. I. and Gnenyuck, T. S. .... (A) 438
pilot-trial of short treatment of leprosy by associated chemotherapy and. León, A. P. and Hernandez Silva, J. ..... (A) 440
(A) 530

Indeterminate leprosy,
immunological studies in patients with. Avalos, E. ..... (A) 376
nasal mucosa, significance of changes in. Chacko, C. J. G., *et al.* ..... (A) 538

India,
Bombay, school surveys in. Koticha, K. K. ..... (A) 333
—, urban slums, prevalence rate of leprosy in. Ganapati, R. and Girija, D. ..... (A) 333
Bundelkhand, clinico-epidemiologic study, in rural population of, of leprosy. Nigam, P., *et al.* ..... (A) 92
Datar, J. G., receives governmental award for most efficient handicapped employee, 1979. ..... (N) 202
Foundation for Medical Research issues activities' report for 1975–1978. Skinsnes, O. K. ..... (N) 70
Hind Kusht Nivaran Sangh issues annual report for 1977. ..... (N) 69
Indian Council on Medical Research issues Annual Report for 1977. ..... (N) 619
"Mandukaparni," common Indian herb, in leprosy treatment. Chaudhuri, S. ..... (A) 411
(A) 637
non-lepromatous leprosy among Indian armed forces personnel. Kapur, T. R. ..... (A) 533
Saidapet, 19 year follow-up of children, with untreated leprosy. Ramanujam, K. ..... (A) 347
Schieffelin Leprosy Research Centre holds ophthalmology seminar. ..... (N) 203
Seventh Workshop on Leprosy held at Acworth. ..... (N) 524
South, epidemiology of leprosy in. Christian, M. and Radhakrishna, S. ..... (A) 324

Indonesia,
Third National Congress of Indonesian Society of Dermato-Venereology to meet. Harahap, M. H. ..... (N) 524

INTERNATIONAL JOURNAL OF LEPROSY,
Board of Directors meeting takes place, on 27 September 1979. ..... (N) 621
By-Laws of the INTERNATIONAL JOURNAL OF LEPROSY, of the International Leprosy Association, Inc. ..... — 625
Dr. Robert C. Hastings, Editor IJL. SKINSNES, O. K. ..... (E) 58
editorial transition completed. HASTINGS, R. C. ..... (E) 515
notes on 47/4. HASTINGS, R. C. ..... (E) 609
Olaf K. Skinsnes, M.D., Ph.D.—an appreciation. HASTINGS, R. C. ..... (E) 59
reviewers, list of. ..... — 699
Special Grantors and Sustaining Members, acknowledgement. ..... — 117
— 235
— 559
— 700
statement of financial condition. ..... — 555
— of ownership, management, and circulation. ..... — 698

International Leprosy Association,
Constitution and By-laws of. ..... (S) 265
officers and members, list. ..... — 686
officers, list of. ..... (S) 243

International Year for Disabled Persons (IYDP),
to be celebrated in 1981. ..... (N) 525

Iran,
children in, clinical and epidemiological study of. Assefi, V. ....(A) 323
histocompatibility antigens, in leprosy patients, from Azarbaijan. MOHAGHEGHPOUR, N., *et al.* ....(O) 597
ocular leprosy in, at Baba Baghi Leprosarium. Ramanujam, K., *et al.* ....(A) 215

Iron,
serum, and total iron binding capacity, in leprosy patients. Bharadwaj, V. P., *et al.* ...(A) 219

Irradiation,
whole body, distribution in pregnant mice of radioactivity after injection of ^{131}I and immunosuppressive effects. Sushida, K. and Nakano, H. ....(A) 231

Isolates,
in vitro examination, observations of supposed contamination with another acid-fast bacillus, isolation culture. Ogawa, T. ....(A) 226

Isoniazid,
and ethionamide, toxic psychosis to, in a patient with pulmonary tuberculosis. Sharma, G. S., *et al.* ....(A) 640
combined with prothionamide and DDS, in treatment of pulmonary tuberculosis, in adults. Orlowski, E. H. ....(A) 182
treatment of tuberculosis and rifampin-associated neuritis, symptomatic neuritic leprosy precipitated by rifampin and. Goodwin, C. S., *et al.* ....(A) 428

Isoprodian (L73A),
combined with rifampin, in the treatment of *M. leprae* infections, in mice. Matsuo, Y., *et al.* ....(A) 531

Japan,
carbol fuchsin staining of mycobacteria in leprosy institutes of, and Southeastern Asia. Harada, K., *et al.* ....(A) 102
Okinawa, present situation in. Saito, T. ....(A) 335

Kenya,
DDS urine analysis, in leprosy patients, encouraging results of, in Wangas. Huikeshoven, H. and Bijleveld, I. ....(A) 75

Keratosis,
seborrheic, with exacerbated leproma, case report. Matsumoto, T. and Sasaki, N. .....(A) 76

Khanolkar, V. R.,
obituary. ....(Ob) 197

Korea,
diagnosis of tuberculosis using . . . chipmunks. Bae, E. D. and Choi, T. K. ....(A) 552
Dr. Stanley C. Topple receives award from National Awards Foundation. ....(N) 71
hepatitis B antigen, positivity, in leprosy patients. Choi, S. R. and Chung, W. K. .....(A) 329

Latapí, F.
personal. ....(S) 256

Leishmaniasis,
experimental cutaneous, with *Leishmania tropica*, in albino hairless mice. Packchanian, A. ....(A) 554

Lepromatous leprosy,
acedapsone in the treatment of 70 patients. Samson, P. D., *et al.* ....(A) 435
acute infiltration reaction (Tajiri) in, studies of clinical course and prognosis during chemotherapy. Takizawa, H. ....(A) 78
and arthritis. Pernambuco, J. C. de A., *et al.* ....(A) 353
— onchocerciasis. Prost, A., *et al.* ....(A) 654
animal model of human disease. Storrs, E., *et al.* ....(A) 230
antibody activity against *M. leprae* antigen 7 during first year DDS treatment. Melsom, R., *et al.* ....(A) 85
BCG immunotherapy trial in. Kim, D. I. ....(A) 387
chemotaxis in. Azulay, R. D., *et al.* ....(A) 345
circulating anticoagulant in. COLE, F. S., *et al.* ....(O) 121

clinical and histological studies of the nose in treated. Barton, R. P. E., *et al.* .....(A) 348
— trial of rifampin in. Babu, N. V. .....(A) 444
clinically normal appearing skin in, histopathologic study. Bedi, T. R., *et al.* .....(A) 537
combination rifampin-levamisole in a double-blind trial in treatment. Liturri, M. and Wilkinson, F. .....(A) 442
concentration and persistence of bacilli in fingers and toes of patients with. Hiramalini, S. .....(A) 221
culture of leprosy bacillin *in vitro* in a case of. Massalski, W. K. .....(A) 225
demonstration of *M. leprae* in tissues from bacteriologically negative treated patients. Krieg, R. E. and Myers, W. M. .....(A) 367
discharge of *M. leprae* from the mouth in patients. Hubscher, S., *et al.* .....(A) 222
early and late reactions in patients with lepromins from *M. leprae* and five selected cultivable mycobacteria. Mustafa, A. S. and Talwar, G. P. .....(A) 543
effect of tubercin-3 on serum electrophoretic patterns in. Byun, S. Y. and Chung, T. H. .....(A) 538
efficacy and tolerability of rifampin in Burmese patients with. Shwe, T. .....(A) 640
electromyographic recording and muscle biopsy in. Sebille, A. and Gray, F. .....(A) 552
electronmicroscopical studies of *M. leprae* during breakdown in human tissue. Bourges, M. .....(A) 364
evaluation of treatment of patients in The Netherlands. Faber, W. R. and Leiker, D. ..(A) 637
experimental, in the white-handed gibbon (*Hylobatus lar*), successful inoculation with leprosy bacilli of human origin. Waters, M. F. R., *et al.* .....(A) 231
—, nude mouse as model, enhancing effect of thymus cells in. Nakamura, K. and Yogi, Y. .....(A) 105
favorable effect of clofazimine in. Cottenot, F. and Pennec, J. .....(A) 80
four-weekly "pulse" therapy with rifampin in sulfone-resistant. Laing, A. B. G. .....(A) 437
gut-associated IgA deficiency in. Saha, K., *et al.* .....(A) 545
histoid nodules in. Saúl, A. and Payro, E. .....(A) 351
histopathologically documented reversal reaction following treatment with transfer factor. Hastings, R. C. and Job, C. K. .....(A) 439
humoral and cellular immunity in. Meneghini, C., *et al.* .....(A) 382
immune deficit in patients, nature and relation to genetic factors, spectrum, and duration of illness. SAHA, K. and AGARWAL, S. K. .....(O) 1
immunological findings in. Ilter, Ö., *et al.* .....(A) 378
— status of patients, assessment. Pervukhin, Yu. V., *et al.* .....(A) 378
immunomodulatory action of two drugs given together in bacilliferous. Sasiain, M. C. *et al.* .....(A) 442
immunopathologic observations in long-term BI negative patients. Koseki, M., *et al.* .(A) 115
introductory rifampin therapy in, six month follow-up study. Girdhar, B. K., *et al.* ....(A) 529
in vitro lymphoproliferative response, to *M. leprae,* in normal siblings of patients. Stoner, G. L., *et al.* .....(A) 374
—, —, of HLA-D-identical siblings of patients. Stoner, G. L., *et al.* .....(A) 546
— modulation of lymphocyte responses to photohemagglutinin by plasma, increased in babies of affected mothers at time of birth. Bjune, G., *et al.* .....(A) 538
in vivo response of mast cells to serum. Kumar, R., *et al.* .....(A) 542
long-term sulfone therapy with special reference to renal abnormalities and frequency of drug resistance. Terencio de las Aguas, J. .....(A) 433
Lucio's phenomenon and diffuse nonnodular. Rea, T. H. and Levan, N. E. .....(A) 77
masquerading as disseminated tuberculosis. Weissman, J. B. and Neu, H. C. .....(A) 644
methods of stimulating cell-mediated immunity in cases, clinical, bacteriological, and histopathological study with immunological control. Saint-André, P., *et al.* .....(A) 376
MIF response to lepromin, PPD, and SK-SD in patients and healthy individuals. Castro-Mussot, M. E., *et al.* .....(A) 380
M. avium skin infection resembling. Cole, G. W. and Gebhard, J. .....(A) 641
neutrophil activation, in adjuvant disease, implications for reactional. Convit, J., *et al.* .....(A) 382
—, significance in reactional, *in vivo* and *in vitro* effects of thalidomide. Goihman-Yahr, M., *et al.* .....(A) 220
persistence and drug resistance of *M. leprae,* obstacles to successful chemotherapy of. Levy, L. .....(A) 408

pharmacological considerations of drug combinations for treatment. Ellard, G. A. .....(A) 408
phospholipid composition of leukocytes in. Kalofoutis, A., *et al.* .....(A) 420
placebo-controlled clinical trial of transfer factor in. Faber, W. R., *et al.* .....(A) 439
(A) 637
posterior . . . uveitus, reaction as an etiologic factor. Chovet, M., *et al.* .....(A) 74
reactional, demonstration of intracytoplasmic *M. leprae* antigen in inflammatory exudate. González-Mendoza, A., *et al.* .....(A) 383
relapse in. Sanada, K., *et al.* .....(A) 419
remnants of quiescent leprosy bacilli in deep organs of patients, improved acid-fast staining method. Sasaki, N. and Kawatsu, K. .....(A) 419
results of immunotherapy in patients. Nozarov, K. I. and Gnenyuck, T. S. .....(A) 438
reversal reactions, following transfer factor therapy. Hastings, R. C. and Job, C. K. ..(A) 221
—, in patients, after transplantation of human fetal thymic grafts. Saha, K., *et al.* .....(A) 223
rifampin, for treatment. Jacobson, R. R. .....(A) 682
—, in treatment. Gatti, J. C., *et al.* .....(A) 436
—, nine years' experience. Waters, M. F. R., *et al.* .....(A) 83
sequential biochemical investigations in. Venkatesan, K. and Bharadwaj, V. P. .....(A) 224
statistical analysis of two chemotherapy trials, interactions among patient variables. U. S. Leprosy Panel. .....(A) 219
—, response to therapy measured by inoculation of mice. U.S. Leprosy Panel. .....(A) 218
therapeutic effects of adding rimactane® (rifampin) 450 mg daily or 1200 mg once monthly in a single dose to dapsone 50 mg daily in patients. LANGUILLON, J., *et al.* .....(O) 37
(A) 436
treatment with long-acting sulfonamides. Schulz, E. J. and Kok, S. H. .....(A) 440
— with clofazimine (B663 Lamprene). Venkatesan, T. V. .....(A) 82
tuberculoid relapse in. Waters, M. F. R. and Ridley, D. S. .....(A) 350
ultrastructure of, morphological analysis of development of therapeutics. Wilkinson, F. F., *et al.* .....(A) 364
untreated, histopathological findings in cutaneous blood vessels. CORUH, G. and McDOUGALL, A. C. .....(O) 500

Lepromin,
armadillo, leukocyte migration inhibition, in human lymphocytes of healthy donors. Fumarola, D. and Jirillo, E. .....(A) 84
comparative study on skin reactions to *M. leprae-*, and to ICRCin, antigen from cultivable acid-fast bacilli isolated from lepromatous nodules. Bapat, C. V. .....(A) 381
delayed hypersensitivity skin reactions to, and antigens from four other mycobacteria. Govil, D. C. and Bhutani, L. K. .....(A) 540
—, prepared from *M. leprae* and selected cultivable mycobacteria. Hogerzeil, L. M. and Prabhudass, N. .....(A) 541
double blind trial, effect of certain soluble cytoplasmic mycobacterial antigens on reactivity. Haddad, N., *et al.* .....(A) 387
-induced suppressor cells in patients, evidence for mediation by TH_2^+ T-cell subset. Mehra, V., *et al.* .....(A) 679
lymphocyte transformation test (LTT) in patients, in presence of phytohemagglutinin, . . . , and *M. leprae*, in culture medium with normal homologous serum. Pagnano, P. M. G., *et al.* .....(A) 389
MIF response to, PPD and SK-SD in patients and healthy individuals. Castro-Mussot, M. E., *et al.* .....(A) 380
Mitsuda-type reactions, host resistance in *M. lepraemurium* infection. Curtis, J. and Turk, J. L. .....(A) 652
M. leprae-, and antigens from cultivable saprophytic mycobacteria, comparative study of skin reactions in patients. Sharma, R. C. and Singh, R. .....(A) 546
test results using human . . . (H) and armadillo . . . A. Tarabini, G., *et al.* .....(A) 389

Leprosy,
A Window On. Chatterjee, B. R. .....(B) 206
absorption in fingers in, ten-year radiologic study. MacMoran, J. W. and Brand, P. W. .....(A) 671
action of 2-mercapto-propionil glycine on. Wilkinson, F. and Gervaci, V. S. .....(A) 440

an overview. Browne, S. G. ..... (A) 635
and ABO blood groups. Datar, S. V., *et al.* ..... (A) 532
— acro-osteolysis. Moleres, R. and Enna, C. D. ..... (A) 422
— anemia. Verma, K. C., *et al.* ..... (A) 216
— eczema. Ghosh, S., *et al.* ..... (A) 352
— genetic markers, in South African Negroes, serum protein polymorphisms. Hitzeroth, H. W., *et al.* ..... (A) 551
— HLA, in Chinese. Chan, S. H., *et al.* ..... (A) 641
— hand lesions. Gomez V., M. and Rodriguez Padilla, A. ..... (A) 450
— lower limb angiography. Johnson, A. C., *et al.* ..... (A) 84
— pregnancy. Maurus, J. ..... (A) 214
— psoriasis, in light of common history. Eckes, L. K. ..... (A) 527
— renal dysfunction. Mohanty, H. ..... (A) 418
— respiratory system involvement. KAUR, S., *et al.* ..... (O) 18
— scalp alopecia. Fraguela Rangel, J. V., *et al.* ..... (A) 533
— the Bureau Barriere syndrome. Galli, J. J. and Vincitorio, A. G. ..... (A) 351
— the rheumatoid factor. Ellis, B. P. B. ..... (A) 351
— therapy. Noussitou, F. ..... (A) 432
— water and sewage. ..... (N) 68
antibodies reacting with fibroblasts, Schwann cells, and connective tissue microfibrils in. Lindner, E., *et al.* ..... (A) 384
anticonnective tissue antibodies in. Fleury, R. N., *et al.* ..... (A) 384
articular manifestations in two cases. David-Chaussé, J., *et al.* ..... (A) 532
associated cases in the families of school children with. Ganapati, R., *et al.* ..... (A) 91
association with pulmonary tuberculosis. Nigam, P., *et al.* ..... (A) 534
autoantibodies in. Masala, C., *et al.* ..... (A) 393
cellular basis for extremity bone loss in. MARKS, S. C., JR. ..... (O) 26
changes in the skull. Møller-Christensen, V. ..... (B) 210
chemotherapy of, with nude mice. Kohsaka, K., *et al.* ..... (A) 673
classification, three instructive cases. Jopling, W. H. and Ridley, D. S. ..... (A) 415
clinical and biochemical aspects. Ryzhova, N. Ya. ..... (A) 417
— and histological evaluation of 417 suspected cases. Delpino, G. de S. ..... (A) 416
— spectrum of leprosy. Opromolla, D. V. A. and Fleury, R. N. ..... (A) 416
clinico-pathological aspects. Convit, J., *et al.* ..... (A) 415
comes of age. FITE, G. L. and FASAL, P. ..... (E) 607
complications of. Karat, A. B. A. ..... (A) 533
compression neuropathy of the radial nerve in. Charosky, C., *et al.* ..... (A) 450
coronary heart disease in. Diamantopoulos, E., *et al.* ..... (A) 419
current societal attitudes, changing role of National Leprosy Control Centre, Sungei Buloh, Malaysia. Kandiah, N., *et al.* ..... (A) 213
dapsone as a chemoprophylactic, value of. Noordeen, S. K. and Neelan, P. N. ..... (A) 320
default among patients, observations in. Bhagoliwal, A., *et al.* ..... (A) 531
determination of T and B lymphocytes, in patients with different types of. Padierna, J., *et al.* ..... (A) 383
development of Hodgkin's disease in a patient. Weshler, Z., *et al.* ..... (A) 536
— of vaccine, introduction. Talwar, G. P. ..... (A) 547
dinitrochlorobenzene responsitivity throughout the granulomatous spectrum of. Rea, T. H. and Levan, N. E. ..... (A) 389
effect of . . . in mothers on their children, before and after birth. Duncan, M. E. ..... (A) 350
elective surgical decompression of nerves in, technics and results. Pandya, N. J. and Antia, N. H. ..... (A) 76
electron microscopy of. Okada, S. ..... (A) 665
electrophysiological evidence for motor unit impairment during. Sebille, A. ..... (A) 428
endemic, ancestral immunity in the evolution of, in tropical zones. Aguiar Pupo, J. de ..... (A) 393
etiology of bone changes in the foot, population-based study. Karat, S. ..... (A) 418
evaluation of male gonadal function in. Dash, R. J., *et al.* ..... (A) 532
experimental model for, new. Soto, J., *et al.* ..... (A) 363
extensor pollicis brevis transfer to flexor digitorum sublimis in, four-year follow-up study. Vaidyanathan, E. P. and Anthony, P. ..... (A) 79
FLA-ABS test, to screen for case detection at an early stage. Mitsiali, M., *et al.* ..... (A) 391

fluorescent leprosy antibody absorption (FLA-ABS) test for early serodiagnosis. Bharadwaj, V. P. and Desikan, K. V. ..... (A) 391
found in a dermatology clinic in Taiwan. Li, W. M. and Wong, C. K. ..... (A) 76
genetics of susceptibility to. Fine, P. E. M., *et al.* ..... (A) 321
greater auricular nerve in diagnosis of. Lynch, P. ..... (A) 534
Guide to . . . and to Control. Kapoor, P. ..... (B) 208
HLA-DRW antigens in Mexican patients with. Rea, T. H. and Terasaki, P. I. ..... (A) 680
Handbook of. Jopling, W. H. ..... (B) 208
has, come of age? ACKLEY, R. K. ..... (E) 608
hematologic profile in, related to severity of disease and treatment. Karat, A. B. A. and Rao, P. S. S. ..... (A) 214
histology, contribution of, in early diagnosis. Bianchi, O. and Cabrera, H. ..... (A) 414
immunological profile of patients, resident in a hospital, with different types of. Estrada-Parra, S. ..... (A) 394
— studies in patients in reaction treated with thalidomide. Rodríguez-Padilla, C. ..... (A) 396
immunology of, WHO Special Programme. Godal, T. ..... (A) 372
in a chimpanzee, morphology of skin lesions, characterization of the organism. Leininger, J. R., *et al.* ..... (A) 550
— Literature. Contreras Duenas, F. ..... (B) 207
— primary health care. González Galvan, A. ..... (A) 320
— the United States. Enna, C. D., *et al.* ..... (A) 232
(A) 332
in vitro electrophysiological, light and electronmicroscopical studies, in neuropathy, correlations. Pandya, S. S., *et al.* ..... (A) 430
indigenous, in armadillos. Walsh, G. P., *et al.* ..... (A) 342
—, in the armadillo. Convit, J. ..... (A) 548
infectious and immunological disorder of the nervous system. Dastur, D. K. ..... (A) 645
infectiousness of human bacilli in mice. Sushida, K. and Nakano, H. ..... (A) 342
inflammatory arthropathy in. Alcocer, J., *et al.* ..... (A) 350
involvement of cranial nerves in, with reference to treatment. Namba, M. and Kobayashi, S. ..... (A) 428
Leprosy. ..... (A) 232
—. Kirchheimer, W. F. ..... (A) 528
lipid staining in classification, importance of. Garriso Neves, R. and Azulay, R. D. .... (A) 420
micro-technique enzyme-iinked immuno-sorbent assay, of Clq-reactive circulating immune complexes in. Stek, M. ..... (A) 392
microbial persistence in. Waters, M. F. R., *et al.* ..... (A) 432
microbiology of, reflections on. Delville, J. ..... (A) 548
motor nerve conduction velocity in, correlation with clinical and histological findings. Chopra, J. S., *et al.* ..... (A) 427
nerve, changes in. Klingmüller, G. ..... (A) 84
—, damage in, prospects for study and applications for therapy. Pearson, J. M. H. .... (A) 426
—, —, quantitative study. Ramchandra Bhat, K., *et al.* ..... (A) 341
—, function in, assessment of. Naafs, B. and van Droogenbroeck, J. B. A. ..... (A) 427
—, lesions in, evolution of. Antia, N. H., *et al.* ..... (A) 427
—, surgery in. van Droogenbroeck, J. B. A. and Naafs, B. ..... (A) 452
nervous sytem in. Dastur, D. K. ..... (A) 646
neuropathy in, results of surgical treatment. Ganopol, J., *et al.* ..... (A) 452
non-lepromatous, maintenance therapy in. Vellut, C., *et al.* ..... (A) 432
notes on the history of, in Louisiana. Gussow, Z. ..... (A) 527
pathology of. Ridley, D. S. ..... (A) 636
peripheral nerve biopsies in diagnosis of, in Aboriginal patients, from Northern Territory of Australia. McDougall, A. C., *et al.* ..... (A) 534
— vascular deficit in, role in pathogenesis of neuropathy. Kaur, S., *et al.* ..... (A) 429
policy. Northern Territory Department of Health (Australia). ..... (A) 635
practical experience with combined therapy in. Rosenfeld, M., *et al.* ..... (A) 434
prevention of disability in patients with. Arvelo, J. J. ..... (A) 447
primary care of patients. Monzon, H. and Rassi, E. ..... (A) 528
— involvement of nasal mucosa, in apparently healthy contacts of patients. Chacko, C. J. G., *et al.* ..... (A) 417

prognostic considerations, study of 38 patients, submitted to Mitsuda tests 23 to 35 years previously. Alchorne, M. M. A., *et al.* ..... (A) 388
prothionamide, results of treatment with. Bragina, V. S. ..... (A) 437
proven dapsone-resistant, in Cebu, Philippines, study of. Fajardo, T. T. and Abalos, R. M. ..... (A) 415
pseudocholinesterase types, distribution of, in patients with. Navarrete, J. I., *et al.* ... (A) 344
rational chemotherapy of. Prabhakaran, K., *et al.* ..... (A) 359
reaction and levamisole (R12564). Cardarma, J. E., *et al.* ..... (A) 440
rehabilitation, medical and socio-economic, in Cuban patients. Werthein, L. J., *et al.* (A) 447
-related and non-related families, comparative serum profile in. Quesada-Pascual, F., *et al.* ..... (A) 394
renal changes, clinical, bacteriological, histological, and functional appraisal. Thomas, A., *et al.* ..... (A) 421
— damage in. Loginov, V. K. and Sluvko, Z. A. ..... (A) 350
research in. ..... (A) 636
—, rehabilitation, social and medical. Mehta, J. M. and Gokhale, S. W. ..... (B) 209
respiratory system in, involvement of. KAUR, S., *et al.* ..... (O) 18
—, —. Kumar, B., *et al.* ..... (A) 349
revival of interest in antibody studies in. Harboe, M. and Closs, O. ..... (A) 372
Schweninger-Buzzi type of anetodermia in patients. Margarido, L. and Rotberg, A. ... (A) 355
secondary bacterial infections in chronic trophic ulcers in. Chow, S. K. W. ..... (A) 370
segmental demyelination in human and mouse model, assessed by teased fiber technique, electrophysiological correlation. Shetty, V. P., *et al.* ..... (A) 429
serum beta-glucuronidase in. Venkatesan, K., *et al.* ..... (A) 644
— calcium and magnesium, in different types of. Sinha, S. N., *et al.* ..... (A) 224
— immunoglobulins in. Kelkar, S. S., *et al.* ..... (A) 642
skeletal deformities of the denervated hand in. Enna, C. D. ..... (A) 656
Some Facts About. Dharmendra. ..... (B) 628
squamous cell carcinoma, complication of plantar ulcer in. Opromolla, D. V. A. and Fleury, R. N. ..... (A) 354
sulfone-resistant, case communication. Vega-Nuncz, J. ..... (A) 444
—, in Ethiopia. Haile, G. S., *et al.* ..... (A) 329
—, prevention of. Pearson, J. M. H., *et al.* ..... (A) 328
—, treatment of. Jacobson, R. R. ..... (A) 433
superficial peroneal nerve thickening, early diagnostic sign in. Vaidyanathan, E. P. and Vaidyanathan, S. I. ..... (A) 79
suppressor cells in. Nath, I., *et al.* ..... (A) 391
surgery, role in rehabilitation in. Antia, N. H. ..... (A) 446
surgical treatment of ulnar nerve paralysis in. Palande, D. D. ..... (A) 451
The Book of Outlines. Hasan, S. ..... (B) 207
The Challenge of. Jagadisan, T. N. ..... (B) 207
the Marchoux Institute, center for research and care of persons with. Pelletier, P. ..... (A) 636
today. Jopling, W. H. ..... (A) 213
treatment defaulters in, retrospective study of 42,000 cases. KOTICHA, K. K. and NAIR, P. R. R. ..... (O) 50
ultrastructural changes, in blood vessels of peripheral nerves and skin of patients. Boddingius, J., *et al.* ..... (A) 430
ultrastructure, of beginning and progressive nerve involvement, in patients. Boddingius, J. ..... (A) 425
untreated, Saidapet story, nineteen year follow-up of children. Ramanujam, K. ..... (A) 347
use of information, to evaluate vaccination trial, besides incidence rates. Irgens, L. M., *et al.* ..... (A) 319
when to think of? Basset, A. ..... (A) 635
with Waardenburg's syndrome. Reddy, B. S. N., *et al.* ..... (A) 77

Leprosy Mission,
sponsors seminars in Africa. ..... (N) 66

Lesion(s),
cerebrovascular, frequency of, in leprosaria. Furuta, M., *et al.* ..... (A) 214
comparison of reaction to Dharmendra antigen in normal skin and, in leprosy patients. Price, J., *et al.* ..... (A) 535

direct and indirect immunofluorescent studies of. Saylan, T., *et al.* ..... (A) 392
early. Cardama, J. E. ..... (A) 347
hand, in leprosy. Gomez V., M. and Rodríguez Padilla, A. ..... (A) 450
immunological relatedness of ribosomes from mycobacteria, nocardiae, corynebacteria, and microorganisms in leprosy. Laub, R., *et al.* ..... (A) 542
leprous skin, periodic acid-carbol pararosanilin stain and acid-methenamine silver stain, to stain leprosy bacilli in. Harada K. and Kasai, T. ..... (A) 366
nasal mucosa, evolution of, histopathological study. Mehta, L., *et al.* ..... (A) 416
nerve, evolution of, in leprosy. Antia, N. H., *et al.* ..... (A) 427
skin, granulomatous hypersensitivity and cutaneous nerve damage, induced by sensory peripheral nerve as antigen. Crawford, C. L. and Hardwicke, P. M. D. .... (A) 340
—, morphology of, in a chimpanzee, Leininger, J. R., *et al.* ..... (A) 550
tongue, histopathology of, in leprosy. Mukherjee, A., *et al.* ..... (A) 223

Leucine,
stimulating effect of, on *M. leprae* growth. Murohashi, T. and Yoshida, K. ..... (A) 226

Leukocyte(s),
migration inhibition, analogous to *M. leprae*, five cultivable mycobacterial strains giving blast transformation and. Mustafa, A. S. and Talwar, G. P. ..... (A) 544
—, with armadillo lepromin, in human lymphocytes of healthy donors. Fumarola, D. and Jirillo, E. ..... (A) 84
peripheral blood, endocytic ability of, measured by capacity to ingest *M. lepraemurium in vitro*. Rojas-Espinosa, O. and Aponte-Vazquez, J. ..... (A) 422
phospholipid composition, in lepromatous leprosy. Kalofoutis, A., *et al.* ..... (A) 420
polymorphonuclear, interaction of *M. microti* and *M. lepraemurium* with mouse. Smith, C. C., *et al.* ..... (A) 658

Leukotaxis,
defective, in monocytes from patients with pulmonary tuberculosis. Campbell, P. R. .. (A) 552

Levamisole,
and tetramisole, therapeutic trial with immunomodulators, in leprosy. Carvalho, J. C. de S., *et al.* ..... (A) 441
combined with rifampin, double-blind trial of treatment of lepromatous leprosy. Liturri, M. and Wilkinson, F. ..... (A) 442
(R12564) and leprosy reaction. Cardama, J. E., *et al.* ..... (A) 440

Lewis rats,
neonatally thymectomized (NTLR), combined dapsone-rifampin therapy in, chronically infected with *M. leprae*. Fieldsteel, A. H. and Levy, L. ..... (A) 108
—, infected with *M. leprae*, histopathologic and electron microscopic observations. Dawson, P. J., *et al.* ..... (O) 561

Light microscopy,
correlations, of *in vitro* electrophysiological, . . . , and electronmicroscopical studies, in neuropathy of leprosy. Pandya, S. S., *et al.* ..... (A) 430

Lipid(s),
staining, importance of, in classification. Garriso Neves, R. and Azulay, R. D. ..... (A) 420

Literature,
Leprosy in. Contreras Duenas, F. ..... (B) 207
The Chronicles of Thomas Covenant the Unbeliever. Donaldson, S. R. ..... (B) 629

Liver,
armadillo, tissue, immunochemical and structural integrity of surface protein antigens of mycobacteria during separation from. Caldwell, H. D., *et al.* ..... (O) 469
diseases, incidence of hepatitis B surface antigen and antibody in patients with. Thyagarajan, S., *et al.* ..... (A) 87
histopathologic study of, in leprosy. Verma, K. C., *et al.* ..... (A) 87
involvement of, in leprosy reactions. Tolentino, M. M., *et al.* ..... (A) 353

Lucio's leprosy,
—. Castro, E. and Novales, J. ..... (A) 414
epidemiology and therapy. Saúl, A. ..... (A) 551

histopathological aspects. Novales, J. ..... (A) 544
history and concepts. Rodríguez, O. ..... (A) 529
immunological profile. Estrada-Parra, S., *et al.* ..... (A) 539
laboratory and theoretical clinical aspects. Ortiz, Y. and Giner, M. ..... (A) 535

Lucio's phenomenon,
an overview. Rea, T. H. ..... (A) 643
and diffuse nonnodular lepromatous leprosy. Rea, T. H. and Levan, N. E. ..... (A) 77
comparative histological study. REA, T. H. and RIDLEY, D. S. ..... (O) 161
Dermatologia Revista Mexicana devotes issue to. ..... (N) 524
in tuberculoid leprosy. Miranda, R. N. ..... (A) 418

Lymph node(s),
draining, enlargement of, by four selected cultivable strains of mycobacteria. Mustafa, A. S. and Talwar, G. P. ..... (A) 544
histopathologic study in 43 cases, in leprosy. Gupta, J. C., *et al.* ..... (A) 221

Lymphocyte(s)
ability of *M. leprae*, *M. w*, and ICRC bacillus to produce macrophage activating factors from, of leprosy patients. Prasad, H. K., *et al.* ..... (A) 544
allogeneic, transfusion of, inactivated with mitomycin C, passive transfer to patients by transfusion of. Saha, K., *et al.* ..... (A) 86
function in progressive *M. lepraemurium* infection. Banerjee, D. K. ..... (A) 385
human, of healthy donors, leukocyte migration inhibition with armadillo lepromin in. Fumarola, D. and Jirillo, E. ..... (A) 84
responses, *in vitro*, in borderline leprosy reactions. Bjune, G. and Barnetson, R. St. C. ..... (A) 396
—, to *M. leprae* and phytohemagglutinin, in mother and baby, at birth. Barnetson, R. St. C., *et al.* ..... (A) 378
—, to photohemagglutinin, by plasma, in mother and baby, at birth. Bjune, G., *et al.* (A) 538
splenic suppressor cell populations in *M. lepraemurium* infected mice, cell mediated lymphocytotoxic activity. Bullock, W. E., *et al.* ..... (A) 677
surface markers on, and cells of mononuclear phagocyte series, in skin sections of leprosy. Ridley, M. J., *et al.* ..... (A) 86
T, alteration of subpopulations of, immunoregulation in infection caused by *M. tuberculosis*, presence of suppressor monocytes. Katz, P., *et al.* ..... (A) 657
T and B, and blastogenesis, in leprosy. Sharma, S., *et al.* ..... (A) 650
—, determination of, in patients with different types of leprosy. Padierna, J., *et al.* .... (A) 383

Lymphocyte transformation,
cultures, phytohemagglutinin (PHA)-induced, *in vivo* effect of DDS on, in normal healthy volunteers. SENGUPTA, U., *et al.* ..... (O) 167
test, in healthy contacts of leprosy patients, influence of consanguinity with the patient, sex, and age. MENZEL, S., *et al.* ..... (O) 153
—, —, influence of household exposure. MENZEL, S. ..... (O) 138
(A) 374
—, decreased lymphocyte reactivity to *M. leprae* in lepromatous leprosy, no evidence of generalized impairment. Faber, W. R., *et al.* ..... (A) 539
—, presence of phytohemagglutinin, lepromin, and *M. leprae*, in culture medium with normal homologous serum. Pagnano, P. M. G., *et al.* ..... (A) 389

Lysosome(s),
phagosome-, fusion, and cyclic adenosine 3′:5′-monophosphate, in *M. microti*, *M. bovis* BCG, or *M. lepraemurium* infected macrophages. Lowrie, D. B., *et al.* ..... (A) 649
—, —, in cultured macrophages, *M. lepraemurium* as ingested organism, effects of anionic inhibitors of. Draper, P., *et al.* ..... (A) 653

Lysozyme,
serum amyloid protein SAA, C-reactive protein and, in leprosy, SCHEINBERG, M. A., *et al.* ..... (O) 133

McDougall, A. C.,
personal. Browne, S. G. ..... (N) 68

Macrocyclon,
and Triton WR-1339, effect of treatment *in vivo* with, on *M. leprae* mouse foot pad infection. Deville, J. and Jacques, P. J. ..... (A) 80

Macrophage(s),
ability of *M. leprae, M. w,* and ICRC bacillus to produce . . . activating factors, from lymphocytes of leprosy patients. Prasad, H. K., *et al.* ..... (A) 544
activated, scanning electron microscopic studies of, in the mouse. Nabarra, B., *et al.* (A) 229
armadillo, leprous and uninfected, peroxidase and acid phosphatase, electron microscopy of. McKeever, P. E., *et al.* ..... (A) 228
cultured, effect of anionic inhibitors of phagosome-lysosome fusion in, *M. lepraemurium* as ingested organism. Draper, P., *et al.* ..... (A) 653
diffusion chamber cultures, comparative effects of sulfones and rifampin on *M. lepraemurium* growth in. Rightsel, W. A., *et al.* ..... (A) 218
infected with *M. microti, M. bovis* BCG, or *M. lepraemurium,* phagosome-lysosome fusion and cyclic adenosine 3′:5′-monophosphate in. Lowrie, D. B., *et al.* ..... (A) 649
interaction between *M. fortuitum* and, from mouse peritoneal exudate, concerning intracellular ecology. Chu, C. Y. ..... (A) 553
lysozyme in, immunohistochemical observation of, in leprosy. Yamashita, K., *et al.* .. (A) 547
-mediated immunity, in *M. lepraemurium* infection, serum from infected mice suppresses. Preston, P. M. ..... (A) 653
non-stimulated and stimulated mouse peritoneal-derived and bone marrow-derived, *in vitro,* growth of *M. lepraemurium* in. Alexander, J. and Smith, C. C. ..... (A) 536
of nude mice, figures of multiplication of acid-fast bacilli in, electron microscope findings. Fukunishi, Y., *et al.* ..... (A) 668
role of, in lymphoproliferative response, to *M. leprae, in vitro.* Hirschberg, H. ..... (A) 649
———, studied by protein synthesis, resistant and susceptible mouse and human hosts, in leprosy. Birdi, T. J., *et al.* ..... (A) 537
systemic activation in *M. leprae* immunized mice. Patel, P. J. ..... (A) 679

Malawi,
dermatological clinic, leprosy control scheme in, ten years' experience. Rampen, F. ... (A) 92

Malaysia,
societal attitudes towards leprosy, changing role of the National Leprosy Control Centre, Sungei Buloh. Kandiah, N., *et al.* ..... (A) 213

Mali,
Marchoux Institute, Bamako, center for research and patient care. Pelletier, P. ..... (A) 636
twenty years of surgery at the Marchoux Institute, Bamako. Bourrel, P., *et al.* ..... (A) 449

Malta,
leprosy eradication project in, 6 year report. Depasquale, G. and Bonnici, E. ..... (A) 332

Mast cells,
in vivo response of, to lepromatous serum. Kumar, R., *et al.* ..... (A) 542
morphological changes in, and levels of serotonin and histamine, in leprosy patients. Kumar, R., *et al.* ..... (A) 391

Medical ethics,
Council for International Organizations of Medical Sciences (CIOMS) holds conference on medical experimentation and human rights, in Portugal. ..... (N) 71

Medication monitor,
potential uses in treatment of leprosy. MOULDING, T. S. ..... (O) 601

Mehta, J. N.,
obituary. ..... (Ob) 197

Mental illness,
mental state of leprosy patients. Campos, F. J., *et al.* ..... (A) 403
psychological rehabilitation of leprosy patients using group dynamics. Avila, J. J., *et al.* ..... (A) 403

Mercado, R.,
personal. ..... (N) 203

Mexico,
Dermatologia Revista Mexicana devotes August 1978 (Vol. 22, No. 2) issue to Lucio's leprosy. ..... (N) 524
XI International Leprosy Congress, held in Mexico City. ..... (S) 237
HLA-DRW antigens, in . . . leprosy patients. Rea, T. H. and Terasaki, P. I. ..... (A) 680
Morelos, leprosy control in. Villarreal, J. O. ..... (A) 331
official program of leprosy control in, history of. Ayala Uribe, G. ..... (A) 325
peripheral neuropathy and renal failure in a young . . . woman. Dawson, D. M., *et al.* ..... (A) 642

Microbiology,
reflections on, of leprosy. Delville, J. ..... (A) 548
workshop on. ..... (S) 291

Micronesia,
acedapsone in leprosy prevention, field trial, in three high prevalence villages in. Russell, D. A., *et al.* ..... (A) 329
(A) 655

Mitomycin C,
transfusion of allogeneic lymphocytes inactivated with, passive transfer of immunity, to leprosy patients. Saha, K., *et al.* ..... (A) 86

Morocco,
leprosy in. Sekkat, A., *et al.* ..... (A) 326
relapse and dapsone resistance in. Rollier, M., *et al.* ..... (A) 434

Morphology,
analysis of development of therapeutics, ultrastructure of lepromatous leprosy. Wilkinson, F. F., *et al.* ..... (A) 364
changes in mast cells and levels of serotonin and histamine, in leprosy patients. Kumar, R., *et al.* ..... (A) 391

Mother Teresa,
personal. Gordon, G. ..... (N) 624

Mouth,
clinical study of, in untreated lepromatous leprosy. Girdhar, B. K. and Desikan, K. V. ..... (A) 214
discharge of *M. leprae* from, in lepromatous leprosy patients. Hubscher, S., *et al.* ..... (A) 222

Murine leprosy,
attenuation of drug-treated, acid-fast bacilli isolated from mice administered with drugs (*in vivo*), drug-resistant bacilli (*in vitro*). Sushida, K. ..... (A) 230
cultivated, pathogenicity of Hawaiian-Ogawa strain, in mice. Kawaguchi, Y., *et al.* ..... (A) 653
—, —, —, pathogenicity of bacilli from rough colonies. Kawaguchi, Y., *et al.* ..... (A) 227
experimental, effect of *E. coli*-12 treated with liquid paraffin against the development of, in mice. Kunigoshi, U., *et al.* ..... (A) 88
systemic immunological reactivity in the absence of delayed-type hypersensitivity during. Poulter, L. W. ..... (A) 229

Muscle,
biopsies, 18 routine, data supplied by examining, in leprosy. Gray, F., *et al.* ..... (A) 541
—, electromyographic recording and, in lepromatous leprosy. Sebille, A. and Gray, F. ..... (A) 552
striated, *M. leprae* in, of tuberculoid leprosy patients. Koranne, R. V., *et al.* ..... (A) 541

Mycobacterial media,
newly formulated, application in rapid diagnosis of chronic mycobacterial diseases. Lew, J., *et al.* ..... (A) 553

Mycobacteriophage D_{29},
adsorption of, on *M. leprae*. David, H. L., *et al.* ..... (A) 547
interaction of *M. leprae* and. David, H. L., *et al.* ..... (A) 548

Mycobacteriosis,
examination of North American armadillos for. Sanchez, R. M. and Kirchheimer, W. F. ..... (A) 361

Mycobacterium,
host-phage relationships in the genus, clinical significance. Grange, J. M. and Redmond, W. B. ..... (A) 225

Mycobacterium avium,
infection of the skin, resembling lepromatous leprosy. Cole, G. W. and Gebhard, J. ... (A) 641

Mycobacterium balnei,
electroncytochemical study of cytochrome oxidase and peroxidase of, and other mycobacteria. Juscenko, A. A. and Maslov, A. K. ..... (A) 360

***Mycobacterium bovis* BCG,**
antibody response in rabbits to. Mshana, R. N., *et al.* ..... (A) 543
phagosome-lysosome fusion and cyclic adenosine 3′:5′-monophosphate with, and other mycobacteria. Lowrie, D. B., *et al.* ..... (A) 649

Mycobacterium fortuitum,
interaction between . . . and macrophages from mouse peritoneal exudate concerning intracellular ecology. Chu, C. Y. ..... (A) 553

Mycobacterium intracellulare,
Serotype Davis, comparative experiments in animals with, with reference to pathogenicity and virulence. Peters, M. and Kazda, J. ..... (A) 94

Mycobacterium kansasii,
action of dapsone on a susceptible strain of. Panitch, M. L. and Levy, L. ..... (A) 94
electroncytochemical study of cytochrome oxidase and peroxidase of, and other mycobacteria. Juscenko, A. A. and Maslov, A. K. ..... (A) 360

Mycobacterium leprae,
ability of, to produce macrophage activating factors from lymphocytes of leprosy patients. Prasad, H. K., *et al.* ..... (A) 544
absence of B-glucuronidase in, elevation of enzyme in infected tissues. Prabhakaran, K., *et al.* ..... (A) 223
acid-fastness of, problems raised by cultivation. Delville, J. ..... (A) 357
activity of combined drugs on, in mice. Pattyn, S. R. ..... (A) 412
— dihydrofolate reductase inhibitors against mouse foot pad infection. Gelber, R. and Levy, L. ..... (A) 409
— thiacetazone, thiambutosine, thiocarlide, and sulfamethoxypyridazine against, in mice. Colston, M. J., *et al.* ..... (A) 79
adsorption of mycobacteriophage D_{29} on. David, H. L., *et al.* ..... (A) 547
aminoglycoside antibiotics for, killing potential for various. Gelber, R. and Gibson, J. (A) 684
analysis of mycolates in, using high performance liquid chromotography and mass-spectrometry. Kusaka, T., *et al.* ..... (A) 667
and diphenoloxidase activity. Kim, S. J., *et al.* ..... (A) 360
— hamster cheek-pouch cells, host-parasite relationship between. Campo-Aasen, I. and Convit, J. ..... (A) 88
antigen 7, antibody activity against, during first year DDS treatment in lepromatous leprosy. Melsom, R., *et al.* ..... (A) 85
—, —, variation in antibody content throughout spectrum, effect of DDS treatment, relapse in BT leprosy. Yoder, L., *et al.* ..... (A) 651
—, formation of antibody against, in armadillos. Harboe, M., *et al.* ..... (A) 548
antigenic analysis of. Closs, O., *et al.* ..... (A) 374
— interrelationships of, studies on. Hastings, R. C., *et al.* ..... (A) 112
—, among selected mycobacterial species relative to, manifested by cell-mediated immunity, in guinea pigs. Shannon, E. J., *et al.* ..... (A) 674
— relationships, between *M. vaccae, M. nonchromogenicum* and. Collins, F. M., *et al.* ..... (A) 113
antithyroid drugs, action of. Levy, L. and Anandan, J. A. ..... (A) 531
athymic rat, immunological status and infection with. Colston, M. J., *et al.* ..... (A) 679

autoradiographic and metabolic studies of. Khanolkar, S. R., *et al.* ..... (A) 225
cell culture of, and of *M. lepraemurium*. Nomaguchi, H., *et al.* ..... (A) 368
cell-mediated immunity to, in mice. Lefford, M. J. ..... (A) 372
—, induction of, in guinea pigs. Mehra, V. and Bloom, B. R. ..... (A) 111
(A) 649
—, —, in mice. Patel, P. J. and Lefford, M. J. ..... (A) 90
cultivated, and antigenic reactions. Skinsnes, O. K. ..... (A) 360
cultivation, from human skin biopsy. Scollard, D. M. and Honey, N. R. ..... (A) 365
— trial, in cell-free liquid medium. Nakamura, M. ..... (A) 669
—, —, enigmatic growth in ND-15 MT and ST medium. Nakamura, M. ..... (A) 104
death and intracellular degradation of, after exposure *in vitro* to enzymatic free-radical generators. Delville, J. and Jacques, P. J. ..... (A) 80
delayed hypersensitivity, attempts to induce to, in healthy individuals and in "burnt-out" lepromatous patients. Smelt, A. H. M., *et al.* ..... (A) 377
—, responses in mice and guinea pigs to . . . cytoplasmic proteins, and by other mycobacteria. Watson, S. R., *et al.* ..... (A) 650
—, —, —. Collins, F. M. and Morrison, N. E. ..... (A) 375
—, skin reactions to homologous and heterologous antigens in guinea pigs immunized with, and other mycobacteria. Mustafa, A. S. and Talwar, G. P. ..... (A) 543
demonstration of, in tissues from bacteriologically negative lepromatous leprosy patients. Krieg, R. E. and Myers, W. M. ..... (A) 367
discharge of, from mouth, in lepromatous leprosy patients. Hubscher, S., *et al.* ..... (A) 222
early cellular response to. Chandi, S. M. and Job, C. K. ..... (A) 365
(A) 539
— immune responses in nude mice following intravenous infection of. Minagawa, F., *et al.* ..... (A) 89
(A) 542
electron microscopic observations of, by means of serial ultrathin sectioning. Hirata, T. ..... (A) 101
— studies of, during . . . breakdown in human lepromatous tissue. Bourges, M. ..... (A) 364
electroncytochemical study of cytochrome oxidase and peroxidase of, and other mycobacteria. Juscenko, A. A. and Maslov, A. K. ..... (A) 360
fetal immunity, lymphocyte responses to, and phytohemagglutinin in mother and baby at birth. Barnetson, R. St. C., *et al.* ..... (A) 378
five cultivable mycobacterial strains giving blast transformation and leukocyte migration inhibition of leukocytes analogous to. Mustafa, A. S. and Talwar, G. P. (A) 544
fluorescence microscopy for detection of, in tissue sections. JARIWALA, H. J. and KELKAR, S. S. ..... (O) 33
fluorescent leprosy antibody adsorption (FLA-ABS) test for detecting subclinical infection with. Abe, M. ..... (A) 379
fractionation of antigens of. Gillis, T. P. and Buchanan, T. M. ..... (A) 674
freezing and storage of, in liquid nitrogen. Hilson, G. R. F. and Colston, M. J. ..... (A) 368
from infected armadillos, studies on. Draper, P. ..... (A) 357
growth of, in thyroxine treated culture medium. Biswas, S. K. ..... (A) 87
heat stability of . . . immunogenicity. Shepard, C. C., *et al.* ..... (A) 654
hedgehogs (*Erinaceus europaeus*), inoculation with. Klingmüller, G. ..... (A) 374
ICRC bacilli, effect of vaccine from, against mouse foot pad infection. Bhide, M. B., *et al.* ..... (A) 339
identification of. Kirchheimer, W. F., *et al.* ..... (A) 666
immunity to infections, induced in mice by BCG vaccination, before and after challenge. Shepard, C. C., *et al.* ..... (A) 90
immunization, with antigen, in mice. Shepard, C. C. and Minagawa, F. ..... (A) 115
in the striated muscle of tuberculoid leprosy patients. Koranne, R. V., *et al.* ..... (A) 541
— tissue cultures of the nine-banded armadillo (*Dasypus novemcinctus*). Fieldsteel, A. H., *et al.* ..... (A) 669
-induced suppression of *in vitro* responses, in leprosy patients. Mehra, V., *et al.* ..... (A) 373
in vitro activation of, neutrophils by suspensions of. GOIHMAN-YAHR, M., *et al.* ..... (O) 570
— lymphoproliferative response to, in normal siblings, of lepromatous leprosy patients. Stoner, G. L., *et al.* ..... (A) 374

—, of HLA-D-identical siblings, —. Stoner, G. L., *et al.* ....(A) 546
in vitro test, for drug response and drug resistance of, using labelled metabolites. Ambrose, E. J., *et al.* ....(A) 410
inoculation, into 3 species of autochthonous armadillos, in Argentina. Baliña, L. M., *et al.* ....(A) 339
interaction of, and mycobacteriophage D_{29}. David, H. L., *et al.* ....(A) 548
intracytoplasmic . . . antigen, in inflammatory exudate of reactional lepromatous leprosy. González-Mendoza, A., *et al.* ....(A) 383
isolation of, using semisynthetic solid agar medium. Murohashi, T. and Yoshida, K. ..(A) 225
-lepromin, comparative study of skin reactions in leprosy patients to, and to antigens from cultivable saprophytic mycobacteria. Sharma, R. C. and Singh, R. ....(A) 546
leucine, stimulating effect of, on the growth of. Murohashi, T. and Yoshida, K. ....(A) 226
lymphocyte response, to human-derived and purified armadillo-derived . . . BCG and PPD. Smelt, A. H. M., *et al.* ....(A) 224
— transformation test, decreased lymphocyte reactivity to, in lepromatous leprosy. Faber, W. R., *et al.* ....(A) 539
—, in leprosy patients, presence of phytohemagglutinin, lepromin and, in culture medium with normal homologous serum. Pagnano, P. M. G., *et al.* ....(A) 389
lymphoproliferative response, role of macrophages in, *in vitro*. Hirschberg, H. ....(A) 649
99m TcO_4 brain scan in . . . infection. Raizada, N., *et al.* ....(A) 418
NI (neuron invasion) gene of. Barksdale, L. ....(A) 358
neonatally thymectomized Lewis rats, infected, combination dapsone-rifampin therapy in. Fieldsteel, A. H. and Levy, L. ....(A) 108
—, —, histopathologic and electron microscopic observations. Dawson, P. J., *et al.* .(O) 561
neuritis after intradermal tests, in tuberculoid leprosy patients. Serial, A. ....(A) 426
ocular histopathology, in experimentally infected animals, . . . and *M. lepraemurium* in mice. Hobbs, H. E., *et al.* ....(A) 549
—, —, infection in the 9-banded armadillo (*Dasypus novemcinctus*). McDougall, A. C., *et al.* ....(A) 549
other mycobacteria and a possible vaccine. Stanford, J. C., *et al.* ....(A) 357
penicillin, effect of, on experimental infection in mice. Delville, J., *et al.* ....(A) 227
persistence and drug resistance of, obstacles to chemotherapy of lepromatous leprosy. Levy, L. ....(A) 408
pleomorphic organism with non-mycobacterial, cultivable, precursor phase. Chatterjee, B. R. ....(A) 359
"proportional bactericidal test," to assess drug activity against. Colston, M. J., *et al.* (A) 79
protein derivative, from . . . suspensions, in semi-synthetic medium. Kantor, I. de, *et al.* ....(A) 387
purified armadillo-derived (PAD), immunological studies in guinea pigs and man, on bacteria and cell-free extracts of. Rees, R. J. W., *et al.* ....(A) 380
pyridine extractability of acid-fastness from. McCormick, G. T. and Sanchez, R. M. ....(O) 495
— extraction of. Convit, J. ....(C) 517
quantitative aspects of experimental infection of armadillos with. Kirchheimer, W. F., *et al.* ....(A) 337
rifampin and isoprodian combined, to treat infection in mice. Matsuo, Y., *et al.* ....(A) 531
serum glycoprotein studies in armadillos experimentally infected with. Harris, E. B., *et al.* ....(A) 344
skin reactions, to -lepromin and to ICRCin, antigen from cultivable acid-fast bacilli from. Bapat, C. V. ....(A) 381
— reactive antigens of. Ulrich, M., *et al.* ....(A) 386
— test, responsiveness, using soluble . . . antigen, and *M. tuberculosis* antigen, and mixture of two, investigation of mechanisms regulating. Samuel, N. M., *et al.* ....(A) 385
—, trial, with non-acid-fast organism from leprous tissues, to establish immunological identity with. Delville, J. and Chatterjee, B. R. ....(A) 366
specific and nonspecific resistance, in mice immunized with irradiated. Patel, P. J. and Lefford, M. J. ....(A) 116
(A) 229

— antibodies, detected by radioimmunoassay. Harboe, M., *et al.* ..... (A) 84
— protein antigen, serodiagnosis of leprosy. CALDWELL, H. D., *et al.* ..... (A) 114
(O) 477
— vaccine, on cell-mediated immunity of armadillos against. Kirchheimer, W. F., *et al.* ..... (A) 390
streptomycin, evaluation of activity of. Pattyn, S. R. and Saerens, E. ..... (A) 531
susceptibility of armadillos to infection by. Innami, S., *et al.* ..... (A) 339
systemic macrophage activation in . . . immunized mice. Patel, P. J. ..... (A) 679
Triton WR-1339 and Macrocyclon, effect of treatment *in vivo* with, on mouse foot pad infection. Delville, J. and Jacques, P. J. ..... (A) 80
ultrastructural study, . . . obtained from a human leproma. Sanabria, N. J. ..... (A) 364
—, of cells in peritoneal exudate of mice exposed to. Diaz Almeida, J. G., *et al.* ..... (A) 365
ultrastructure, comparative, of . . . and *M. lepraemurium* cell envelopes. Nguyen, H.T., *et al.* ..... (A) 652
—, of . . . in human leproma. Sanabria, Kh., *et al.* ..... (A) 652
vaccination experiments with . . . preparations, and with cultivable mycobacteria. Shepard, C. C. ..... (A) 677
vaccine from ICRC bacilli, against mouse foot pad infection. Bhide, M. B., *et al.* ..... (A) 537
viability of, outside human body. Desikan, K. V. and Sreevatsa ..... (A) 366
yeast glucan, therapeutic effect in mice infected with. Delville, J. and Jacques, P. J. .. (A) 227

Mycobacterium lepraemurium,
analysis of mycolates in *M. leprae* and, using high performance liquid chromotography and mass-spectrometry. Kusaka, T., *et al.* ..... (A) 667
and phenoloxidase activity. Kim, S. J., *et al.* ..... (A) 651
antigenic substances of. Mzkino, M., *et al.* ..... (A) 397
cell culture of *M. leprae* and. Nomaguchi, H., *et al.* ..... (A) 368
continuous *in vitro* growth of. Dhople, A. M. and Hanks, J. H. ..... (A) 103
(A) 361
cord factor of *in vivo*-derived. Goren, M. G., *et al.* ..... (A) 651
cultivation of, in flask system. Nakamura, M. ..... (A) 369
cytochromes of. Mori, T. ..... (A) 369
delayed-type hypersensitivity, development of, in infections in resistant and susceptible strains of mice. Alexander, J. and Curtis, J. ..... (A) 652
—, relationship between, and the progression of . . . infection. Poulter, L. W. and Lefford, M. J. ..... (A) 230
effects of anionic inhibitors of phagosome-lysosome fusion, in cultured macrophages, . . . as ingested organism. Draper, P., *et al.* ..... (A) 653
electron microscopic observations, by means of serial ultrathin sectioning. Hirata, T. (A) 101
—, of intracytoplasmic membrane systems and cell division in. HIRATA, T. ..... (O) 585
electron transport and ATP generation in host-grown. Ishaque, M., *et al.* ..... (A) 363
electroncytochemical study of cytochrome oxidase and peroxidase of, and other mycobacteria. Juscenko, A. A. and Maslov, A. K. ..... (A) 360
endocytic ability of peripheral blood leukocytes, measured by capacity to ingest . . . *in vitro*. Rojas-Espinosa, O. and Aponte-Vázquez, J. ..... (A) 422
growth factors of, egg yolk protein fraction. Mori, T. and Nyein, M. M. ..... (A) 103
— of, in mouse, human, and chick cells, by soft agar technique. Nomaguchi, H., *et al.* ..... (A) 667
—, in non-stimulated and stimulated mouse peritoneal-derived and bone marrow-derived macrophages *in vitro*. Alexander, J. and Smith, C. C. ..... (A) 536
interaction of, and BCG infections in mice. Lefford, M. J. ..... (A) 678
— *M. microti* and, with mouse polymorphonuclear leukocytes. Smith, C. C., *et al.* ... (A) 658
lymphocyte function in progressive . . . infection. Banerjee, D. K. ..... (A) 385
Mitsuda-type lepromin reactions as a measure of host resistance in . . . infection. Curtis, J. and Turk, J. L. ..... (A) 652
ocular histopathology in animals experimentally infected with *M. leprae* and, in the mouse. Hobbs, H. E., *et al.* ..... (A) 549
—, in the 9-banded armadillo. McDougall, A. C. and Rees, R. J. W. ..... (A) 549
partial inhibition of the growth of, in C3H mice immunized with cell wall skeletons. TANAKA, Y. ..... (O) 487

phagosome-lysosome fusion and cyclic adenosine 3′:5′-monophosphate in macrophages infected with, or other mycobacteria. Lowrie, D. B., *et al.* ..... (A) 649
radiometric measurement of differential metabolism of fatty acids by. CAMARGO, E. E., *et al.* ..... (O) 126
serum from infected mice suppresses macrophage-mediated immunity in . . . infection. Preston, P. M. ..... (A) 653
sulfones and rifampin on growth of, in macrophage diffusion chamber cultures. Rightsel, W. A., *et al.* ..... (A) 218
ultrastructure, comparative, of *M. leprae* and . . . cell envelopes. Nguyen, H. T., *et al.* ..... (A) 652

Mycobacterium marinum,
granuloma, ultrastructure of, in man. Marsch, W. C., *et al.* ..... (A) 234

Mycobacterium microti,
interaction of . . . and *M. lepraemurium,* with mouse polymorphonuclear leukocytes. Smith, C. C., *et al.* ..... (A) 658
phagosome-lysosome fusion and cyclic adenosine 3′:5′-monophosphate in macrophages infected with, and other mycobacteria. Lowrie, D. B., *et al.* ..... (A) 649

Mycobacterium nonchromogenicum,
cytoplasmic proteins, delayed hypersensitivity responses in mice and guinea pigs to, and other mycobacteria. Watson, S. R., *et al.* ..... (A) 650

Mycobacterium tuberculosis,
electroncytochemical study of cytochrome oxidase and peroxidase of, and other mycobacteria. Juscenko, A. A. and Maslov, A. K. ..... (A) 360
immunoregulation in infection caused by. Katz, P., *et al.* ..... (A) 657
soluble antigen, and of *M. leprae,* and mixture of the two, investigation of mechanisms regulating skin test responsiveness in leprosy patients. Samuel, N. M., *et al.* ..... (A) 385

Mycobacterium vaccae,
antigenic evaluation of, mycobacterium possibly related taxonomically to *M. leprae.* Navalkar, R. G., *et al.* ..... (A) 390
cytoplasmic protein, antigens, delayed hypersensitivity responses to *M. leprae* and. Collins, F. M. and Morrison, N. E. ..... (A) 375
—, delayed hypersensitivity responses in mice and guinea pigs to, and other mycobacteria. Watson, S. R., *et al.* ..... (A) 650

Mycobacterium w,
ability of *M. leprae,* . . . , and ICRC bacillus to produce macrophage activating factors from lymphocytes of leprosy patients. Prasad, H. K., *et al.* ..... (A) 544
local reactions to intradermal instillation of . . . and ICRC bacilli in mice. Fotedar, A., *et al.* ..... (A) 540

Mycobacterium xenopi,
sensitin, skin sensitivity of adults on the Isthmus of Panama to. Larrabee, W. F., Jr. and Talavera, R. ..... (A) 553

Mycolates,
in *M. leprae* and, analysis of, using high performance liquid chromotography and mass-spectrometry. Kusaka, T., *et al.* ..... (A) 667

Nerve(s),
changes in leprosy. Klingmüller, G. ..... (A) 84
conduction velocities, respective importance of different, in leprosy. Sebille, A. ..... (A) 552
cranial, involvement of, with reference to treatment, in leprosy. Namba, M. and Kobayashi, S. ..... (A) 428
damage, permanent, prevention of, reversal reaction, short and long-term steroid treatment compared. NAAFS, B., *et al.* ..... (O) 7
—, prospects for study and application for therapy, in leprosy. Pearson, J. M. H. ..... (A) 426
—, quantitative study, in leprosy. Ramchandra Bhat, K., *et al.* ..... (A) 341
decompression, elective surgical, technics and results, in leprosy. Pandya, N. J., *et al.* ..... (A) 76

—, pathological and hemodynamic bases of. Carayon, A. ..... (A) 425
electrophysiological evidence for motor-unit impairment during treatment. Sebille, A. (A) 428
function, assessment of, in leprosy. Naafs, B. and van Droogenbroeck, J. B. A. ..... (A) 427
greater auricular nerve in diagnosis of. Lynch, P. ..... (A) 534
hypertrophy, major tuberculoid leprosy with. Cottenot, F. and Pennec, J. ..... (A) 84
involvement, ultrastructure of beginning and progressive, in leprosy patients. Boddingius, J. ..... (A) 425
leprosy, an infectious and immunological disorder of the nervous system. Dastur, D. K. ..... (A) 645
lesions, evolution of, in leprosy. Antia, N. H., *et al.* ..... (A) 427
motor, conduction velocity, in leprosy, correlation with clinical and histological findings. Chopra, J. S., *et al.* ..... (A) 427
nervous system, in leprosy. Dastur, D. K. ..... (A) 646
non-myelin human, antigen producing granulomatous hypersensitivity in rabbits. Hardwicke, P. M. D. and Crawford, C. L. ..... (A) 341
peripheral, biopsies in leprosy diagnosis, in Aboriginal patients, Northern Territory of Australia. McDougall, A. C., *et al.* ..... (A) 534
—, ultrastructural changes in blood vessels of, and of skin in leprosy patients. Boddingius, J., *et al.* ..... (A) 430
review of recent findings concerning a case of leprosy affecting the. Khoubessarian, P., *et al.* ..... (A) 642
segmental demyelination in, in human and mouse model, assessed by teased fiber technique, with electrophysiological correlation. Shetty, V. P., *et al.* ..... (A) 429
sensory peripheral, as antigen, skin lesions, granulomatous hypersensitivity, cutaneous . . . damage. Crawford, C. L. and Hardwicke, P. M. D. ..... (A) 340
superficial peroneal . . . thickening, as early diagnostic sign, in leprosy. Vaidyanathan, E. P. and Vaidyanathan, S. I. ..... (A) 79
surgery, in leprosy. van Droogenbroeck, J. B. A. and Naafs, B. ..... (A) 452
ulnar, calcified abscess in the, in a leprosy patient. Lichtman, D. M., *et al.* ..... (A) 642
—, paralysis, surgical treatment of, in leprosy. Palande, D. D. ..... (A) 451

Neuritis,
adaptation of decompression methods, to clinical forms of. Carayon, A. ..... (A) 451
after intradermal tests with *M. leprae*, in patients with tuberculoid leprosy. Serial, A. (A) 426
decompression in leprosy, as a therapeutic and preventive measure. Bose, K. S. ..... (A) 451
experimental allergic. Vaidya, M. C., *et al.* ..... (A) 341
— sensory poly-, electrophysiological studies of, in rabbits. Pascoe, J. E. and Crawford, C. L. ..... (A) 341
leprous, pathological and immunological basis of medical intervention in. Job, C. K. .. (A) 426
rifampin-associated, symptomatic neuritic leprosy, precipitated by rifampin and isoniazid treatment of tuberculosis and. Goodwin, C. S., *et al.* ..... (A) 428

Neuropathy,
autonomic, in leprosy, cardiovascular evaluation. Radhakrishnan, K., *et al.* ..... (A) 215
compression, of the radial nerve, in leprosy. Charosky, C., *et al.* ..... (A) 450
correlations of *in vitro* electrophysiological, light, and electronmicroscopical studies in, in leprosy. Pandya, S. S., *et al.* ..... (A) 430
multiple mono-, in lymphomatoid granulomatosis, similarities to leprosy. Garcia, C. A., *et al.* ..... (A) 533
peripheral, and renal failure, in a young Mexican woman. Dawson, D. M., *et al.* ..... (A) 642
— vascular deficit, in leprosy, role in pathogenesis of. Kaur, S., *et al.* ..... (A) 429
results of surgical treatment, in leprosy. Ganopol, J., *et al.* ..... (A) 452

Neutrophil(s),
activation in adjuvant disease, implications for reactional lepromatous leprosy. Convit, J., *et al.* ..... (A) 382
in vitro activation of, by suspensions of *M. leprae*. GOIHMAN-YAHR, M., *et al.* ..... (O) 570
significance of activation, in reactional lepromatous leprosy, effects of thalidomide *in vivo* and *in vitro*. Goihman-Yahr, M., *et al.* ..... (A) 220

New Guinea (Papua),
Karimui, acedapsone (DADDS) trial, ten year status, of leprosy patients. Russell, D. A., *et al.* ..... (A) 435
—, leprosy in, genetic susceptibility investigated. Shields, E. D., *et al.* ..... (A) 334

New Hebrides,
epidemiology of leprosy in. Ratard, R. C. and Bravo, L. I. ..... (A) 92

Nicaragua,
past, present, and future of leprosy in. Gomez Urcayo, F., *et al.* ..... (A) 331
psycho-social change, in National Dermatological Center, in leprosy. Soto-Garcia, G., *et al.* ..... (A) 404

Niskanen, O.,
personal. ..... (N) 202

Nobel Prize,
Mother Teresa receives. Gordon, G. ..... (N) 624

Nocardiae,
immunological relatedness of ribosomes, from mycobacteria, . . . , and corynebacteria, and microorganisms in leprosy lesions. Laub, R., *et al.* ..... (A) 542

Norway,
medical researcher position available at AHRI. ..... (N) 619

Nose,
evolution of nasal mucosal lesions, histopathological study, in leprosy. Mehta, L., *et al.* ..... (A) 416
in treated lepromatous leprosy, clinical and histopathological studies of the. Barton, R. P. E., *et al.* ..... (A) 348
primary leprosy involvement of nasal mucosa, in apparently healthy household contacts, of leprosy patients. Chacko, C. J. G., *et al.* ..... (A) 417

Nude mice,
albino (*Mus musculus*), experimental cutaneous leishmaniasis with *Leishmania tropica* in. Packchanian, A. ..... (A) 554
as an experimental lepromatous leprosy model, enhancing effect of thymus cells. Nakamura, K. and Yogi, Y. ..... (A) 105
(A) 338
chemotherapy of leprosy with. Kohsaka, K., *et al.* ..... (A) 107
(A) 673
establishment of experimental leprosy in. Kohsaka, K., *et al.* ..... (A) 228
figures of multiplication of acid-fast bacilli in the macrophage of, electron microscope findings. Fukunishi, Y., *et al.* ..... (A) 668
for research in leprosy. Kohsaka, K. ..... (A) 337

Obituaries,
Khanolkar, V. R. ..... (Ob) 197
Mehta, J. N. ..... (Ob) 197
Théorêt, P. E. Skinsnes, O. K. ..... (Ob) 198
Torsuev, N. A. Juscenko, A., *et al.* ..... (Ob) 61

Onchocerciasis,
and lepromatous leprosy. Prost, A., *et al.* ..... (A) 654

Ophthalmology,
Dr. Margaret Brand lectures on, at Schieffelin Leprosy Research Centre. ..... (N) 203

Panama,
skin sensitivity of adults on the Isthmus of, to *M. xenopi* sensitin. Larrabee, W. F., Jr. and Talavera, R. ..... (A) 553

Paraguay,
Leprosy Board of, present control program. Masi, D. A. ..... (A) 405

Passive transfer,
of immunity to leprosy patients, by transfusion of allogeneic lymphocytes, inactivated by mitomycin C, attempt at. Saha, K., *et al.* ..... (A) 86

Pathology,
at International Congresses. AZULAY, R. D., *et al.* ..... (C) 63
changes in testis and epididymis of infertile leprolic males. IBRAHIEM, A. A., *et al.* ..... (O) 44
of leprosy. Ridley, D. S. ..... (A) 636
— tropical and extraordinary diseases. Binford, C. H. and O'Connor, D. H. ..... (B) 206

Peroxidase,
electron microscopy of, and acid phosphatase, in leprous and uninfected armadillo macrophages. McKeever, P. E., *et al.* ..... (A) 228

PHA, (see phytohemagglutinin),

Phagocyte(s),
defective blood mononuclear . . . function, in leprosy patients. ESTEVEZ, M. E., *et al.* ..... (O) 575
mononuclear- . . . series, cellular responses in leprosy and related diseases, with reference to cells of the. Ridley, M. J., *et al.* ..... (A) 393
surface markers on lymphocytes and cells of the mononuclear . . . series, in skin sections, in leprosy. Ridley, M. J., *et al.* ..... (A) 86

Phagocytosis,
in leprosy, endocytic ability of peripheral blood leukocytes, measured by capacity to ingest *M. lepraemurium in vitro*. Rojas-Espinosa, O. and Aponte-Vázquez, J. ..... (A) 422

Phenoloxidase,
M. leprae and. Kim, S. J., *et al.* ..... (A) 651

Philippines,
DDS chemoprophylaxis, for children, at Culion Sanitarium, Palawan. Lara, C. B. ..... (A) 216
Mercado, Dr. R., becomes Director of Health Services Development and Planning, for WHO Western Pacific Regional Office. ..... (N) 203

Phosphatase,
acid, electron microscopy of peroxidase and, in leprous and uninfected armadillo macrophages. McKeever, P. E., *et al.* ..... (A) 228

Phytohemagglutinin (PHA),
in vitro modulation of lymphocyte responses to, by plasma, in mother and baby at birth. Bjune, G., *et al.* ..... (A) 538
in vivo effect of DDS on -induced lymphocyte transformation cultures, in normal healthy volunteers. SENGUPTA, U., *et al.* ..... (O) 167
lymphocyte responses to *M. leprae* and, in mother and baby, at birth, fetal immunity in leprosy. Barnetson, R. St. C., *et al.* ..... (A) 378
— transformation test (LTT) in leprosy patients, presence of . . . in culture medium with normal homologous serum. Pagnano, P. M. G., *et al.* ..... (A) 389
skin test in leprosy patients, compared with other delayed type hypersensitivity skin tests. Ozawa, T., *et al.* ..... (A) 422

Portugal,
Council for International Organizations of Medical Sciences meets. ..... (N) 71

Postage stamp(s),
official stamping of the commemorative postage stamp of the XI International Leprosy Congress. ..... (S) 262

Pregnancy,
leprosy in. Maurus, J. N. ..... (A) 214

Protein,
identification of an *M. leprae* specific . . . antigen, possible application for serodiagnosis of leprosy. CALDWELL, H. D., *et al.* ..... (A) 114
(O) 477
serum, polymorphisms, genetic markers and leprosy in South African Negroes. Hitzeroth, H. W., *et al.* ..... (A) 551

synthesis, of macrophages from resistant and susceptible hosts, role as studied by. Birdi, T. J., *et al.* ..... (A) 537

Prothionamide,
administration, of combination of isoniazid, DDS, and, in pulmonary tuberculosis, in adults, clinical report. Orlowski, E. H. ..... (A) 82
effect of ethionamide and, in experimental leprosy. Pattyn, S. R. ..... (A) 229
experimental studies on antileprosy activity of ethionamide and. Colston, M. J., *et al.* ..... (A) 79
results of treating leprosy patients with. Bragina, V. S. ..... (A) 437

Pseudocholinesterase,
types, distribution of, in leprosy patients. Navarrete, J. I., *et al.* ..... (A) 344

Pseudomonas putrefaciens,
opportunistic infection of chronic skin ulcers with. Applebaum, P. C. and Bowen, A. J. ..... (A) 74

Psoriasis,
and leprosy, in light of common history. Eckes, L. K. ..... (A) 527

Pyoderma gangrenosum,
clofazimine in the treatment of. Thomsen, K. and Rothenborg, H. W. ..... (A) 554

Pyridine,
extractability, of acid-fastness from *M. leprae*. McCormick, G. T. and Sanchez, R. M. ..... (O) 495
extraction of *M. leprae*. Convit, J. ..... (C) 517
reply to Dr. Convit's Letter to the Editor. Slosarek, M. ..... (C) 518

Rabbit(s),
antibody response in, to *M. bovis* BCG. Mshana, R. N., *et al.* ..... (A) 543
electrophysiological studies of experimental sensory polyneuritis in. Pascoe, J. E. and Crawford, C. L. ..... (A) 341
non-myelin human nerve antigen producing granulomatous hypersensitivity in. Hardwicke, P. M. D. and Crawford, C. L. ..... (A) 341

Radioactivity,
distribution in pregnant mice of, after injection of ^{131}I and immunosuppressive effects, after whole body irradiation. Sushida, K. and Nakano, H. ..... (A) 231

Radioimmunoassay,
M. leprae specific antibodies detected by. Harboe, M., *et al.* ..... (A) 84

Radio-immunology,
detection of the surface antigen and the antibody of hepatitis B by. Chiron, J. P., *et al.* ..... (A) 532
measurement of differential metabolism of fatty acids by *M. lepraemurium*. Camargo, E. E., *et al.* ..... (O) 126

Radiology,
bone absorption in fingers, in leprosy, ten-year study. MacMoran, J. W. and Brand, P. W. ..... (A) 671

Reaction,
and levamisole (R 12564). Cardama, J. E., *et al.* ..... (A) 440
clinical aspects, reactional episodes. Hastings, R. C. ..... (A) 348
comparison of, to Dharmendra antigen, in normal skin and lesion, of leprosy patients. Price, J., *et al.* ..... (A) 535
early and late, in tuberculoid and lepromatous leprosy patients, with lepromins from *M. leprae* and five selected cultivable mycobacteria. Mustafa, A. S. and Talwar, G. P. ..... (A) 543
immunofluorescence studies, with reference to treatment. Faber, W. R., *et al.* ..... (A) 220
immunological studies, in leprosy patients treated with thalidomide. Rodríguez-Padilla, C., *et al.* ..... (A) 396
lepra, nine thalidomide derivatives in, study of. Skeskin, J. ..... (A) 218
liver, involvement of, in leprosy. Tolentino, M. M., *et al.* ..... (A) 353

local, to intradermal instillation of *M. w* and ICRC bacilli in mice. Fotedar, A., *et al.* (A) 540
Mitsuda-type lepromin, as a measure of host resistance to *M. lepraemurium* infection. Curtis, J. and Turk, J. L. (A) 652
neutrophil activation in, in adjuvant disease, effects of thalidomide *in vivo* and *in vitro*. Goihman-Yahr, M., *et al.* (A) 220
—, —, implications for. Convit, J., *et al.* (A) 382
polymorphonuclear activation in, effects of thalidomide *in vivo* and *in vitro*. Goihman-Yahr, M., *et al.* (A) 373
reversal, histopathologically documented, following treatment with transfer factor, in lepromatous leprosy. Hastings, R. C. and Job, C. K. (A) 439
—, in lepromatous leprosy patients, after transplantation of human fetal thymic grafts. Saha, K., *et al.* (A) 223
—, nerve damage, permanent, short and long-term steroid treatment. NAAFS, B., *et al.* (O) 7
skin, delayed hypersensitivity, to lepromin, and antigens prepared from four other mycobacteria. Govil, D. C. and Bhutani, L. K. (A) 540
—, —, to lepromins prepared from *M. leprae* and selected cultivable mycobacteria. Hogerzeil, L. M. and Prabduhass, N. (A) 541
—, induced by lepromin and four other mycobacterial antigens. Sahib, H. S. M. and Vellut, C. (A) 545
—, to *M. leprae*-lepromin and to antigens from cultivable saprophytic mycobacteria. Sharma, R. C. and Singh, R. (A) 546
treatment, of lepromatous lepra, with reference to thalidomide. Sheskin, J. (A) 433
—, of reversal. Barnetson, R. St. C. (A) 434

Rees, R. J. W.,
personal. (N) 202

Rehabilitation,
health education. Neville, P. J. (A) 446
—, evaluation in leprosy. Mutatkar, R. K. (A) 94
medical and socio-economic of Cuban leprosy patients. Werthein, L. J., *et al.* (A) 447
method for standardizing physiotherapy assessments. Kolumban, S. L. (A) 450
planning, of leprosy patients. Manzi, R. O. (A) 446
pragmatic approach, in a developing country. Gershon, W. and Mani, R. S. (A) 447
prospects, through self-employment, of leprosy patients. Mehendale, M. S. and Shriyan, S. K. (A) 93
protection of anesthetic limbs, of patients in rural areas, in developing countries. Palani, N. (A) 449
role of surgery in, overview, in leprosy. Antia, N. H. (A) 446
social, of leprosy patients. Maldonado-Romero, D. (A) 448

Rehabilitation International,
announcement of available publications. (N) 619
to hold 1980 World Congress in Winnipeg, Canada. (N) 68

Relapse,
and dapsone resistance, in Morocco, Rollier, M., *et al.* (A) 434
in BT leprosy, antibody activity against *M. leprae* antigen 7, variation in antibody content, effect on DDS treatment and. Yoder, L., *et al.* (A) 651
— lepromatous leprosy. Sanada, K. (A) 419

Renal disease,
abnormalities, results of long-term sulfone therapy for lepromatous leprosy, frequency of drug resistance. Terencio de las Aguas, J. (A) 433
changes, in leprosy, clinical, bacteriological, histological, and functional appraisal. Thomas, A., *et al.* (A) 421
complications, of infectious diseases, Eknoyan, G. and Dillman, R. O. (A) 533
damage, in leprosy. Loginov, V. K. and Sluvko, Z. A. (A) 350
dysfunction, in leprosy. Mohanty, H. (A) 418
failure, in a young Mexican woman, peripheral neuropathy and. Dawson, D. M., *et al.* (A) 642

percutaneous biopsy study, immune complex deposit in leprosy. Almeida Brandao, C. B. P., *et al.* ..... (A) 421
tuberculosis, clinical observations of. Kim H. S. ..... (A) 233
—, —, in 122 inpatients. Choi, S. H. ..... (A) 233

Respiratory system,
involvement of, in leprosy. KAUR, S., *et al.* ..... (O) 18
—, —. Kumar, B., *et al.* ..... (A) 349

Rheumatoid factor,
and leprosy. Ellis, B. P. B. ..... (A) 84

Ribosomes,
immunological relatedness of, from mycobacteria, nocardiae, corynebacteria, and microorganisms in leprosy lesions. Laub, R., *et al.* ..... (A) 542

Rifampin,
and isoprodian, combination, in treatment of *M. leprae* infections in mice. Matsuo, Y., *et al.* ..... (A) 531
-associated neuritis, symptomatic neuritic leprosy precipitated by . . . and isoniazid treatment of tuberculosis. Goodwin, C. S., *et al.* ..... (A) 428
clinical trial of, in lepromatous leprosy. Babu, N. V. ..... (A) 444
comparative effects of sulfones and, on *M. lepraemurium* growth, in macrophage diffusion chamber cultures. Rightsel, W. A. *et al.* ..... (A) 218
dapsone-, combination therapy, in neonatally thymectomized Lewis rats, with *M. leprae* infection. Fieldsteel, A. H. and Levy, L. ..... (A) 108
—, tissue levels of dapsone, during combined therapy. Peters, J. H. ..... (A) 408
efficacy and tolerability of, in Burmese lepromatous leprosy patients. Shwe, T., *et al.* (A) 640
erythema multiforme bullosum due to. Nigam, P., *et al.* ..... (A) 639
for lepromatous leprosy, nine years' experience. Waters, M. F. R., *et al.* ..... (A) 83
—, treatment. Jacobson, R. R. ..... (A) 682
four-weekly "pulse therapy" with, in sulfone-resistant lepromatous leprosy, interim report. Laing, A. B. G., *et al.* ..... (A) 437
hepatotoxicity and functional acute renal insufficiency due to. Errasti, P., *et al.* ..... (A) 529
in the treatment of lepromatous leprosy. Gatti, J. C., *et al.* ..... (A) 436
influence of, on DDS excretion in urine. Balakrishnan, S. and Sheshadri, P. S. ..... (A) 529
interacts with steroids. JOPLING, W. H. and PETTIT, J. H. S. ..... (C) 610
introductory . . . therapy, six month follow-up study, in lepromatous leprosy. Girdhar, B. K., *et al.* ..... (A) 529
-levamisole, combination, double-blind trial, in lepromatous leprosy treatment. Liturri, M. and Wilkinson, F. ..... (A) 442
metabolic disposition of dapsone (DDS) and, in nine-banded armadillos (*Dasypus novemcinctus*). Murray, J. F., Jr., *et al.* ..... (A) 409
short course treatment, of TT and BT leprosy. Bourland, J. and Pattyn, S. R. ..... (A) 437
—, of two months, of paucibacillary leprosy. Pattyn, S. R., *et al.* ..... (A) 639
therapeutic effects of adding Rimactane® 450 mg daily or 1200 mg once monthly in a single dose to dapsone 50 mg daily, in lepromatous leprosy patients. LANGUILLON, J., *et al.* ..... (O) 37
(A) 436
treatment of 5000 leprosy patients, in Cuba. Abreu, A., *et al.* ..... (A) 436

Riordan, D.
personal. ..... (N) 205

Saudi Arabia,
leprosy in, preliminary study of. Sebai, Z. A., *et al.* ..... (A) 333

Scalp,
alopecia, in leprosy. Fraguela Rangel, J. V., *et al.* ..... (A) 533

Serotonin,
morphological changes in mast cells and levels of, and histamine in. Kumar, R., *et al.* ..... (A) 391

Serra, Rev. R.,
personal. ..... (N) 203

Serum (sera),
alpha-1-antitrypsin, in various forms of leprosy. Agarwal, S. K. and Saha, K. ..... (A) 219
amyloid protein (SAA), C-reactive protein, lysozyme, in leprosy. SCHEINBERG, M. A., *et al.* ..... (O) 133
antilymphocyte . . . (ALS), on experimental transmission of leprosy bacilli, in mice. Sushida, K. ..... (A) 105
beta-glucuronidase, preliminary report, in leprosy. Venkatesan, K., *et al.* ..... (A) 644
calcium and magnesium in different types of leprosy. Sinha, S. N., *et al.* ..... (A) 224
comparative profile, in leprosy-related and non-leprosy-related families. Quesada-Pascual, F., *et al.* ..... (A) 394
dapsone in urine and, demonstration of, by enzyme-linked immunosorbent inhibition technique. Huikeshoven, H., *et al.* ..... (A) 328
direct and indirect immunofluorescent studies of lesions, normal skin and, of leprosy patients. Saylan, T., *et al.* ..... (A) 392
electrophoretic patterns, in lepromatous leprosy, effect of tubercin-3 on. Byun, S. Y. and Chung, T. H. ..... (A) 538
fibrinolytic activity, in leprosy. Sharda, D. P., *et al.* ..... (A) 643
free fatty acid levels, glucose tolerance and, in leprosy. Bharadwaj, V. P., *et al.* ..... (A) 641
from infected mice suppresses macrophage-mediated immunity on *M. lepraemurium* infection. Preston, P. M. ..... (A) 653
glycoprotein studies, in *M. leprae* infected armadillos. Harris, E. B., *et al.* ..... (A) 344
immunoglobulins, in leprosy. Kelkar, S. S., *et al.* ..... (A) 642
immunological assessment of, of leprosy patients. Sengupta, U., *et al.* ..... (A) 535
iron and total iron binding capacity, in leprosy patients. Bharadwaj, V. P., *et al.* ..... (A) 219
lepromatous, *in vivo* response of mast cells to. Kumar, R., *et al.* ..... (A) 542
protein polymorphisms, genetic markers and leprosy in South African Negroes. Hitzeroth, H. W., *et al.* ..... (A) 551

Sexual dysfunction,
pathologic changes in testis and epididymis of infertile leprotic males. IBRAHIEM, A. A., *et al.* ..... (O) 44

Shepard, C. C.,
personal. ..... (N) 72
—. ..... (S) 279
—. ..... (N) 526

Sierra Leone,
leprosy statistics. ..... (N) 203
Serra, Rev. Rocco, receives Award of Officer of the Order of Rokel (O.R.). ..... (N) 203

Singapore,
leprosy statistics. ..... (N) 203

Skin,
direct and indirect immunofluorescent studies of lesions, normal . . . , and sera, of leprosy patients. Saylan, T., *et al.* ..... (A) 392
histopathologic study of clinically normal appearing, in lepromatous leprosy. Bedi, T. R., *et al.* ..... (A) 537
in vivo study of trace elements in leprous. Sheskin, J. and Zeimer, R. ..... (A) 224
morphology of lesions, characterization of organism, in a chimpanzee. Leininger, J. R., *et al.* ..... (A) 550
M. avium infection of the, resembling lepromatous leprosy. Cole, G. W. and Gebhard, J. ..... (A) 641
sections, surface markers on lymphocytes and cells of the mononuclear phagocyte series in. Ridley, M. J., *et al.* ..... (A) 86
sensitivity, to *M. xenopi* sensitin, of adults on the Isthmus of Panama. Larrabee, W. F., Jr. and Talavera, R. ..... (A) 553
study of apparently uninvolved, regarding bacillary population at various sites, in leprosy. Kaur, S. and Kumar, B. ..... (A) 222
titration, immunologic, in leprosy patients and contacts. CAUZZI, N. J., *et al.* ..... (O) 13

tuberculosis, tuberculoid leprosy and, comparative histopathological study. Nirmala, V., *et al.* ..... (A) 85
ulcers, chronic, opportunistic infection of, with *Pseudomonas putrefaciens*. Applebaum, P. C. and Bowen, A. J. ..... (A) 74
ultrastructural changes in blood vessels of peripheral nerves and of, in leprosy patients. Boddingius, J., *et al.* ..... (A) 430

Skin reaction(s),
comparative study of, in leprosy patients to *M. leprae*-lepromin and to antigens from cultivable saprophytic mycobacteria. Sharma, R. C. and Singh, R. ..... (A) 546
comparison of Dharmendra antigen in normal, and in lesions of leprosy patients. Price, J., *et al.* ..... (A) 535
delayed hypersensitivity, to homologous and heterologous antigens, in *M. leprae* immunized guinea pigs, and four cultivable mycobacterial strains. Mustafa, A. S. and Talwar, G. P. ..... (A) 543
—, to lepromin, and antigens prepared from four other mycobacteria. Govil, D. C. and Bhutani, L. K. ..... (A) 540
—, —, prepared from *M. leprae* and selected cultivable mycobacteria. Hogerzeil, L. M. and Prabhudass, N. ..... (A) 541
observations on, induced by lepromin and four other mycobacterial antigens. Sahib, H. S. M. and Vellut, C. ..... (A) 545

Skin test(s),
comparative trial, with non-acid fast organism isolated from leprous tissues, to establish immunological identity with *M. leprae*. Delville, J. and Chatterjee, B. R. (A) 366
delayed . . . response, characterization in mouse and man of two distinct forms. Rook, G. A. W., *et al.* ..... (A) 377
investigation of mechanisms regulating responsiveness, using soluble *M. leprae* and *M. tuberculosis* antigens, and mixture of the two, in leprosy patients. Samuel, N. M., *et al.* ..... (A) 385
results of, with five different mycobacteria. Girdhar, B. K. and Desikan, K. V. ..... (A) 540

Social aspects of leprosy,
and epidemiology, in Sri Lanka. Sabapathy, D. S. P. ..... (A) 325
communication, importance of methods of, in Dominican Republic (1966–1977). Hilario de González, M. and Bogaert Diaz, H. ..... (A) 405
community factors influencing the leprosy patient and his treatment. Frist, T. ..... (A) 400
current attitudes towards leprosy, changing role of National Leprosy Control Centre, Sungei Buloh, Malaysia. Kandiah, N., *et al.* ..... (A) 213
domiciliary visiting in cases of leprosy. Castaneda, S., *et al.* ..... (A) 404
employment and re-employment. Fritschi, E. P. ..... (A) 401
in 1063 cases of leprosy. Agoitia, D. and Flores, O. ..... (A) 404
leprosy policy. Northern Territory of Australia. ..... (A) 635
— Research, Rehabilitation, Social and Medical. Mehta, J. M. and Gokhale, S. W. .... (B) 209
methodology, of investigating, in leprosy work. Varkevisser, C. M. ..... (A) 400
—, of research, of leprosy control. Varkevisser, C. M. ..... (A) 655
of leprosy, in Pará State, Amazon valley. Appel, G. E. ..... (A) 405
psycho-social change, in National Dermatological Center, Nicaragua, in leprosy. Soto Garcia, G., *et al.* ..... (A) 404
social change and social class. Berra y Pamiés, F. F. and Kaufmann, A. E. ..... (A) 403
the several faces of leprosy. Fite, G. L. and Fasal, P. ..... (A) 401
workshop, on human aspects, of treatment of leprosy patients. ..... (S) 307
World Leprosy Day. Recipon, A. ..... (A) 401

Somalia,
hepatitis B virus markers, and leprosy, in Somalian patients. NUTI, M., *et al.* ..... (O) 580
leprosy control campaign in, integration into National Health Services. Tarabini, G. L. and Tarabini, G. ..... (A) 325

South Africa,
genetic markers and leprosy in . . . Negroes, serum protein polymorphisms. Hitzeroth, H. W., *et al.* ..... (A) 551

South Pacific,
leprosy control in. ..... (N) 204
Makogai, Image of Hope. Stella, Sr. M. ..... (B) 211

Spain,
epidemiology of leprosy in. Terencio de las Aguas, J. ..... (A) 232
leprosy courses held at Fontilles. ..... (N) 204

Spleen,
microcirculation of the, open or closed circulation. Chen, L. T. ..... (A) 83

Sri Lanka,
social aspects and epidemiology of leprosy in. Sabapathy, D. S. P. ..... (A) 325

Stain(s),
acid-carbol pararosanilin, periodic, application of, and periodic acid-methenamine silver, to stain leprosy bacilli, in leprous skin lesions. Harada, K. and Kasai, T. .... (A) 366
acid-fast, improved method, remnants of leprosy bacilli in deep organs of patients, with quiescent lepromatous leprosy. Sasakai, N. and Kawatsu, K. ..... (A) 419
carbol-fuchsin, effects of "basic fuchsin" used in formula, or mycobacteria, in Southeastern Asia and Japan. Harada, K., *et al.* ..... (A) 102
lipid, importance in classification of leprosy. Garriso Neves, R. and Azulay, R. D. ..... (A) 420

Statistics,
analysis, two chemotherapy trials, in lepromatous leprosy, interaction among patient variables. U.S. Leprosy Panel ..... (A) 219
—, —, —, response to therapy measured by inoculation of mice. U.S. Leprosy Panel ... (A) 218
leprosy, in Sierra Leone. ..... (N) 203
—, in Singapore. ..... (N) 203

Steroid(s),
comparison of short and long-term treatment, reversal reaction, prevention of permanent nerve damage. NAAFS, B. ..... (O) 7
rifampin interacts with. JOPLING, W. H. and PETTIT, J. H. S. ..... (C) 610

Stigma,
and its effects on patients' self-concept, attitudes toward society. Meisels, L., *et al.* .. (A) 402
— leprosy. González del Cerro, S. ..... (A) 402
Bible, a non-stigmatizing. Rotberg, A. ..... (A) 636
fact of. ..... (A) 656
lepro-. Dogliotti, M. ..... (A) 527
term leprosy carries prejudice. Mangiaterra, M. de ..... (A) 403

Streptomycin,
evaluation of activity of, on *M. leprae*, in mice. Pattyn, S. R. and Saerens, E. ..... (A) 531

Sulfetrone,
effect of treatment, on pathological changes, of deep organs, infected by passage strain of *M. leprae*. Umerov, Z. G. and Tsvetkova, G. M. ..... (A) 411

Sulfonamides, long-acting,
treatment of lepromatous leprosy with. Schulz, E. J. and Kok, S. H. ..... (A) 440

Sulfone(s),
association of clofazimine and, in leprosy treatment. Terencio de las Aguas, J. and Gatti, C. F. ..... (A) 82
comparative effects of . . . and rifampin, on *M. lepraemurium* growth, in macrophage diffusion cultures. Rightsel, W. A., *et al.* ..... (A) 218

Sulfone resistance,
case communication, in leprosy. Vega-Nunez, J. ..... (A) 444
epidemiology and implications of. Pearson, J. M. H. ..... (A) 318
in Ethiopia, Haile, G. S., *et al.* ..... (A) 329
primary, preliminary report. Girdhar, B. K., *et al.* ..... (A) 529

Sulphamethoxypyridazine (SMP),
activity of thiacetazone, thiambutosine and, against *M. leprae* in mice. Colston, M. J., *et al.* ..... (A) 79

Superoxide,
production in PMNs from leprosy patients. GOIHMAN-YAHR, M. ..... (C) 520
reply to Dr. Goihman-Yahr's Letter to the Editor. ROJAS-ESPINOSA, O. ..... (C) 521
superoxide, superoxide dismutase, lipoperoxidation, and *M. leprae*. BERGEL, M. ..... (C) 200

Surgery,
decompression in neuritis, therapeutic and preventive measure. Bose, K. S. ..... (A) 451
nerve, in leprosy. van Droogenbroeck, J. B. A. and Naafs, B. ..... (A) 452
neuropathy in leprosy, results of treatment. Ganopol, J., *et al.* ..... (A) 452
neurovascular island pedicle transfer, in partially anesthetic hands, due to ulnar denervation, protective value of, in leprosy. Ranney, D. A. and Lennox, W. M. ... (A) 215
new operation handsplint for intrinsic replacement tendon transfers. Fritschi, E. ..... (A) 551
place and importance of, in national program of leprosy control. Giraudeau, P. ..... (A) 448
reconstructive, disabilities, displacement and role of, in leprosy. Lobo, D. ..... (A) 448
—, of claw hand, in leprosy. Lakhan Pal, V. P., *et al.* ..... (A) 656
role of, in leprosy rehabilitation, overview. Antia, N. H. ..... (A) 446
treatment of ulnar nerve paralysis, in leprosy. Palande, D. D. ..... (A) 451
twenty years of, at Institut Marchoux, Bamako. Bourrel, P., *et al.* ..... (A) 449
use of intramedullary polypropylene peg for joint stabilization, in leprosy. Finseth, F. and Harrison, S. ..... (A) 551

Switzerland,
Ciba-Geigy publishes booklet on Lamprene. Peterson, L. W. ..... (N) 71
International Year for Disabled Persons (IYDP) to be celebrated in 1981. ..... (N) 526
Thirty-second World Health Assembly adopts WHA 32.39, dealing with leprosy control. ..... (N) 525
WHO Voluntary Fund announces 1978 contributions. ..... (N) 620

2-mercapto-propionilglycine,
action of, on leprosy. Wilkinson, F. and Gervaci, V. S. ..... (A) 440

Taiwan,
leprosy found in a dermatology clinic in. Li, W. M. and Wong, C. K. ..... (A) 76
Miss Marjorie Bly recognized for nursing work. ..... (N) 204

Tanzania,
Leprosy Association, inauguration of. ..... (N) 66
Tanzania Doctor. Stirling, L. ..... (B) 211

Taxonomy,
validation, continuous *in vitro* growth of *M. lepraemurium*, one year at 38°. Hanks, J. H., *et al.* ..... (A) 667

Teaching,
and training, in leprosy. JOHANNESSEN, B. ..... (C) 521
—, MCDOUGALL, A. C. ..... (E) 176
(C) 522
material, workshop on, for leprosy workers. ..... (S) 310

Testis,
pathologic changes in, and epididymis of infertile leprotic males. IBRAHEIM, A. A., *et al.* ..... (O) 44

Tetramisole,
therapeutic trial with immunomodulators, in leprosy, levamisole and. Carvalho, J. C. de S., *et al.* ..... (A) 441

Thailand,
HLA system and leprosy in. Greiner, J., *et al.* ..... (A) 221
north-eastern, Mahasarakam Province, 20 year results of leprosy control in. Prachompol, O., *et al.* ..... (A) 334

perspectives in dermatology in, 1973–1977. Piamphongsant, T. ..... (A) 232
rural areas of, comparative operational study of two methods of population survey in. Teera, R., *et al.* ..... (A) 333
southern, Phuket Island, five year integration of leprosy control, into Provincial Health Service of. Surasek, S., *et al.* ..... (A) 326

Thalidomide,
analogs, with potential activity in erythema nodosum leprosum. Hastings, R. C., *et al.* ..... (A) 672
anti-inflammatory mechanism of action of. Morales, M. J., *et al.* ..... (A) 395
effects of, *in vivo* and *in vitro,* neutrophil activation, in reactional lepromatous leprosy. Goihman-Yahr, M., *et al.* ..... (A) 220
—, —, polymorphonuclear activation, in reactional lepromatous leprosy. Goihman-Yahr, M., *et al.* ..... (A) 373
—, on *de novo* antibody synthesis. Shannon, E. J., *et al.* ..... (A) 381
immunological studies, in leprosy reaction treated with. Rodríguez-Padilla, C., *et al.* ..... (A) 396
nine derivatives of, in lepra reaction. Sheskin, J. ..... (A) 218
treatment of lepromatous lepra reaction, with special reference to. Sheskin, J. ..... (A) 433

The Netherlands,
evaluation of treatment of lepromatous leprosy patients in. Faber, W. R. and Leiker, D. L. ..... (A) 637
leprosy in, review of patients registered at Department of Dermatology, University of Amsterdam, 1972–1976. Faber, W. R. ..... (A) 654

Théorêt, P. E.
obituary. Skinsnes, O. K. ..... (Ob) 198

Therapy,
epidemiology and, in Lucio's leprosy. Saúl, A. ..... (A) 551
maintenance, in non-lepromatous leprosy. Vellut, C., *et al.* ..... (A) 432
of leprosy. Noussitou, F. ..... (A) 432
physical, in leprosy. ..... (N) 73

Thiacetazone,
activity of, and other drugs, against *M. leprae* in mice. Colston, M. J., *et al.* ..... (A) 79

Thiambutosine,
activity of, and other drugs, against *M. leprae,* in mice. Colston, M. J., *et al.* ..... (A) 79

Thioamides,
and thioamide-S-oxides, for leprosy chemotherapy. Peters, J. H., *et al.* ..... (A) 682

Thiocarlide (Isoxyl),
activity of, and other drugs, against *M. leprae,* in mice. Colston, M. J., *et al.* ..... (A) 79

Thiosemicarbazone,
antimycobacterial activity of, in relation to their chemical structure. Morrison, N. E., *et al.* ..... (A) 670
derivatives, antimycobacterial activity of, *in vitro,* and in infected mice. Collins, F. M., *et al.* ..... (A) 683

Thymus,
cells, enhancing effect of, in infected nude mice. Nakamura, K. and Yogi, Y. ..... (A) 105
grafts, human fetal, reversal reaction in patients with lepromatous leprosy after transplantation of. Saha, K., *et al.* ..... (A) 223

Thyroxine,
treated culture medium, growth of *M. leprae* in. Biswas, S. K. ..... (A) 87

Tilorone,
effects of, on mycobacterial infections in mice. Levy, L., *et al.* ..... (A) 228

Tissue(s),
detection of mycolic acid in leprous. DEVI, S. and STEWART-TULL, D. E. S. ..... (O) 484

sections, fluorescence microscopy for detection of *M. leprae* in. JARIWALA, H. J. and KELKAR, S. S. ..... (O) 33

Topple, S. C.,
personal. ..... (N) 71

Torsuev, N. A.,
obituary. Juscenko, A., *et al.* ..... (Ob) 61

Transfer factor,
exerts nonspecific effects? SAHA, K. ..... (C) 615
histopathologically documented reversal reaction in lepromatous leprosy following treatment with. Hastings, R. C. and Job, C. K. ..... (A) 439
placebo-controlled clinical trial of, in lepromatous leprosy. Faber, W. R., *et al.* ..... (A) 439
(A) 637
progressive BCG infection in an immunodeficient child treated with. Sharma, M. K., *et al.* ..... (A) 546
therapy, reversal reactions in lepromatous leprosy following. Hastings, R. C. and Job, C. K. ..... (A) 221

Transmission,
experimental, of a feline non-tuberculous mycobacterial skin disease resembling leprosy. Schiefer, H. B. ..... (A) 340
role of arthropods in, of leprosy. Bedi, B. M. S., *et al.* ..... (A) 327

Trautman, J. R.,
personal. ..... (N) 205

Treatment,
considerations on, of leprosy. BERGEL, M. ..... (C) 518
dapsone, and deformities, retrospective study. Gupte, M. D. ..... (A) 656
defaulters in leprosy, retrospective study of 42,000 cases. KOTICHA, K. K. and NAIR, P. R. R. ..... (O) 50
evaluation of, of lepromatous leprosy patients, in The Netherlands. Faber, W. R. and Leiker, D. L. ..... (A) 637
"Mandukaparni," common Indian herb in, of leprosy. Chaudhuri, S., *et al.* ..... (A) 411
(A) 637
potential uses of the medication monitor in, of leprosy. MOULDING, T. S. ..... (O) 601
rifampin for, of lepromatous leprosy. Jacobson, R. R. ..... (A) 682
risks of leprosy, in a general hospital. Mathai, R., *et al.* ..... (A) 322
short course two months, of paucibacillary leprosy, with rifampin. Pattyn, S. R., *et al.* ..... (A) 639
with rifampin, of 5000 leprosy patients, in Cuba. Abreu, A., *et al.* ..... (A) 436

Triton WR-1339,
effect of treatment *in vivo* with, and Macrocyclon, on *M. leprae* mouse foot pad infection. Delville, J. and Jacques, P. J. ..... (A) 80

Tropical disease,
Pathology of. Binford, C. H. and O'Connor, D. H. ..... (B) 206

Tubercin-3
effects of, on rifampin induced T-lymphocytopenia, in tuberculosis patients. ..... (A) 233
—, on serum electrophoretic patterns, in lepromatous leprosy. Byun, S. Y. and Chung, T. H. ..... (A) 538

Tuberculin,
allergy, effect on, of . . . tests given 18 months earlier. Narain, R., *et al.* ..... (A) 657

Tuberculoid leprosy,
acetycholine sweat function test (SFT) in, effect of different therapeutic regimens on. Venetsanos, P., *et al.* ..... (A) 349
and tuberculosis skin, comparative histopathological study. Nirmala, V., *et al.* ..... (A) 85

bone marrow in. Koranne, R. V., *et al.* ..... (A) 222
early and late reactions in, and lepromatous leprosy, with lepromins from *M. leprae* and five selected cultivable mycobacteria. Mustafa, A. S. and Talwar, G. P. ..... (A) 543
HLA-linked control of susceptibility to, evidence to demonstrate. de Vries, R. R. P., *et al.* ..... (A) 321
Lucio's phenomenon in. Miranda, R. N. ..... (A) 418
major, with nerve hypertrophy. Cottenot, F. and Pennec, J. ..... (A) 84
M. leprae in the striated muscle of. Koranne, R. V., *et al.* ..... (A) 541
nasal mucosa in, significance of changes in, and other forms of leprosy. Chacko, C. J. G., *et al.* ..... (A) 538
neuritis after intradermal tests with *M. leprae* in patients with. Serial, A. ..... (A) 426
post-traumatic, Kapur, T. R. and Rao, S. M. B. ..... (A) 533
short course rifampin treatment of TT and BT leprosy. Bourland, J. and Pattyn, S. R. (A) 437
stable. Malacara, M. and Avalos, E. ..... (A) 355
—. Zambrano, D. T. ..... (A) 354

Tuberculosis,
active, unrecognized until necropsy. Edlin, G. P. ..... (A) 94
and leprosy, discussed at 24th World Conference of the International Union against Tuberculosis, in Brussels, Belgium. ..... (N) 67
diagnosis of, using Korean chipmunks. Bae, E. D., and Choi, T. K. ..... (A) 552
disseminated, masquerading as lepromatous leprosy. Weissman, J. B. and Neu, H. C. (A) 644
effects of Tubercin-3 on rifampin induced T-lymphocytopenia in. Chung, T. H., *et al.* (A) 233
miliary, in adults, clinical study of. Yoon, C. Y., *et al.* ..... (A) 234
pulmonary, association of leprosy and. Nigam, P., *et al.* ..... (A) 534
—, defective leukotaxis in monocytes from patients with. Campbell, P. R. ..... (A) 552
—, toxic psychosis to isoniazid and ethionamide in a patient with. Sharma, G. S., *et al.* ..... (A) 640
—, treatment with isoniazid, prothionamide and DDS in, in adults. Orlowski, E. H. ... (A) 82
renal, clinical observations of. Kim, H. S. ..... (A) 233
—, —, on 122 inpatients. Choi, S. H. ..... (A) 233
skin, tuberculoid leprosy and, comparative histopathological study. Nirmala, V., *et al.* ..... (A) 85
spectrum of human. Lenzini, L., *et al.* ..... (A) 553

Uganda,
genetic factors, of children in, in leprosy. White. S. J., *et al.* ..... (A) 92

Ulcer(s),
chronic skin, opportunistic infection of, with *Pseudomonas putrefaciens*. Applebaum, P. C. and Bowen, A. J. ..... (A) 74
diabetes mellitus, screening for, in leprosy patients with chronic. Smith, W. C. S. ..... (A) 644
plantar, in leprosy. Brand, P. W. and Beach, R. B. ..... (A) 671
—, squamous cell carcinoma as a complication of, in leprosy. Opromolla, D. V. A. and Fleury, R. N. ..... (A) 354
trophic, chronic, secondary bacterial infections in, in leprosy. Chow, S. K. W. ..... (A) 370
—, squamous cell carcinoma arising from. Boopalraj, J. M. and Muthusami, T. C. ..... (A) 532

Urine,
dapsone in, and serum, demonstration of, by ELISA inhibition. Huikeshoven, H., *et al.* ..... (A) 75
—, —, —, by enzyme-linked immunosorbent inhibition technique. Huikeshoven, H., *et al.* ..... (A) 328
encouraging results from DDS . . . analysis, in leprosy patients, in Wangas, Kenya. Huikeshoven, H. and Bijleveld, I. ..... (A) 75
influence of rifampin on DDS excretion in. Balakrishnan, S. and Sheshadri, P. S. ..... (A) 529

U.S.A.,
Dr. C. H. Binford receives honorary degree. ..... (N) 620
Dr. Charles C. Shepard receives Richard and Hinda Rosenthal Foundation Award. .... (N) 526
Drs. John R. Trautman and Daniel Riordan presented Companionate of Merit in the Rank of Officer, by Southern Delegation of the Military and Hospitaller Order of Saint Lazarus of Jerusalem. ..... (N) 205

Dr. Paul Fasal retires from U.S.P.H.S. ..... (N) 72
Fourth World Congress of International Society of Tropical Dermatology meets, in New Orleans, Louisiana. ..... (N) 620
Gulf South Research Institute (GSRI), account of activities. ..... (N) 205
—, ends leprosy research program. ..... (N) 72
Heiser Program for Research in Leprosy announces research possibilities. ..... (N) 621
IJL Board of Directors meets, on 27 September 1979. ..... (N) 621
leprosy, among Indochinese refugees. ..... (N) 620
— in the. Enna, C. D., *et al.* ..... (A) 232
(A) 332
leprosy-like disease, of wild armadillos, in French Acadiana, Louisiana. Smith, J. H., *et al.* ..... (A) 230
19th Annual International Seminar on Leprosy meets in April 1978 at Carville. ..... (N) 71
notes on the history of leprosy in Louisiana. Gussow, Z. ..... (A) 527
21st Annual International Seminar on Leprosy to meet at Carville in April 1980. ..... (N) 620

U.S.–Japan Cooperative Medical Science Program,
Fourteenth Joint Leprosy Research Conference, New Orleans, Louisiana, U.S.A., 24–26 September 1979. ..... (A) 659
Thirteenth Joint Leprosy Research Conference, Osaka, Japan, 27–29 September 1978. (A) 96

Uveitus,
anterior, chemotherapy for leprosy and. Okamura, K. ..... (A) 111
posterior lepromatous, reaction as an etiologic factor. Chovet, M., *et al.* ..... (A) 74

Vaccination,
BCG, immunity to *M. leprae* infections induced in mice by, before and after challenge. Shepard, C. C., *et al.* ..... (A) 90
experiments with *M. leprae* preparations and with cultivable mycobacteria. Shepard, C. C. ..... (A) 677

Vaccine,
development of, against leprosy. Talwar, G. P. ..... (A) 547
from ICRC bacilli, against *M. leprae* infection, in mouse foot pad. Bhide, M. B., *et al.* ..... (A) 339
(A) 537
M. leprae, other mycobacteria, and a possible. Stanford, J. L., *et al.* ..... (A) 357
specific, effect of, on cell-mediated immunity of armadillos against *M. leprae*. Kirchheimer, W. F., *et al.* ..... (A) 390

Venezuela,
Estado Miranda, distribution of leprosy, in population groups at different risks. Zuniga, M., *et al.* ..... (A) 322

Western Samoa,
leprosy in. Lopez-Bravo, L. and Kamu, L. ..... (A) 335

World Health Organization (WHO),
activities in leprosy, 1973–1978. Sansarricq, H., *et al.* ..... (A) 319
Special Programme, immunology of leprosy and. Godal, T. ..... (A) 372
statement by Professor M. F. Lechat, to Thirty-second World Health Assembly. ..... (E) 514
WHO Voluntary Fund announces 1978 contributions. ..... (N) 620

World Leprosy Day,
celebration of. Recipon, A. ..... (A) 401